














© 2019 Robyn E. Ellerbrock
EVALUATION OF THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY 




Submitted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy in VMS- Comparative Biosciences 
in the Graduate College of the 
University of Illinois at Urbana-Champaign, 2019 
Urbana, Illinois 
Doctoral Committee: 
Assistant Professor Igor Canisso, Chair and Director of Research 
Professor Jay Ko 
Professor Indrani Bagchi 
Professor Kevin Kline 





Antimicrobial therapy is necessary in pregnant mares affected by severe bacterial 
infections such as cellulitis, bronchopneumonia, or placentitis. Despite the many antimicrobials 
available for human use, very few antimicrobials are cost-effective and approved for use in the 
horse. Enrofloxacin is a fluoroquinolone antibiotic that is available in both oral and intravenous 
formulations and is commonly used in veterinary medicine. This fluoroquinolone acts by inhibiting 
bacterial DNA synthesis. Previous work suggests that the neonatal animal is sensitive to 
fluoroquinolones, and that exposure during development will affect cartilage in the neonate.  
However, fluoroquinolones are used in some pregnant species without obvious effects on the fetus. 
To understand potential toxic effects on the fetus, the pharmacokinetics and pharmacodynamics 
of the enrofloxacin in both the intravenous form and a newer oral form were evaluated in the 
pregnant mare. After determining the optimal dose, and a higher dose that might be used to treat 
intermediately susceptible bacteria, mares were treated with intravenous enrofloxacin at 260 days 
gestation. Both enrofloxacin and its active metabolite ciprofloxacin crossed the placenta, and 
reached therapeutic levels in the fetus and fetal fluids, without apparent effects on the fetus.  Next, 
to explore long-term effects of enrofloxacin on fetal development, mares were treated for 14 days 
at 280 days gestation, and allowed to foal.  Foal cartilage and tendon strength were then evaluated 
at 30 days of age, and no effects of treatment were observed on gross or histologic examination. 
In contrast, foals treated with enrofloxacin at 14 days postnatally developed clinical lameness and 
moderate to severe lesions on histopathology. All foals were then subjected to additional testing 
to determine if normal veterinary assessments were insufficient to detect long term effects of mild 
in utero toxicity. Structural MRI, qMRI and RT-PCR analysis failed to detect changes in cartilage 
properties in the in utero-exposed animals. Overall, it is proposed that enrofloxacin and its active 
metabolite ciprofloxacin cross the equine placenta and reach the equine fetus at therapeutic 
concentrations.  At therapeutic doses, exposure to these fluoroquinolones in utero during the first 
or third trimesters does not appear to cause either acute, or chronic cartilaginous lesions in the 
developing fetus.  
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CHAPTER 1: OVERVIEW 
 
Antimicrobial therapy is necessary in broodmare practice to treat a variety of systemic 
diseases, from cellulitis to peritonitis and placentitis. Placentitis alone is a significant cause of 
pregnancy loss in the horse, and affects 3-5% of all equine pregnancies [1–4].   Despite the many 
antimicrobials available for human use, very few antibiotics are cost effective and approved for 
use in the horse, and none are approved for use in pregnant mares. Fluoroquinolones would be an 
excellent choice as a second-line antibiotic in pregnant mares; however, they are believed to be 
toxic to the fetus based upon questionable reports in other species and are mostly avoided during 
pregnancy [5–7].  To date, only a few studies have assessed in vivo effects of enrofloxacin in the 
horse, often using supratherapeutic doses to attain maximum toxicity [8].  No studies have assessed 
the safety of enrofloxacin administration to pregnant mares, therefore the use of enrofloxacin is 
generally avoided in pregnant mares due to the assumption it crosses the placenta and will cause 
cartilage lesions in the fetus. 
 Traditionally, toxicity studies have determined adverse effects based on clinical signs, 
blood work, and histological evaluations of tissues of interest. Given the athletic demands of the 
horse, toxicity studies should ensure that enrofloxacin does not affect tendon tensile strength or 
cartilage strength in treated animals. Additionally, given the significant pressure to reduce the 
number of animals used in research, there is a critical need to validate noninvasive means, such as 
magnetic resonance imaging (MRI), for monitoring drug toxicity to cartilage and tendons.   
 This dissertation details administration of enrofloxacin to the pregnant mare in the first and 
third trimester, and the subsequent evaluation of the pharmacokinetics, pharmacodynamics, and 
potential drug toxicity in the developing fetus and resulting foal. The dissertation is divided into 
eight chapters, and each chapter stands alone, with the figures, tables and references included at 
the end of each chapter. The appendix that follows the end of the dissertation details four unrelated 
studies completed during my graduate studies that were carried out to improve our understanding 
of male subfertility and infertility in the horse.  
 Chapter 2 provides a brief background on antimicrobial use in the horse, with special detail 
paid to known effects on reproduction, and known effects of pregnancy on drug distribution and 
metabolism. In addition, background is provided on the advanced imaging techniques and 
biomechanical tests used in subsequent chapters. Chapters 3-7 are composed of the five 
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publications derived from this dissertation; four have been submitted for publication at time of 
dissertation submission, two of which have been accepted at this time. Chapter 3 details the 
evaluation of enrofloxacin pharmacokinetics and pharmacodynamics in pregnant mares. Chapter 
4 confirms the transplacental diffusion of enrofloxacin and ciprofloxacin in the horse, and 
investigates potential effects on fetal histology.  Chapter 5 is a follow-up to Chapter 4, where mares 
were allowed to foal to determine the long-term effects of in utero fluoroquinolone exposure. 
Chapter 6 explores the use of advanced imaging and biomechanical testing to detect subtle 
differences in cartilage strength and biomechanics in the horse. This is followed by the study in 
Chapter 7 investigating potential effects of in utero exposure to enrofloxacin during the first 
trimester of equine pregnancy.  Our project conclusions and future directions for research are 
outlined in the final chapter, Chapter 8.  
While it is important to note that failure to demonstrate toxicity in a small number of 
healthy animals does not promise safety, this dissertation details studies exploring enrofloxacin’s 
potential effects on the developing equine fetus and foal, and provides critical information for 








CHAPTER 2: INTRODUCTION AND REVIEW OF PERTINENT LITERATURE 
 
ANTIMICROBIAL USE IN THE HORSE 
Antimicrobial therapy is necessary in pregnant mares when treating a variety of severe 
bacterial diseases such as placentitis, bronchopneumonia, pleuropneumonia, cellulitis, or septic 
arthritis.  Despite the many antimicrobials available for human use, very few antibiotics are cost 
effective and approved for use in the horse, and none are approved for use in pregnant mares. 
Additionally, the assumption of antimicrobial safety in the mare is based almost entirely on 
anecdotal clinical experience, rather than prospective or retrospective analysis.  
It is assumed that β-lactams, potentiated sulfonamides, and metronidazole are safe in 
pregnant mares based both on reports in other species and the widespread use of these 
antimicrobials in equine clinical practice [7,9,10].  Interestingly, while trimethoprim sulfa is 
widely used throughout the entire equine gestation, sometimes even in a prophylactic manner to 
prevent placentitis, human retrospective studies suggest an increased risk of cardiovascular defects 
and neural tube defects in infants when mothers are treated with trimethoprim in the first trimester 
[9,11,12]. A similar association has not been described in the horse, and trimethoprim sulfas are 
commonly prescribed in the horse from pre-conception to treat endometritis, all the way through 
late gestation to treat placentitis [1,7,12,13], in part because trimethoprim sulfa has good uterine 
penetration and is able to cross the third trimester equine placenta [13]. Unfortunately, and perhaps 
in part due to trimethoprim sulfa’s widespread use in equine practice, there is an increasing 
resistance among common equine pathogens, especially Escherichia coli, to trimethoprim sulfa 
[14,15]. 
Penicillin and gentamicin are commonly prescribed in combination for broad-spectrum 
antimicrobial coverage in horses with more severe systemic infections that are resistant to 
trimethoprim sulfa and require parental antibiotics. Both penicillin and gentamicin are believed to 
be safe for use throughout gestation, with penicillin considered to have no known negative effects 
on human pregnancy [16]. Gentamicin was classified as FDA class D due to isolated reports of 
potential risks of otic toxicity [17], however large retrospectives have failed to demonstrate risks 
to the human fetus, and gentamicin in often prescribed during human pregnancy [9,18,19].  
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 Penicillin has previously been shown to cross the equine placenta and reach effective 
concentrations in the fetal fluids [20], however there are conflicting reports on gentamicin. After 
one dose of gentamicin was administered within 2 hours of parturition, gentamicin was not 
detected in the resulting foals (n=3) or amniotic fluid (n=1). In another study using microdialysis, 
gentamicin was detected in the fetal fluids at low concentrations (3.9-8.5 ug/ml).  These lower 
concentrations may indicate that a combination of gentamicin and penicillin is not adequate for 
placental or fetal infections with Gram-negative bacteria.  The other disadvantage to penicillin and 
gentamicin administration is the need for intravenous administration (gentamicin) and frequent 
administration (penicillin).  
Cephalosporins are beta lactam antibiotics with broader spectrum activity than penicillin 
and are excellent antimicrobials frequently used in large animal species. Besides increased 
resistance to beta-lactamases, cephalosporins are bactericidal, effectively penetrate bacterial cell 
walls, and are generally considered less likely to cause side effects seen with the administration of 
other antimicrobials such as renal or hepatic toxicity or colitis [21].  The main disadvantages are 
that cephalosporins must be administered parentally, and that cephalosporins are also considered 
antimicrobials of importance in human medicine, and thus, like enrofloxacin, should be reserved 
for second line treatment due to both cost and appropriate antimicrobial stewardship. 3rd generation 
cephalosporins such as ceftiofur are considered safe for pregnant animals due to anecdotal data in 
horses, and retrospective studies in humans [9].  Unfortunately, while ceftiofur reaches therapeutic 
concentrations in the non-gravid equine uterus [22], it does not cross the equine placenta and thus 
is not useful for reproductive related diseases such as placentitis [23].  
Tetracyclines are bacteriostatic in nature, and act by reversibly binding the 30S subunit of 
the bacterial ribosome to inhibit protein synthesis. Oxytetracycline, doxycycline, and occasionally 
minocycline are used in equine practice to treat systemic infections from Borrelia burgdorferi to 
Neorickettsia risticii.  Oxytetracycline is often the drug of choice for fevers of unknown origin in 
the horse. While there is no data on toxicity or transplacental diffusion in equine species, 
oxytetracycline is also commonly administered in the final trimester of ruminant pregnancy to 
prevent abortion in herds or flocks at risk of aborting due to Chlamydia infection [24].  Despite 
widespread use without consequence in ruminants, tetracyclines are avoided in human pregnancy 
given the reported effects on tooth discoloration in neonates and young children [25]. Interestingly, 
given the effectiveness of doxycline against fevers of unknown origin, and in tropical diseases 
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such as typhus in humans, attitudes towards doxycline use during pregnancy may be changing in 
human medicine [26]. More recent reports have suggested that short courses of doxycline 
treatment during gestation have no negative effects on the resulting child’s teeth, or overall health 
[27]. Regardless, aside from anecdotal clinical experience, the pharmacokinetics, 
pharmacodynamics, and side effects of tetracycline use in the pregnant horse are still unknown.  
In summary, there are limited options for gram negative placental or fetal infections in the 
horse that are resistant to trimethoprim sulfa. Other than trimethoprim sulfas and the tetracyclines, 
enrofloxacin is the only other widely available broad-spectrum antibiotic affordable and safe to 
use in horses. In addition, enrofloxacin, doxycycline, minocycline, and the trimethoprim sulfas are 
the only commonly prescribed oral antibiotics available for use in the horse.  Oral antibiotics have 
the benefit of increased ease of treatment on farm by owners, and increased owner compliance. 
Enrofloxacin is the sole oral antibiotic that can be administered once a day in the horse, making 
enrofloxacin an attractive choice if it can be safely administered during pregnancy. 
Enrofloxacin is a lipophilic fluoroquinolone with activity against both Gram-negative and 
Gram-positive pathogens. Fluoroquinolones inhibit topoisomerase I (DNA Gyrase) and 
topoisomerase IV, which results in inhibition of DNA synthesis and separation in dividing bacteria 
[28,29]. Fluoroquinolones are attractive antimicrobials because they act rapidly in a dose 
dependent manner, and provide a post-antibiotic effect [28,30]. Enrofloxacin is also converted in 
vivo into ciprofloxacin, which is an active metabolite effective against many common pathogens. 
While ciprofloxacin cannot be safely and effectively administered to horses [31,32], enrofloxacin 
is commonly safely administered to horse either orally or intravenously [8,33,34]. Oral 
availability, rapid onset of action, and relative affordability in equine sized doses makes 
enrofloxacin an excellent choice when first-line antibiotics such as sulfonamides and β-lactams 
fail.  
Fluoroquinolones are believed to be toxic to the fetus based upon questionable reports in 
other species and are mostly avoided in pregnant mares [5,35–37].  According to FDA guidelines 
for risk assessment during human pregnancy, a product is teratogenic if the product has teratogenic 
potential at clinical doses used in humans.  Most studies demonstrating  fluroquinolone toxicity in 
neonates used doses far exceeding clinical doses, and thus to do not meet the clinical dose criteria 
for a teratogen [38]. Additionally, the assumption that fluoroquinolones are teratogenic is based 
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on effects in the juvenile animal, and so far the teratogenicity assumption has not been validated 
by the few existing animal studies [16], or by human retrospective studies [9,39] . 
 
FLUOROQUINOLONE TOXICITY 
Fluoroquinolones are avoided in pregnant animals because in vitro and in vivo studies have 
provided evidence that administration of enrofloxacin can cause tendonitis and arthropathies, 
especially in young, growing animals [5,6,37,40].  To date, only a few studies with small sample 
sizes have assessed in vivo effects of enrofloxacin in the horse, often using supratherapeutic doses 
to attain maximum toxicity.  When enrofloxacin was administered at 3 to 5 times the recommended 
therapeutic dose for 21 days, 3 of 12 horses developed musculoskeletal complications such as 
lameness, cellulitis, tendinitis and tarsal sheath effusion [8]. Horses receiving the recommended 
therapeutic dose (5 mg/kg q 24h) did not develop these complications, suggesting that prolonged 
administration of enrofloxacin at a therapeutic dose is safe in adult non-pregnant horses. When 
four two-week old foals were treated with twice the recommended dose (10 mg/kg, IV, q 24 hours) 
for eight days, three foals became moderately to severely lame and had tibial-tarsal joint effusion 
with roughening of the articular cartilage, suggesting that foals might be more sensitive to cartilage 
damage [6].  However, this increased dosage is generally not used and no studies have assessed 
the effects of the recommended dose on foals.  
No studies have assessed the safety of enrofloxacin administration to pregnant mares. Use 
of enrofloxacin is generally avoided in pregnant mares under the assumption it crosses the placenta 
and will cause cartilage lesions in the fetus. In pregnant rabbits, both enrofloxacin and 
ciprofloxacin diffuse through the placenta, with enrofloxacin achieving much higher diffusion 
rates than ciprofloxacin [41].  However, rabbits have a hemochorial placenta, and it is possible that 
enrofloxacin does not cross the thicker epitheliochorial equine placenta.  As studies with ceftiofur 
have shown, transplacental diffusion can differ between species [23]. Additionally the degree of 
fluoroquinolone toxicity depends on the specific antibiotic and species [42], and it is possible that 
enrofloxacin administration does not have the same effects on fetal cartilage that it does on 
neonatal animals.  
Quinolones are believed to induce arthropathies by chelating divalent cations such as 
magnesium (Mg+2) [43–46]. Cartilage and tendon are poorly vascularized tissues, and a decrease 
in available magnesium impairs fibronectin signaling in the extracellular matrix (ECM) [44,47]. 
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This impairment disturbs cell adhesion, proliferation, and reduces proteoglycan synthesis, which 
is the main component of ECM [44,47]. Disturbances in cell adhesion and proliferation can lead 
to severe changes in cartilage architecture, as seen in studies where supratherapeutic doses of 
enrofloxacin were administered to chickens and puppies [5,37]. In vitro studies have demonstrated 
enrofloxacin exposure has a greater detrimental effect on chondrocyte glycosaminoglycan 
production in neonatal cartilage than in adult cartilage [46,48]). In vitro work by Davenport et al 
suggests that concentrations of enrofloxacin as low as 25 µg/ml will have a detrimental effect on 
neonatal equine cartilage; in comparison, in no effect was seen on adult cartilage proteoglycan 
concentrations until media enrofloxacin concentrations reached 1000 µg/ml [46].  
While in vivo studies of enrofloxacin’s effects on matrix metalloprotease and cartilage 
related gene mRNA expression are lacking, in vitro studies have shown conflicting results [46,49] 
.When neonatal and adult equine cartilage explants and chondrocyte cultures were exposed to 
varying concentrations of enrofloxacin or magnesium deficient cultures, a decrease in 
glycosaminoglycan synthesis was seen, but no differences were seen in mRNA expression of 
aggrecan, Coll II, biglycan, decorin, link protein, or MMPs 1,3, and 13 in the cultured 
chondrocytes[46].  In contract, when canine chondrocytes were cultured with an unknown 
concentration of enrofloxacin, chondrocytes produced less s-GAG, and increased expression of 
IL-1B, TNF, and MMP3 [42].  In the same study, marbofloxacin had a more severe effect on canine 
chondrocytes, highlighting the importance of caution when assuming similar toxicities between 
fluoroquinolones.  Additionally, it is likely that in vitro systems do not adequately reflect the 
dynamics of cartilage gene expression, and data on gene expression in fluoroquinolone-treated 
cartilage is lacking.  
 
CARTILAGE BIOLOGY 
 Articular cartilage is a viscoelastic tissue comprised of chondrocytes and extracellular 
matrix, and healthy articular cartilage is vital to the performance animal. Normal adult cartilage 
consists of a superficial, middle, and deep zone, and each zone is composed of its own arrangement 
of chondrocytes and extracellular matrix.  Equine cartilage extracellular matrix is approximately 
70% water, 15 % collagen, and 10% proteoglycans, and 5% other lipids and minerals [50,51]. The 
superficial zone consists of flat cells oriented along the axis of joint movement, and chondrocytes 
in this zone both produce lubricating molecules that aid in joint movement, and resist shear stress 
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on the joint. Extracellular matrix is dense in the superficial zone. The middle and deep zones 
contain larger, round chondrocytes organized in vertical rows, perpendicular to the joint surface. 
These chondrocytes produce collagen II, aggrecan, and other cartilage matrix molecules, and 
provide articular cartilage with biomechanical resilience. Collagen II is organized in fibrils 
providing tensile strength, and aggrecan provides the necessary elasticity.  The deep zone contains 
the largest chondrocytes, which both produce extracellular matrix and interact with the underlying 
subchondral bone.   
Neonatal articular cartilage is less organized than adult cartilage, and at birth, is compact, 
highly cellular, and contains relatively less matrix [52]. Equine neonatal articular cartilage is 
thicker than adult cartilage[53], contains high levels of collagen II, and expresses a high degree of 
matrix adaptation [52,54,55]. After birth, articular cartilage thins as chondrocytes hypertrophy, 
matrix accumulates, and zonal organization begins [53,56]. Proteoglycan and collagen content 
vary in the cartilage based on age, joint of interest, and region within the joint [54,57].  Normally, 
glycosaminoglycan chains in the proteoglycan molecules carry a negative charge, which attracts 
sodium, and draws water into the cartilage by osmotic pressure. When cartilage is compressed, 
some water is expelled, but returns as soon as compression, or loading ceases. When cartilage 
begins to degrade and glycosaminoglycans are lost, less water is retained in the tissue.  
Cartilage that forms after injury is described as fibrocartilage, and usually contains more 
collagen type I, and fewer proteoglycans than normal articular cartilage [58]. This repair tissue is 
also less strongly bound to the surrounding healthy cartilage, and often detaches or separates from 
surrounding cartilage when injured, or as seen in damaged cartilage exposed to high concentrations 
of enrofloxacin [5,37].  
While there is an extensive body of research surrounding cartilage injury and repair, there 
is still a relatively poor understanding of embryonic cartilage formation and development 
throughout gestation. The early embryonic skeleton forms as continuous uninterrupted cartilage 
masses [59],  and then “interzones” form at future joint sites [60]. Cells present in the interzone of 
the forming embryonic joint are critical for proper joint formation [60,61], and these interzones 
are composed of compacted and flat mesenchymal cells that originate from de-differentiated 
chondrocytes after they stop expressing Col 2a1 [62–64]. Cell lineage tracing experiments have 
demonstrated that progenitor cells of the interzone contribute to the formation of the articular 
cartilage, synovial lining, and joint ligaments [62,65–68]. Articular chondrocytes descend from 
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progenitor cells present in the interzone, and signals affecting these cells could compromise 
articular cartilage in the resulting foal. 
Normal limb bud development begins around 20 days gestation in the horse, and is quickly 
followed by footpad and elbow joint formation (days 30 to 40).  Next the femorotibial joint 
develops, from initial cavitation at 45 days gestation, to complete joint formation by 65 days [61]. 
Around day 40, the equine fetus first begins intrinsic muscular activity such as head movements 
[69]. Fetal movement is vital to proper joint formation, and avian and murine studies that prevented 
embryo limb movement demonstrated a failure in normal joint development [70–72].  Any insult 
resulting in failure in proper interzone formation, or initiation of fetal movement could have severe 
effects on fetal development. Collectively, 45-60 days of gestation is a critical time-point in equine 
synovial joint development, making fluoroquinolone exposure potentially harmful during this time 
period. 
 Post-natally, articular cartilage thickens, matrix accumulates, and zonal organization 
occurs that is vital to joint biomechanical function[52,56]. While relatively little is known about 
postnatal cartilage growth, a few equine studies have compared gene expression in neonatal 
cartilage to mature repair cartilage, and to stem cells.  Mienaltowski et al demonstrated that equine 
neonatal cartilage gene expression was consistent with cellular growth and expansion, while 
mature cartilage was functionally focused on withstanding the stress associated with weight 
bearing and locomotion [73]. While the exact time frame is not known for the organization of the 
articular cartilage into three zones, murine and bovine studies have demonstrated differential gene 
expression between cartilage zones [64,74], with deeper cartilage similar to the resting growth 
plate, and superficial cartilage similar to the hypertrophic zone of the growth plate. Collectively, 
it is possible that fluoroquinolone exposure during this time of intense reorganization postnatally 
may have more drastic effects than if exposure occurs in utero, before zonal reorganization occurs.  
 
DRUG PHARMACOKINETICS AND PHARMACODYNAMICS 
Given the potentially narrow margin of safety of enrofloxacin administration to pregnant 
mares, it was essential to determine enrofloxacin pharmacokinetics and pharmacodynamics in the 
pregnant mare.  While very little is known about how pregnancy affects pharmacodynamics in the 
mare, pregnancy can affect maternal drug absorption, distribution, and elimination in other species. 
Plasma volume, total body water, and renal blood flow increase during and can have an effect on 
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pharmacokinetics and pharmacodynamics. Pregnant humans can experience delayed gastric 
emptying and decreased gastrointestinal motility, which is believed to be progesterone mediated 
[75–78]. Progesterone can also induce changes in hepatic microsomal enzyme activity [78,79]. 
These physiologic changes can have profound effects on the bioavailability, distribution, 
metabolism, and excretion of drugs [79,80]. In addition to maternal physiological changes, the 
fetal-placental unit can affect drug distribution and elimination if the placenta or fetus is involved 
in drug metabolism, or if the fetal fluids affect volume of drug distribution[78]. As a result, it may 
be necessary to adjust doses and dosing intervals of an antibiotic during pregnancy to optimize 
maternal and fetal health.  
Traditionally, serum drug concentrations and bacterial minimum inhibitory concentrations 
(MIC) have been used to determine optimal antimicrobial dosage. For fluoroquinolones, pathogens 
with an MIC<0.5 µg/ml are considered susceptible to enrofloxacin according 2008 CLSI 
breakpoints[81]. However, this single parameter is not sufficient to predict cure rate in many cases, 
and other efficacy parameters are important to consider. The ratio of AUC24: MIC has been used 
to predict antimicrobial efficacy, and a study assessing fluoroquinolone efficacy for gram-negative 
infections in mice suggested that a AUC24: MIC > 100 is optimal for bacterial cure [82]. However, 
the AUC24:MIC ratio needed for clinical cure varies, and in animals with competent immune 
systems, ratios of 30 to 60 may be sufficient for treatment some infections [83,84].  
 One limitation of using AUC24: MIC ratios as a marker of clinical efficacy is the fact that 
ciprofloxacin is an active metabolite of enrofloxacin. If enrofloxacin and ciprofloxacin have an 
additive effect in bacterial infections, then the AUC24/MIC ratio may be calculated by adding 
enrofloxacin and ciprofloxacin AUC24, as it was calculated in previous poultry and bovine studies 
[85,86]. However, if enrofloxacin and ciprofloxacin act synergistically, or in cases where 
ciprofloxacin MIC90 and enrofloxacin MIC90 are vastly different (Strep. zooepidemicus for 
example), then addition of the two AUC24 is likely not appropriate [87]. In such cases, it may be 
preferable to evaluate only the enrofloxacin AUC24: MIC90 ratios.  
 The AUC24: MIC ratio cut-offs for clinical cure and bacterial resistance are not only 
antibiotic and species specific, but pathogen specific as well. While there is no in vivo data for 
enrofloxacin, or for equine infections, in vitro studies with ciprofloxacin and human dosing 
regimens have suggested that AUC/MIC ratios > 45 h may be sufficient for bacterial and clinical 
cure of certain gram-positive bacteria such as Streptococcus pneumonia [84,88,89]. The 
11 
 
recommended AUC24:MIC ratios for a cure rate are based on free plasma concentrations. While 
local tissue concentrations are important to consider for ocular or central nervous system 
infections, fluoroquinolones are lipophilic drugs that are moderately protein bound in the plasma 
and penetrate most tissues well in the horse [90]. Reported endometrial enrofloxacin 
concentrations after systemic administration range from 1.689 µg/g after an single dose [91] to 
10.19 µg/g (n=2) two hours after the 6th dose of enrofloxacin [90], and it has recently been shown 
that both enrofloxacin and ciprofloxacin cross the equine placenta [92]. Similarly, enrofloxacin 
and ciprofloxacin reach synovial fluid concentrations similar to the plasma in horses [90] and reach 
interstitial fluid similar to plasma concentrations in calves [86] and pigs [83], suggesting that 
plasma AUC24:MIC ratios are sufficient to estimate local interstitial fluid concentrations at the site 
of infection.  
Appropriate antimicrobial stewardship necessitates the selection of the optimal drug for a 
given microorganism without compromising patient health. Regardless of in vitro sensitivity 
patterns, antimicrobial efficacy depends on multiple factors, including the pathogen present, the 
infected tissue, the potential synergistic effects of ciprofloxacin and enrofloxacin, systemic 
concentrations after multiple doses, and the known post-antibiotic effect observed with 
fluoroquinolones [28]. Pregnancy can affect drug metabolism and excretion, and these changes are 
especially important to consider for medications with apparently narrow therapeutic windows, or 
a large volume of distribution that may encompass both foetal tissues and fluids.  
 
FETAL FLUID ANALYSIS 
While amniocentesis is a commonly employed practice in human medicine, few studies 
have attempted fetal fluid analysis in the pregnant horse. Options include transabdominal amnio- 
and allocentesis [93], fluid collection at parturition [94], or placement of microdialysis probes for 
continuous monitoring [20].  Transabdominal ultrasound-guided fluid collection allows for 
differentiation between amniotic and allantoic fluids, and enables the collection of larger volumes 
of fluid, but also results in large bore puncture of the fetal membranes, and potentially poses an 
increased risk of bacterial infection, or initiation of parturition. Fluid collection at abortion or 
parturition only allows for the collection of one sample, and the fluid may be contaminated by 
vaginal secretions at time of collection. Microdialysis probes have the benefit of continuous 
analysis without multiple punctures, but only measure the unbound drug fractions, and thus may 
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greatly underestimate, or fail to detect, highly protein bound drugs [20]. Additionally, 
microdialysis probes may not be optimal for long term monitoring. Direct puncture of fetal 
membranes was chosen in the following studies to allow for collection of both allantoic and 
amniotic fluid, and to allow for collection over a period of ten or more days.  
 
TENDON EVALUATION 
Traditionally, toxicity studies have determined adverse effects based on clinical signs, 
blood work, and histological evaluations of tissues of interest. Given the athletic demands of the 
horse, it was vital to confirm that enrofloxacin did not affect tendon tensile strength or cartilage 
strength in treated animals. Flexor tendon tensile strength has been evaluated in equine studies 
investigating regenerative techniques [95], and may be one method to detect small weaknesses in 
tendon strength that would predispose foals to tendon rupture as is occasionally seen in humans 
with Achilles tendon rupture [96].    
 
ADVANCED IMAGING 
At a time when there is a significant pressure to reduce the use of animals in research, there 
is a critical need to develop noninvasive means, such as magnetic resonance imaging (MRI), for 
monitoring toxicity to cartilage and tendons over time. Traditionally, radiographs and ultrasound 
have been used to evaluate equine musculoskeletal disease, however both methods are relatively 
insensitive to articular surface changes. Most subtle early bony changes are not detectable on 
radiographs, and only severe joint effusion is visible. Ultrasonography is excellent for evaluating 
tendon and ligament lesions, but is only capable of detecting small areas of cartilage[97]. In 
addition, cartilage thickness and appearance is very easily influenced by operator error or 
ultrasound beam angle [57,98].  
As technology improved, and allowed for imaging of larger body segments, MRI became 
available for use in equine medicine. MRI has the advantage that it provides a non-invasive means 
of evaluating cross sectional and three dimensional views of joints and articular cartilage[99]. MRI 
is particularly well suited for analyzing cartilage because it images water and fat within the animal, 
and equine cartilage is roughly 70% water [50].  Many different MRI imaging sequences exist, 
and they are classified by the effect the radiofrequency pulse has on tissue magnetization.  
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T2 relaxation time, or transverse relaxation time, is dependent on cartilage hydration. 
Tissue relaxation times are usually determined using a gradient echo sequences, where a series of 
images are used to determine the relaxation time. A series of images composed of different T2- 
weighted relaxation times can t be fitted to an equation S= S*0exp (-1/T2) to create a single image 
of T2 relaxation time. Articular T2 relaxation time is affected by the collagen fibril network in the 
cartilage. Normal mature cartilage has a laminar appearance in T2 relaxation time maps [100], 
which is attributed to the properties of collagen fibrils causing a magic angle effect [101,102].  The 
histological zones of cartilage are determined by organization of cartilage, and appear distinct on 
T2 maps.  
Quantitative MRI (qMRI) can be used to evaluate proteoglycan content (T1p maps) and 
collagen structure (T2 maps) and has been used to evaluate cartilage damage, cartilage necrosis, 
and juvenile articular cartilage development. Recently, Martel and colleagues used qMRI to 
evaluate proteoglycan and collagen content as well as structure of neonatal equine epiphyseal 
cartilage with q3T MRI [103]. T2 relaxation time is affected by cartilage health, and in general 
increases in degenerating cartilage[104,105].  The expected pathologic changes in T2 relaxation 
times depend on species, chronicity of the lesion, and animal maturity.  Fibrous repairs of 
osteochondral defects are expected to have shorter T2 relaxation times, whereas hyaline-like 
repairs may exhibit prolonged T2 relaxation times [100,106].  Experimental enzymatic digestion 
of cartilage has demonstrated that T2 maps reflect the degree of collagen fibril network integrity 
[107]. Similar changes in T2 relaxation time can be seen in proteoglycan depleted cartilage [108].  
On the contrary, some fibrous cartilage has decreased relaxation times compared to controls 
[109,110]. 
While qMRI has been employed to monitor repair of experimentally induced lesions over 
time, one goal of the following dissertation is to validate the use of qMRI in toxicity studies. By 
comparing qMRI to traditional histology and radiographs, we hope to validate the use of qMRI for 
lesion detection in future toxicity studies.  
Anecdotal reports suggest that enrofloxacin can be administered to pregnant mares without 
apparent major musculoskeletal complications to the resulting foal. Given the current ambiguity 
surrounding the safety of enrofloxacin use in pregnant animals and its potential adverse effects on 
the fetus, there is a critical need to evaluate the relative safety of enrofloxacin to newborn foals 
when pregnant mares are treated with enrofloxacin in late gestation. Identifying a potential 
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negative impact of in utero fluoroquinolone exposure on the fetus and resulting foal is essential 
before recommending use of the drug in the veterinary clinical setting. Information from this 
dissertation will provides critical information for practitioners faced with resistant infections in 
pregnant animals. 
In summary, this dissertation will address the following questions:  
 
DISSERTATION AIMS 
To determine if fluoroquinolones cross the equine placenta and if they accumulate in the 
fetus or fetal fluids without affecting the developing fetus. In addition, to explore advanced 
imaging and biomechanical testing as methods for evaluating subtle toxicities and to allow for 
future long-term studies that reduce animal use.    
 
SPECIFIC AIM 1: Determine pharmacokinetics of enrofloxacin administered orally and 
intravenously to pregnant and non-pregnant stage using a cross-over design. 
1a) Does pregnancy affect the bioavailability, distribution, plasma concentrations and 
excretion of enrofloxacin? 
1b) Is oral enrofloxacin absorbed well in the horse, and is once a day dosing appropriate? 
 
SPECIFIC AIM 2: Evaluate the articular cartilage of long bones and the structure of tendons 
of fetuses from mares treated with intravenous enrofloxacin. 
2a) Do enrofloxacin and ciprofloxacin cross the equine placenta and reach MIC for common 
bacteria in fetal fluids and the fetus? 
2b) Are morphologic lesions detectable in long bone articular cartilage of the fetus after 
enrofloxacin administration to the mare?  
2c) Does exposure to enrofloxacin in utero cause detectable differences in fetal tendon 
morphology? 
 
SPECIFIC AIM 3: Evaluate articular cartilage of long bones and tendons in 35-day-old foals 
from mares treated with enrofloxacin during late pregnancy to determine if toxicity is load-
dependent. 
3a). Does enrofloxacin administration to late term pregnant mares cause changes in the long bone 
articular cartilage and tendon histology of foals at 35 days of age? 
3b). Are lesions detectable on radiographs in 35-day-old foals exposed to enrofloxacin in utero? 
3c). Can qMRI be used to detect lesions in foal tendons in cartilage, and do these findings correlate 
with changes seen on radiographs or histological evaluation?  
3d). Does enrofloxacin exposure in utero affect tendon and cartilage strength at 35 days of age? 
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3f).  Does enrofloxacin exposure in utero result in differences in chondrocyte mRNA expression 
or collagen production in the resulting 35-day-old foals?  
 
SPECIFIC AIM 4: Determine the effects of enrofloxacin exposure in on the first trimester 
equine fetus.  
3a). Determine fluoroquinolone concentrations in the fetal fluids in the early equine pregnancy.  
3b). Evaluate gross and histologic morphology of the 60-day-old equine fetus.  
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ABSTRACT 
Enrofloxacin, a fluoroquinolone antimicrobial with rapid bactericidal activity against 
gram-negative and gram-positive pathogens, may be an alternative to overcome unresponsive 
select cases of severe bacterial infections in pregnant mares. As pregnancy may affect drug 
bioavailability, distribution, metabolism, and excretion, dose adjustment might be necessary for 
pregnant mares. The objectives of this study were to determine the disposition of orally and 
intravenously administered enrofloxacin in pregnant and non-pregnant mares.  Six light-breed, 
healthy pregnant mares (260 d gestation) were randomized in a crossover design for administration 
of single dose of either intravenous (5mg/kg) or oral compounded (7.5mg/kg) enrofloxacin with 
the opposite dose administered after a 7d washout period. The protocol was repeated 45-60 days 
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post-partum, 14-30 days after foals were weaned.  Plasma samples were obtained via venipuncture 
at 0, 5, 10, 20, 30, 45, 60, 90 min, and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72h after enrofloxacin 
administration. Enrofloxacin and ciprofloxacin concentrations were measured by LC-MS/MS. 
Concentration versus time data were analyzed based on non-compartmental pharmacokinetics.  
Enrofloxacin AUC0–∞ was significantly higher in pregnant mares than non-pregnant mares after 
PO administration and tended to be higher after IV administration. Ciprofloxacin maximum 
plasma concentration (Cmax) and concentration at 24 h (C24h) were higher, and half-life of the 
terminal phase (t½λz) was longer in pregnant mares than non-pregnant mares after oral 
administration. Similarly, ciprofloxacin C24h was higher in pregnant mares with intravenous 
administration. Oral bioavailability did not differ based on pregnancy status.  Limitations of the 
study were that only six healthy mares were assessed, and disease may affect the endpoints 
evaluated. Other breed types and horse populations may have different results. A lack of 
established enrofloxacin AUC/MIC targets for equine pathogens limits pharmacokinetic-
pharmacodynamic conclusions. In conclusion, the oral form of enrofloxacin used in this study was 
well absorbed, and oral bioavailability was comparable to previous studies. While differences in 
enrofloxacin and ciprofloxacin pharmacokinetics were seen between pregnant and non-pregnant 
mares, the recommended drug dose and dose intervals are appropriate for MIC < 0.25 µg/ml. 
Dosages may need to be adjusted for bacteria with a MIC > 0.25 µg/ml. 
Keywords: fluoroquinolone, ciprofloxacin, pregnancy, LC-MS/MS, horse 
 
INTRODUCTION 
Antimicrobial therapy is necessary in equine practice to treat bacterial infections during 
pregnancy; however, the pharmacokinetics and pharmacodynamics of many antimicrobials 
during pregnancy are not known. β-Lactam antibiotics and aminoglycosides cross the equine 
placenta [1] and are commonly used in pregnant mares [2]. Cephalosporin antibiotics are also 
commonly and safely used during equine pregnancy but do not cross the equine placenta [3]. 
Potentiated sulphonamides cross the equine placenta [4] and are frequently used to treat 
infections in late-pregnant mares [2,5,6]. 
Fluoroquinolones act rapidly in a dose-dependent fashion and provide a post-antibiotic 
effect [7]. This class of drug inhibits topoisomerases II and IV, thus inhibiting DNA synthesis and 
separation in dividing bacteria [8]. Enrofloxacin is a fluoroquinolone antimicrobial with 
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bactericidal activity against gram-negative and gram-positive pathogens, and is metabolized in 
vivo into ciprofloxacin, an antimicrobial also effective against many pathogens [7,9].  
Pregnancy induces physiologic changes in humans such as increases in plasma volume, 
total body water, and renal blood flow, while gastric emptying can be delayed [10]. Additionally, 
hormonal fluctuations during pregnancy can induce changes in hepatic microsomal enzyme 
activity [10,11]. These changes may affect bioavailability, distribution, metabolism, and excretion 
of many medications [10,12]. As a result, adjustment of dose or dosing interval during pregnancy 
may be needed to optimize maternal and fetal health [13].  Enrofloxacin is toxic in a dose-
dependent manner, thus making dose optimization important, particularly in the pregnant mare 
[14,15]. 
The suggested therapeutic dose of enrofloxacin in horses is 5 mg/kg q24h for intravenous 
administration or 7.5 mg/kg q24h for oral administration [16,17]. The intravenous enrofloxacin 
formulation is used extra-label in horses, and can be irritating when administered intravascular or 
orally [18,19]. A recently available compounded liquid oral formulation is more practical and may 
have fewer side effects than intravenous administration; however, absorption and 
pharmacokinetics have not been evaluated.  
The present study was designed to assess the pharmacokinetics of enrofloxacin 
administration to pregnant mares. The objectives were to determine the pharmacokinetics of oral 
and intravenous enrofloxacin administered to mares during both late gestation and postpartum. We 
hypothesized that the pharmacokinetics of enrofloxacin, and its active metabolite ciprofloxacin, 
differ between pregnant mares and non-pregnant mares. 
 
MATERIALS AND METHODS 
The study protocol was approved by the University of Illinois Institutional Animal Care 
and Use Committee (protocols, #14243 and #17245). and was carried out between 2016 and 2017. 
Six healthy light-breed (four Standardbred, one Thoroughbred, and one cross) pregnant 
mares were enrolled at 260 days gestation and housed at the Veterinary Medicine Research Farm 
at the University of Illinois in Urbana, Illinois. Immediately before enrollment, physical 
examination and transrectal placental ultrasonography of pregnant mares revealed no 
abnormalities, and all mares went on to foal normally after the conclusion of the study. The animals 
were kept on pasture and supplemented with grass hay and trace minerals.  
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Mares were kept on pasture and were not fasted before antibiotic administration; however, 
supplemental hay was not provided until sixty minutes after antibiotic administration. The mares 
were randomly treated in a cross-over design with a single dose of either intravenous (5mg/kg bwt, 
Baytril®)a or compounded oral (7.5mg/kg bwt)b enrofloxacin. The oral formulation is an oil-based 
suspension (200 mg/ml) and was administered orally using a 35 ml syringe. This compounded 
suspension is proprietary but consisted of two vehicles, enrofloxacin, paraben-preserved water, 
and flavor. Three different batches were used in the study, and all batches were used within 90 
days of compounding. Stability information provided by the compounder from a third-party 
reference laboratory demonstrated drug strength consistent with the labeled dose (200 mg/ml), and 
no change in drug concentration for 210 days after compounding.  
Plasma samples were obtained via jugular venipuncture at 0, 5, 10, 20, 30, 45, 60, 90 min, 
and 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 h after enrofloxacin administration (IV or PO).  The opposite 
route of administration was performed following a seven-day washout period with the entire 
protocol repeated 45-60 days post-partum. Foals were weaned at 30 days post-partum for another 
study, and the protocol was repeated 14-30 days after weaning. Thus, at the time of post-partum 
enrofloxacin administration, none of the mares were lactating or pregnant. Blood samples were 
collected in heparinized tubes and centrifuged at 600g/x10 minutes and plasma samples stored at 
-80oC until analysis.  
 
LC-MS assessments and validation 
Concentrations of total plasma enrofloxacin and ciprofloxacin were measured by liquid 
chromatography-tandem mass spectrophotometry (LC-MS) in the Metabolomics Laboratory of the 
Roy J. Carver Biotechnology Center, University of Illinois Urbana-Champaign. Samples were 
prepared by mixing 150 µL plasma with 600 µL acetonitrile and 6 µL 5 µg/mL ofloxacin. After 
vortex, the mixture was centrifuged (5 min, 8,000 rpm), and the supernatant was used for 
instrument injection.  Samples were analyzed with the 5500 QTRAP LC/MS/MS systemc. 
Software Analyst 1.6.2 was used for data acquisition and analysis. The 1200 series HPLC systemd 
includes a degasser, an autosampler, and a binary pump. The LC separation was performed on an 
Agilent SB-Aq columnd (4.6 x 50 mm, 5 µm) with mobile phase A (0.1 % formic acid in water) 
and mobile phase B (0.1 % formic acid in acetonitrile). The flow rate was 0.3 mL/min. The linear 
gradient was as follows: 0-2 min, 95 % A; 10-13 min, 2 % A; 13.1-17 min, 95 % A.  The 
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autosampler was set at 15°C. The injection volume was 1 µL. Mass spectra were acquired under 
electrospray ionization (ESI) with the ion spray voltage of +5000 V. The source temperature was 
450 °C. The curtain gas, ion source gas 1, and ion source gas 2 were 33, 50, and 60 psi, 
respectively. Multiple reaction monitoring (MRM) was used for quantitation with MRM transition 
time and retention time (min) of m/z 360.1 --> m/z 316.1; 9.4 min (ciprofloxacin), m/z 332.1 --> 
m/z 288.1; 9.6 min (enrofloxacin), and m/z 362.1 --> m/z 318.1; 9.3 min (ofloxacin, internal 
standard).  
The limit of detection was 0.3 ng/ml, lowest limit of quantitation was 1 ng/ml, and linearity 
was 1 - 1500 ng/mL for both enrofloxacin and ciprofloxacin. Overall, all standard curves have 
correlation coefficient values larger than 0.998 (the weighting factor is 1/x). 
The recovery was calculated by the signal ratio of spiked standard into the blank plasma to 
spiked standard into 60 % acetonitrile for 6 s. Enrofloxacin recovery ranged from 94.4 ± 3.5 % for 
5 ng/ml to 97.0 ± 3.8 % for 500 ng/ml (mean ± SD). Ciprofloxacin recovery ranged from 91.4 ± 
2.2 % for 500 ng/ml to 93.7 ± 2.3 % for 5 ng/ml.  Ofloxacin recovery was 97.3 ± 2.7%. The matrix 
effect was checked with constant post-column infusion experiment.  There was no notable signal 
up and down, which indicates the absence of matrix effect.  
Between-run and within-run accuracy and precision were calculated by measuring six 
samples of enrofloxacin and ciprofloxacin at concentrations of 5, 50, and 500 ng/ml, and 
measurements were repeated on three different days. Enrofloxacin had a within-run accuracy of 
95.6 ± 2.1% to 99.1 ± 0.6%, and a between- run accuracy of 97.3 ± 2.0% to 98.4 ± 1.0%, and 
ciprofloxacin had a mean within-run accuracy of 95.4 ± 2.3 to 99.6 % ± 1.2 %, and between- run 
accuracy of 97.0 ± 2.4% to 99.2 ± 0.9%. Coefficients of variations between-run and within-run for 
enrofloxacin ranged from 0.9-1.6% and 1.1-3.5%, respectively, whereas coefficients of variations 
for ciprofloxacin between- run and within-run ranged from 0.9- 2.4% and 1.0- 5.4 %, respectively.  
 Plasma stability data was calculated at room temperature and at -75°C (n = 6).  Samples 
stored in the autosampler for 24 h at 15 °C had bias of 3.2-4.8% and samples stored at -75 °C for 
2 months had a bias of 1.3-3.4%.  
 
Pharmacokinetics analyses 
For each horse, plasma enrofloxacin and ciprofloxacin concentration versus time data were 
analyzed based on non-compartmental pharmacokinetics using a commercially available 
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softwaree.  Maximum plasma concentrations (Cmax) and times to achieve maximum plasma 
concentrations (Tmax) were obtained directly from the plasma concentration data. The rate constant 
of the terminal phase (λz) was determined by linear regression of the logarithmic plasma 
concentration versus time curve using a minimum of four data points.  The half-life of the terminal 
phase (t½λz) was calculated as ln 2 divided by λz. The area under the concentration-time curve 
(AUC) and the area under the first moment of the concentration-time curve (AUMC) were 
calculated using the trapezoidal rule, with extrapolation to infinity using C48h/λz, where C48h is the 
plasma concentration at the 48h sampling time. Mean residence time (MRT) was calculated as 
AUMC/AUC.  Bioavailability was calculated as (AUCPO /AUCIV) x (doseIV/dosePO). Apparent 
volume of distribution based on the AUC (Vdarea) was calculated as IV dose /AUC• λz, apparent 
volume of distribution at steady state (Vdss) was calculated as (IV dose/AUC)/(AUMC/AUC), and 
systemic clearance (CL) was calculated from IV dose/AUC. The AUC/MIC ratios were calculated 
as AUC24/MIC, and ratios were calculated in three different ways using the enrofloxacin AUC24, 
ciprofloxacin AUC24, or an AUC24 that combined both the enrofloxacin AUC24 and ciprofloxacin 
AUC24.  
   
Statistical analysis 
Normality of the data was assessed based on histograms of differences in means, normal 
quantiles plots of the residuals, and the Shapiro-Wilk test. Constant variance of the data was 
assessed with Levene’s test.  Comparison of each pharmacokinetic variable between pregnant and 
non-pregnant mares was performed using the paired t-test (parametric data), or the Wilcoxon 




There were no adverse effects noted after administration of oral or intravenous doses of 
enrofloxacin to the mares or resulting foals. Profile plots for enrofloxacin and ciprofloxacin 
concentrations are depicted in Figures 1 and 2. After IV injection, there was no difference in 
enrofloxacin elimination half-life (t½λz), volume of distribution (Vdarea), mean residence time 
(MRT), or C24h between pregnant or non-pregnant mares (Table 3.1).  There was a tendency for 
systemic clearance (CL) to be lower and area under the plasma concentration versus time curve 
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(AUC0–∞) to be higher in pregnant mares compared to non-pregnant mares after administration of 
a single intravenous dose of enrofloxacin. No difference in ciprofloxacin Cmax or Tmax was seen 
after IV enrofloxacin administration to pregnant and non-pregnant mares. Plasma ciprofloxacin 
concentrations 24 h after IV enrofloxacin administration were higher in pregnant  than in non-
pregnant mares, and there was a tendency for ciprofloxacin AUC0–∞ to be higher, and t½λz to be 
longer in pregnant than non-pregnant mares. One pregnant mare in the IV administration group 
had a t½λz double that of the other five mares, contributing to the larger variability seen in the t½λz 
and Vd in the pregnant IV group than the other three groups. 
For oral administration of enrofloxacin, there was a greater enrofloxacin area under the 
curve concentration vs. time curve (AUC0–∞) in pregnant mares than non-pregnant mares (Table 
2), and there was a tendency for Tmax to be longer, and C24h to be higher in pregnant mares than 
non-pregnant mares.  Ciprofloxacin Cmax after oral enrofloxacin administration was lower in 
pregnant mares than in non-pregnant mares, ciprofloxacin t½λz was longer in pregnant mares, and 
ciprofloxacin C24h was higher in pregnant  mares than non-pregnant mares (Table 3.2). There was 
a tendency for time to maximum plasma ciprofloxacin concentration to be longer in pregnant  
mares than non-pregnant mares. Ciprofloxacin AUC0–∞ were not different between pregnant and 
non-pregnant mares after oral enrofloxacin administration.  Oral bioavailability was not 
significantly different between the groups (pregnant mares 67.15 ± 11.36 %; non-pregnant mares 
52.56 ± 16.14 %). 
When oral and intravenous enrofloxacin administration were compared in pregnant mares, 
ciprofloxacin C24h showed a tendency to be higher after IV administration than oral (Table 3). In 
non-pregnant mares, enrofloxacin AUC0–∞ tended to be greater after IV administration, and 
enrofloxacin C24h was significantly higher after IV administration than PO.  In non-pregnant mares, 
ciprofloxacin Cmax, AUC0–∞, and C24h were lower after IV enrofloxacin administration and after 
oral enrofloxacin administration (Table 3.3).  When enrofloxacin or ciprofloxacin AUC24 was used 
to calculate AUC:MIC ratios, the AUCs obtained in this study were adequate for pathogens with 
an enrofloxacin MIC of < 0.25 µg/ml (Table 3.4).   
 
DISCUSSION 
This is first report to compare pharmacokinetic parameters in pregnant mares during late-
gestation and non-pregnant mares. Despite minor variations in the endpoints assessed in the 
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present study, the recommended enrofloxacin dose of 5 mg/kg intravenously, or 7.5 mg/kg orally, 
is appropriate for treatment of susceptible organisms (MIC< 0.25 µg/mL) in both categories. Our 
findings suggest that the oral preparation of enrofloxacin used herein is well-absorbed, and 
bioavailability in the current study was similar to previous studies administering 5 mg/kg of 
crushed enrofloxacin tablets intragastrically (62.53 ± 19.65%) [20], or administering a 10% 
enrofloxacin poultry formulation orally (65.6% ± 14.9%) to non-pregnant mares [21].  No oral 
lesions were seen in any of the mares, in contrast to the lesions previously reported with oral 
administration of the intravenous product [19]. This suggests that mucosal irritation was likely due 
to n-butyl alcohol or benzyl alcohol present in the intravenous preparation, rather than enrofloxacin 
itself. Given the lack of oral lesions, good drug stability, and the satisfactory bioavailability, the 
oral formulation used in this study seems to be a suitable product to treat infections with 
enrofloxacin susceptible microorganisms.  
Enrofloxacin t½λz of the terminal phase after both intravenous and oral administration was 
slightly longer in both pregnant and non-pregnant mares than reported in previous studies 
[20,22,23] while shorter than the t½λz reported in foals (~17h) [16]. Moreover, t½λz was remarkably 
longer (~8h) in the current study than the reported t½λz of 1.4 to 2.5 h in rabbits, calves and dogs 
[24,25]. There were no differences in ciprofloxacin Tmax or Cmax between pregnant and non-
pregnant mares after intravenous enrofloxacin administration.  
While there was no difference in enrofloxacin Cmax after oral enrofloxacin administration, 
ciprofloxacin Cmax was lower in pregnant mares than non-pregnant mares. Despite this difference 
in ciprofloxacin Cmax after oral enrofloxacin administration, there was no difference in the C24 
ciprofloxacin concentrations. Ciprofloxacin AUC24 tended to be greater in pregnant than non-
pregnant mares; however, AUC0–t and AUC0–∞ were not different. Since pregnancy is associated 
with delayed gastric emptying in humans [10], and both enrofloxacin and ciprofloxacin Tmax 
tended to be longer in pregnant than non-pregnant mares, it is possible that the initial decrease in 
Cmax, and AUC24  could be due to delayed gastric emptying, although effects of pregnancy on 
gastrointestinal transit time are unknown in the horse. Delayed transit time in the small intestine 
may also explain the tendency for increased enrofloxacin bioavailability if delayed transit allowed 
for increased absorption.  
Finally, it is possible that a first pass effect contributed to the larger enrofloxacin AUC0–∞ 
in pregnant mares than non-pregnant mares. Ciprofloxacin accounted for 17.2% (pregnant) or 
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16.0% (non-pregnant) of the enrofloxacin AUC0–∞ after intravenous enrofloxacin administration, 
and 20.6% (pregnant) or 38.2 % (non-pregnant) of the enrofloxacin AUC0–∞ after oral 
administration.  The larger ciprofloxacin: enrofloxacin AUC0–∞  ratio after oral administration 
supports a first pass effect previously described after enrofloxacin administration to horses [26]. 
Additionally, the differences observed in oral enrofloxacin AUC0–∞,  and in ciprofloxacin: 
enrofloxacin ratios suggest that the first pass effect may be less pronounced in pregnant mares than 
non-pregnant mares. It remains to be determined if this difference is due to pregnancy associated 
changes in hepatic blood flow or hepatic enzyme activity. Enrofloxacin is metabolized by 
cytochrome p450 enzymes, and hepatic enzyme activity during pregnancy appears to be species 
specific. The activity of many hepatic cytochrome p450 enzymes decreases in pregnant rats and 
mice [27,28],  while only cytochrome p450 3A decreases in dairy cattle [29], and pregnancy 
associated changes are unknown in the horse. Studies in poultry and carp have shown that 
iatrogenic changes in cytochrome p450 enzyme expression affect enrofloxacin pharmacokinetics 
[30,31], suggesting it is possible that pregnancy associated changes in enzymatic activity could 
have an effect on enrofloxacin metabolism in the horse.  
Early enrofloxacin pharmacokinetic studies used an agar well microbiological diffusion 
assay, which did not allow investigators to differentiate between ciprofloxacin and enrofloxacin 
[17,20,23]. More recent studies used reverse phase high-performance liquid chromatography, 
which allows for differentiation between fluoroquinolones [22,32,33]. The analytical approach 
used in the present study enabled the precise measurement of pharmacokinetic curves of both 
enrofloxacin and its metabolite ciprofloxacin, as LC-MS combines high-performance liquid 
chromatography with mass spectrometry to reduce experimental error and improve accuracy. 
Precise determination of enrofloxacin and ciprofloxacin concentrations is valuable when assessing 
drug toxicity and drug dosages based on pathogen MIC. 
Ciprofloxacin t½λz tended to be longer in pregnant than the non-pregnant mares when 
enrofloxacin was administered intravenously. In addition, the t½λz of this metabolite was 
significantly longer in pregnant mares than non-pregnant mares when enrofloxacin was 
administered orally. While early studies assessing enrofloxacin pharmacokinetics were unable to 
assess ciprofloxacin concentrations due to the bioassay used, ciprofloxacin t½λz  reported by 
Boeckh and collaborators were similar to this study [21]. Given that ciprofloxacin has known 
adverse effects such as colitis and laminitis in the horse when administered intravenously [34], 
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further research is needed to determine plasma ciprofloxacin concentrations after prolonged 
enrofloxacin administration to pregnant mares, as prolonged high plasma concentrations could 
potentially cause serious complications.  
As fluoroquinolones are concentration-dependent antimicrobials, the absolute 
concentrations are more important than time exceeding MIC for maximum efficacy. In the present 
study, the AUC0–∞ for enrofloxacin was greater in late-gestation mares than non-pregnant mares 
after oral administration, and tended to be greater after intravenous administration, which is 
consistent with the AUC0–∞ reported elsewhere [21,22].  Enrofloxacin AUC0–∞ for late-gestation 
mares was comparable to a previous study using a bioassay reporting the combined AUC0–∞ of 
enrofloxacin and ciprofloxacin [23]. In contrast, the AUC0–∞ for non-pregnant mares was lower, 
but similar to the values reported in another study using liquid chromatography to measure drug 
concentrations  [21]. These findings are important for determining whether dosing adjustments are 
needed when faced with bacterial infections with intermediate susceptibilities. 
The ratio of AUC24: MIC has been used to predict antimicrobial efficacy, and a study 
assessing fluoroquinolone efficacy for gram-negative infections in mice suggested that a AUC24: 
MIC > 100 is optimal for bacterial cure [35]. At the doses given in the current study, and using 
published MICs for common equine bacterial isolates, these criteria are met consistently only for 
for E .coli isolates (Table 4).  However, the AUC24:MIC ratio needed for clinical cure varies, and 
in animals with competent immune systems it has been suggested that ratios of 30 to 60 may be 
sufficient for some infections [36,37]. Using these guidelines, the enrofloxacin AUCs obtained in 
the present study would be appropriate for bacterial isolates with an MIC of <0.25µg/mL, and 
questionable for isolates that fall in the intermediate range of 0.25 to 1.025µg/mL. Pathogens with 
an MIC<0.5 µg/ml are considered susceptible according to 2008 CLSI breakpoints[38]; however, 
pathogens with an MIC> 0.25µg/mL should be deemed of intermediate susceptibility at the 
dosages used in this study.  
 One limitation of using AUC24: MIC ratios as a marker of clinical efficacy is the fact that 
ciprofloxacin is an active metabolite of enrofloxacin. If enrofloxacin and ciprofloxacin have an 
additive effect in bacterial infections, then the AUC24/MIC ratio may be calculated by adding 
enrofloxacin and ciprofloxacin AUC24, as was calculated in previous poultry and bovine studies 
[38,39]. However, if enrofloxacin and ciprofloxacin act synergistically, or in cases where 
ciprofloxacin MIC90 and enrofloxacin MIC90 are vastly different (Strep. Zooepidemicus, for 
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example), then addition of the two AUC24 is likely not appropriate [26]. In such cases, it may be 
preferable to evaluate only the enrofloxacin AUC24: MIC90 ratios, as Peyrou and collaborators did 
in an equine study [26]. In the present study, combining both AUC24 would change only the 
interpretation of susceptibility for intravenous enrofloxacin administration to non-pregnant 
animals infected with pathogens with an MIC of 0.25 µg/ml (Table 3.4).  
 The AUC24: MIC ratio cut-offs for clinical cure and bacterial resistance are not only 
antibiotic and species specific, but pathogen specific as well. While there is no in vivo data for 
enrofloxacin, or for equine infections, in vitro studies with ciprofloxacin and human dosing 
regimens have suggested that AUC/MIC ratios > 45 h may be sufficient for bacterial and clinical 
cure of certain gram-positive bacteria such as Streptococcus pneumoniae [37,40,41]. A cut-off 
ratio of 50 h was chosen for the current study based on published ratios for in vivo cut-offs for 
human gram-positive pathogens (>40 h),  > 46 h  for bactericidal action with Mannheimia 
haemolytica in calves [42], and  > 60 h used in a previous equine fluoroquinolone study [43].  
Other authors have chosen separate cut-offs for gram-positive (>50 h) and gram-negative (>100 
h) organisms in enrofloxacin-treated pigs [36], or for low likelihood (>60 h) and high likelihood 
(>125 h) of successful clinical outcomes after marbofloxacin administration in horses [43]. Thus, 
while the dosages used in this study are appropriate for most bacterial pathogens with an MIC < 
0.25 µg/ml, dose may need to adjusted for gram-negative pathogens with an MIC>0.06 µg/ml 
(non-pregnant) or MIC >0.12 µg/ml (pregnant) horses to reach an AUC24: MIC predictive of a 
high chance of a successful clinical outcome.  
The recommended AUC24:MIC ratios for a cure rate are based on free plasma 
concentrations. However, previous work in dogs, calves, and pigs demonstrated that for 
antimicrobials with moderate protein binding, such as enrofloxacin and ciprofloxacin, total plasma 
AUCs are similar to the tissue AUCs [36,38,44]. While local tissue concentrations were not 
measured in the current study, fluoroquinolones are also moderately protein bound in the plasma 
and penetrate most tissues well in the horse [20].  Reported endometrial enrofloxacin 
concentrations after systemic administration range from 1.689 µg/g after an single dose [33] to 
10.19 µg/g (n=2) two hours after the 6th dose of enrofloxacin [20], and recently it has been shown 
that both enrofloxacin and ciprofloxacin cross the equine placenta [45]. Similarly, enrofloxacin 
and ciprofloxacin reach synovial fluid concentrations similar to the plasma in horses [20] and reach 
interstitial fluid similar to plasma concentrations in calves [38] and pigs [36], suggesting that total 
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plasma AUC24:MIC ratios are sufficient to estimate local interstitial fluid concentrations at the site 
of infection [26,44].  
Appropriate antimicrobial stewardship necessitates the selection of the optimal drug for a 
given microorganism without compromising patient health. Regardless of in vitro sensitivity 
patterns, antimicrobial efficacy depends on multiple factors, including the pathogen present, the 
infected tissue, the potential synergistic effects of ciprofloxacin and enrofloxacin, systemic 
concentrations after multiple doses, and the known post-antibiotic effect observed with 
fluoroquinolones [7]. Pregnancy can affect drug metabolism and excretion, and these changes are 
especially important to consider for medications with apparently narrow therapeutic windows, or 
a large volume of distribution that may encompass both fetal tissues and fluids. Given the few 
differences in pharmacokinetic variables in this study, both 5 mg/kg IV or 7.5 mg/kg PO 
enrofloxacin appear to be the appropriate doses to treat susceptible equine pathogens (MIC < 0.25 
µg/ml) in the late-gestation mare. However, if enrofloxacin is used to treat pathogens with 
intermediate susceptibility to enrofloxacin (4> MIC> 0.25 µg/ml), dosages may need to be 
adjusted, and further studies exploring the safety and efficacy of increased dosages are warranted.  
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TABLES AND FIGURES 
 
Table 3.1:  Pharmacokinetic variables (mean ± SD) for enrofloxacin and its main metabolite 
ciprofloxacin after IV administration of a single dose of enrofloxacin (5 mg/kg of body weight) to 
6 healthy mares.  Mares were dosed during late gestation (260-275 days) and again 45 to 60 days 





Pregnant  Non-pregnant 
Enrofloxacin    
t½λz (h) 9.2 ± 5.5 8.1 ± 0.5 0.611 
Cinitial (µg/mL) 8.126 ± 4.145 5.853 ± 1.809 0.074 
Vdarea (L/kg) 5.0 ± 4.5 5.0 ± 1.1 0.988 
Vdss (L/kg) 2.6 ± 0.9 2.7 ± 1.3 0.795 
CL (ml/h/kg) 338 ± 100 429 ± 89 0.078 
AUC24 (µg • h/mL) 14.71 ± 3.99  11.42 ± 2.48 0.062 
AUC0–t (µg • h/mL) 15.67 ±4.26 11.94 ± 2.32 0.067 
AUC0–∞ (µg • h/mL) 15.81 ± 4.18 12.03 ± 2.32 0.061 
MRT (h) 7.56 ± 1.72 5.98 ± 1.77 0.139 
C24h (µg/mL) 0.086 ± 0.042 0.050 ± 0.032 0.224 
Ciprofloxacin    
Cmax (µg/mL) 0.272 ± 0.127 0.240 ± 0.064 0.535 
Tmax (h)* 0.6 (0.5 – 6.0) 0.6 (0.5 – 0.75) 0.313 




AUC0–t (µg • h/mL) 2.63 ± 0.73 1.89 ±  0.39 0.078 
AUC0–∞ (µg • h/mL) 2.72 ± 0.7 1.93 ± 0.41 0.065 
C24h (µg/mL) 0.032 ± 0.011 0.017 ± 0.005 0.041 
t½λz (h) 11.4 ± 4.0 8.6 ± 1.5 0.085 
*Median and range 
t½λz = half-life of the terminal phase. Cinitial = Initial measured plasma concentration (at 30 min). 
Vdarea = Apparent volume of distribution based on AUC. Vdss = Apparent volume of distribution 
at steady state. CL = Systemic clearance. AUC24= Area under the plasma concentration versus 
time curve from 0 to 24h. AUC0–t = Area under the plasma concentration versus time curve to limit 
of quantification. AUC0–∞ = Area under the plasma concentration versus time curve extrapolated 
to infinity. MRT = Mean residence time. Cmax = Maximum plasma concentration (observed). Tmax 





Table 3.2:  Pharmacokinetic variables (mean ± SD) for enrofloxacin and its main metabolite 
ciprofloxacin after oral administration of a single dose of enrofloxacin (7.5 mg/kg of body weight) 
to 6 healthy mares.  Mares were dosed during late gestation (260-275 days) and again 45 to 60 




Pregnant  Non-pregnant 
Enrofloxacin    
Cmax (µg/mL) 1.636 ± 0.587 1.777 ± 1.432 0.862 
Tmax (h)* 3.5 (0.5 – 6.0) 1.25 (0.1 – 4.0) 0.063 
AUC24 (µg • h/mL) 14.02 ± 4.04 8.39 ± 1.86 0.046 
AUC0–t (µg • h/mL) 15.62 ± 4.73 9.06 ± 2.11 0.044 
AUC0–∞ (µg • h/mL) 15.74 ± 4.68 9.20 ± 2.17 0.046 
C24h (µg/mL) 0.153 ± 0.079 0.062 ± 0.039 0.055 
t½λz (h) 7.5 ± 0.8 8.0 ± 2.2 0.540 
F (%)  67.1 ± 11.4 52.6 ± 16.1 0.108 
Ciprofloxacin    
Cmax (µg/mL) 0.245 ± 0.089 0.416 ± 0.200 0.048 
Tmax (h)* 3.0 (1.5 – 5.0) 1.3 (0.8 – 4) 0.094 
AUC24 (µg • h/mL) 2.56 ± 0.99 3.07 ± 0.79 0.091 
AUC0–t (µg • h/mL) 3.17 ± 1.20 3.51 ± 0.85 0.305 
AUC0–∞ (µg • h/mL) 3.24 ± 1.19 3.61 ± 0.88 0.273 
C24h (µg/mL) 0.048 ± 0.014 0.037 ± 0.008 0.029 
t½λz (h) 10.6 ± 1.0 9.1 ± 0.9 0.040 
*Median and range 
t½λz = half-life of the terminal phase. AUC0–24h = Area under the plasma concentration versus 
time curve from time 0 to 24 h. AUC0–t = Area under the plasma concentration versus time curve 
to limit of quantification. AUC0–∞ = Area under the plasma concentration versus time curve 
extrapolated to infinity. Cmax = Maximum plasma concentration (observed). Tmax = Time to 
maximum plasma concentration (observed). C24h = Plasma concentrations 24 h after 




Table 3.3:  Pharmacokinetic variables (mean ± SD) for enrofloxacin and its main metabolite 
ciprofloxacin after IV (5mg/kg) or oral (7.5 mg/kg) administration of a single dose of enrofloxacin 
to six healthy mares.  Mares were dosed during late gestation (260-275 days) and again 45 to 60 






Enrofloxacin    
t½λz (h) 9.2 ± 5.5 7.5 ± 0.8 0.449 
AUC24 (µg • h/mL) 14.71 ±  3.99  
0.0461 
14.02 ± 4.04 0.447 
AUC0–t  (µg • h/mL) 15.67 ±4.26 15.62 ± 4.73 0.970 
AUC0–∞ (µg • h/mL) 15.81 ± 4.26 15.74 ± 4.68 0.955 
C24h (µg/mL) 0.086 ± 0.042 0.153 ± 0.079 0.120 
Ciprofloxacin    
Cmax (µg/mL) 0.272 ± 0.127 0.245 ± 0.089 0.583 
Tmax (h)* 0.6 (0.5 – 6.0) 3.0 (1.5 – 5.0) 0.177 
AUC24 (µg • h/mL) 2.25 ± 0.67  2.56 ± 0.99 0.265 
AUC0–t(µg • h/mL) 2.63 ± 0.73 3.17 ± 1.20 0.171 
AUC0–∞ (µg • h/mL) 2.72 ± 0.71 3.24 ± 1.19 0.177 





Enrofloxacin    
t½λz (h) 8.1 ± 0.5 8.0 ± 2.2 0.969 
AUC24 (µg • h/mL) 11.42 ± 2.48 8.39 ± 1.86 0.047 
AUC0–t (µg • h/mL) 11.94 ± 2.33 9.06 ± 2.11 0.055 
 AUC0–∞ (µg • h/mL) 12.03 ± 2.32 9.20 ± 2.17 0.066 
C24h (µg/mL) 0.050 ± 0.032 0.062 ± 0.039 0.001 
Ciprofloxacin    
Cmax (µg/mL) 0.272 ± 0.127 0.416 ± 0.200 0.033 
Tmax (h)* 0.6 (0.5 – 6.0) 1.3 (0.8 – 4) 0.091 
AUC24 (µg • h/mL) 1.71 ± 0.32 3.07 ± 0.79 0.001 
AUC0–t (µg • h/mL) 1.89 ± 0.39 3.51 ± 0.85 0.001 
 AUC0–∞ (µg • h/mL) 1.94 ± 0.41 3.61 ± 0.88 0.001 





Table 3.4a: MIC50 and MIC90 for commonly isolated equine pathogens. MIC data obtained from 
§Trundell et al 2017 [131] , ⌘Ferrer and Palomares 2018 [14],*Estell et al 2016[132].  
Common equine pathogens     
Pathogen Origin Enrofloxacin 
MIC50 
Enrofloxacin MIC90  Ciprofloxacin 
MIC90 
Escherichia coli Endometrial 0.25
⌘ 0.5⌘  0.031§ 
Strep. 
zooepidemicus Endometrial 
1.0⌘ 1.0⌘  4.0§ 
Enterobacter 
spp Endometrial 
0.5⌘ 2.0⌘   
Klebsiella spp Endometrial 0.5
⌘ 0.5 ⌘  1.0§ 
 Lower airway 
≤0.25* ≤0.5*   
Enterococcus 
spp Endometrial 
2.0⌘ 2.0⌘   
Pseudomonas 
aeruginosa Endometrial 














Table 3.4b: Mean AUC24 enrofloxacin and ciprofloxacin after IV (5 mg/kg) or oral (7.5 mg/kg) administration of a single dose of 
enrofloxacin (n=6). Mares were dosed during late gestation (260-275d) and again 45 to 60d post-partum, 15- 30 days after weaning. 
MIC values where AUC24:MIC are > 50 in bold. * AUC= AUC24 (µg • h/mL) after a single dose. 
ENROFLOXACIN  MIC values (µg/ml) 
 Dose AUC* 
0.03 0.06 0.12 0.25 0.5 1 2 4 8 
Pregnant 5 mg/kg IV 14.7 490 245 123 59 29 15 7.4 3.7 1.8 
 7.5 mg/kg PO 14.0 467 233 117 56 28 14 7 3.5 1.8 
Postpartum 5 mg/kg IV 11.4 380 190 95 46 23 11 5.7 2.9 1.4 
 7.5 mg/kg PO 8.4 280 140 70 33 17 8.4 4.2 2.1 1.1 
CIPROFLOXACIN  MIC values (µg/ml) 
 Dose AUC* 0.03 0.06 0.12 0.25 0.5 1 2 4 8 
Pregnant 5 mg/kg IV 2.25 75 37.5 18.8 9 4.5 2.3 1.1 0.6 0.3 
 7.5 mg/kg PO 2.56 85 43 21.3 10.2 5.1 2.6 1.3 0.6 0.3 
Postpartum 
5 mg/kg IV 1.71 57 29 14 6.8 3.4 1.7 0.9 0.4 0.2 
 7.5 mg/kg PO 3.07 102 51 26 12 6.1 3.1 1.5 0.8 0.4 
CIPROFLOXACIN + ENROFLOXACIN MIC values (µg/ml) 
 Dose AUC* 0.03 0.06 0.12 0.25 0.5 1 2 4 8 
Pregnant 5 mg/kg IV 16.95 565 282 141 68 34 17 8.4 4.2 2.1 
 7.5 mg/kg PO 16.56 552 276 138 66 33 17 8.2 4.1 2.1 
Postpartum 5 mg/kg IV 13.11 447 218 109 52 26 13 6.7 3.3 1.6 




Figure 3.1: Mean ± s.d. plasma enrofloxacin concentrations following administration of a single 
enrofloxacin dose intravenously (5 mg/kg bwt, open dots) or orally (7.5 mg/kg bwt, solid squares) 
to healthy mares at 260 days gestation (A) or to non-lactating mares 45-60 days post-partum (B). 
 
Figure 3.2: Mean ± s.d. plasma ciprofloxacin concentrations following administration of a single 
enrofloxacin dose intravenously (5 mg/kg bwt, open dots) or orally (7.5 mg/kg bwt, solid squares) 
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ABSTRACT 
In select cases, enrofloxacin may be an alternative antibacterial agent to treat unresponsive 
infections in pregnant mares. Supratherapeutic doses of enrofloxacin are toxic to adult horses and 
also to newborn foals; however, it is unknown if enrofloxacin crosses the equine placenta or if it 
is toxic to the fetus. The objectives of this study were to assess the diffusion of enrofloxacin and 
its metabolite to fetal fluids and its effects on fetal cartilage when administered to pregnant mares. 
Healthy mares at 260 d gestation were allocated into three groups: untreated (n=3), therapeutic 
treatment (5 mg/kg enrofloxacin, IV, n=7), or supratherapeutic treatment (10 mg/kg, IV, n=6) for 
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11 days. Fetal fluids were collected on days 1, 5, and 11 of treatment. Premature delivery was 
induced on day 11 with oxytocin, and fetal plasma was collected at delivery. Plasma and fetal fluid 
enrofloxacin and ciprofloxacin concentrations were measured by liquid chromatography-mass 
spectrometry. Fetal articular cartilage was examined macroscopically and histologically for 
lesions. Enrofloxacin and ciprofloxacin reached the minimum inhibitory concentrations for 
common pathogens in all fluids. Ciprofloxacin did not increase with the double enrofloxacin dose 
in maternal plasma, but allantoic fluid showed a 10-fold increase relative to fetal trough plasma 
concentrations. Administration of enrofloxacin at recommended doses did not result in 
cartilaginous lesions in fetuses. It remains to be determined if enrofloxacin shows toxicity at other 
stages of pregnancy, after a longer duration of treatment, or once the foals are delivered and 
articular surfaces are weight-bearing. Short-term administration of enrofloxacin to late gestation 
mares resulted in detectable enrofloxacin and ciprofloxacin concentrations in fetal fluids, and did 
not result in macroscopic or microscopic lesions in the fetus. While further research is needed to 
address long-term foal outcomes, enrofloxacin may be useful for select bacterial infections in 
pregnant mares.  
Keywords: fluoroquinolone, ciprofloxacin, LC-MS/MS, fetal toxicity  
 
INTRODUCTION 
Antimicrobial therapy is necessary in equine practice to treat bacterial infections during 
pregnancy, however the pharmacodynamics and toxicity of many antimicrobials in pregnant 
animals are not known. β-Lactam antibiotics and aminoglycosides cross the equine placenta [1] 
and are commonly used in pregnant mares [2,3]. Cephalosporin antibiotics are also commonly and 
safely used during equine pregnancy, but do not cross the equine placenta due to differences in 
molecular structure [4]. Potentiated sulphonamides cross the equine placenta [5] and are frequently 
used to treat infections in late-pregnant mares [2,6,7] despite knowledge that sulphonamides have 
been associated with an increased risk of birth defects in the first trimester in humans [8] and rarely 
in the horse [9]. Conversely, fluoroquinolones are believed to be chondrotoxic to the foetus given 
the known side effects in growing animals, and fluoroquinolones are generally avoided in pregnant 
animals [10–12].   
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Enrofloxacin is a lipophilic fluoroquinolone antimicrobial that inhibits topoisomerase I 
(DNA Gyrase) and topoisomerase IV, and has bactericidal activity against Gram-negative and 
some Gram-positive pathogens [13].  Enrofloxacin either undergoes hepatic metabolism into 
ciprofloxacin, or is excreted unchanged in the urine,  and both enrofloxacin and ciprofloxacin are 
effective against many common equine pathogens [13,14]. Quinolones are believed to induce 
arthropathies by chelating divalent cations such as magnesium (Mg2+) [15–19] , and in vitro and 
in vivo studies have provided evidence that administration of enrofloxacin can cause tendonitis 
and arthropathies, especially in young, growing animals [10–12].   
To date, only two studies have assessed in vivo effects of enrofloxacin in the horse [6, 15]. 
When enrofloxacin was administered at 3 to 5 times the recommended therapeutic dose for 21 
days, 3 of 12 horses developed musculoskeletal complications [20]. Horses receiving the 
recommended therapeutic dose (5 mg/kg q 24h) did not develop complications. When four two-
week-old foals were treated with twice the recommended dose (10 mg/kg, PO, q24 hours) for 8 
days, three foals became moderately to severely lame and developed tibial-tarsal joint effusion 
with roughening of the articular cartilage [11].  However, this increased dosage is generally not 
used in practice, and no studies have assessed the effects of the recommended dose on foals.  
Additionally, no studies have assessed the effects of fluoroquinolones on the equine foetus, and 
there is a clear need to determine potential detrimental effects of fluoroquinolone use in pregnancy. 
The objectives of this study were (i) to determine enrofloxacin and ciprofloxacin 
concentrations in the maternal plasma, foetal plasma, and pregnancy fluids when enrofloxacin is 
administered during late-term pregnancy, and (ii) to evaluate the articular cartilage of long bones 
in foetuses from those mares. We hypothesized that enrofloxacin and its active metabolite 
(ciprofloxacin) cross the equine placenta and that enrofloxacin administration during late-term 
pregnancy is associated with cartilaginous lesions in the foetus. 
 
MATERIALS AND METHODS 
The study protocol was approved by the University of Illinois Institutional Animal Care 
and Use Committee (protocols, #14243 and #17245). The present study was carried out between 
2014 and 2017. Sixteen healthy, light-breed pregnant mares (six Quarter Horses, three 
Standardbreds, three grade horses, one Paint, one Arabian, one Tennessee Walking Horse, and one 
Thoroughbred were enrolled in the study at 260 days gestation. The mares were housed on pasture 
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at the Veterinary Medicine Research Farm at the University of Illinois in Urbana, Illinois, and 
were provided free choice supplemental minerals. 
 
Study Design 
Immediately before enrollment, physical examinations and ultrasonography of the caudal 
placental pole were performed on all mares, and both were within normal limits. Mares were 
randomly allocated into three groups: control (n=3, no treatment), enrofloxacin [Baytril®]a 5 mg/kg 
IV (n=7), and enrofloxacin [Baytril®]a 10 mg/kg IV, (n=6). Enrofloxacin was administrated 
intravenously every 24 hours for 11 days to the treated mares (5 mg/kg and 10 mg/kg groups). A 
second treatment group (10 mg/kg) was included to determine if slight dosing errors, such as those 
that might occur if a weight was inaccurately estimated, or if two doses were accidentally given in 
a day, would induce lesions in the fetus.  Heparinized blood samples were collected via jugular 
venipuncture daily, samples were centrifuged at 600g/x10 minutes, and plasma samples were 
harvested and stored at -80oC until analysis. 
Fetal fluid sampling was performed on days 1, 5 and 11 after treatment onset as previously 
described [21].  Mares were sedated with xylazine hydrochloride [Anasedb] 0.4 mg/kg IV. and 
butorphanol tartrate [Torbogesicc] 0.004 mg/kg IV, placed in stocks, and their ventral abdomens 
were clipped and aseptically prepped with betadine scrub.  After regional analgesia with 10 mL 
2% lidocained, was administered, fetal fluids were collected aseptically with transabdominal 
ultrasound guidance using a SonoScape S8 Exp with convex probee, and an echotip spinal needle 
(18Gx6”; 30o short bevel, Chiba-Type spinal needle, with stylet)f.  Fluid was only collected and 
saved if a pure white colour (amniotic) fluid was obtained. A minimum of 5 mL and maximum of 
12 mL was collected, and the needle was removed.  A new, sterile needle was then used to collect 
a sample of allantoic fluid, and fluid (5-12 mL) was collected only if an amber fluid consistent 
with allantoic fluid was obtained [21].  
Abortion was induced by manual cervical dilation on day 11. Oxytocing (10 IU IV) was 
administered after cervical dilation was at least 15 cm to assist with delivery.  Mares were sedated 
with xylazine hydrochlorideb (0.4 mg/kg- 0.8 mg/kg IV), and fetuses were delivered vaginally. 
Fetuses were euthanised with pentobarbital sodium and phenytoin sodium [Euthasolh], 900 mg/kg 
IV and 115 mg/kg, respectively, immediately following delivery, and plasma samples were 




Mare plasma magnesium was measured on Day 0 and on Day 11. Full chemistry panels 
were run on fetal plasma collected at time of abortion. Concentrations of enrofloxacin and 
ciprofloxacin were measured by liquid chromatography-tandem mass spectrophotomy (LC-
MS/MS) in the Metabolomics Laboratory of the Roy J. Carver Biotechnology Center, University 
of Illinois Urbana-Champaign. Validation and detailed description of LC-MS/MS methods are 
reported in a parallel study [22]. Between-run and within-run accuracy and precision were 
calculated by measuring six samples of enrofloxacin and ciprofloxacin at concentrations of 5, 50, 
and 500 ng/ml, and measurements were repeated on three different days. Enrofloxacin had a 
within-run accuracy of 95.6 ± 2.1 % to 99.1 ± 0.6%, and a between- run accuracy of 97.3 ± 2.0% 
to 98.4 ± 1.0%, and ciprofloxacin had a mean within-run accuracy of 95.4 ± 2.3 to 99.6 % ± 1.2 
%, and between- run accuracy of 97.0 ± 2.4 % to 99.2 ± 0.9%. Coefficients of variations between-
run and within-run for enrofloxacin ranged from 0.9-1.6% and 1.1-3.5%, respectively, whereas, 
coefficients of variations for ciprofloxacin between- run and within-run ranged from 0.9- 2.4% 
and 1.0- 5.4 %, respectively.  Plasma stability data was calculated under various conditions (n= 6).  
Samples stored in the autosampler for 24 h at 15 °C had a bias of 3.2-4.8% and samples stored at 
-75 °C for 2 months had a bias of 1.3-3.4%.  
 
Pathology 
 Fetal limbs were disarticulated, and all joint surfaces were inspected for gross lesions by a 
board-certified veterinary pathologist. Sections of the proximal articular cartilage of the distal 
scapula, proximal and distal humerus, proximal radius, proximal and distal femur, and proximal 
and distal tibia were collected from all four limbs using a bone saw. All slices were preserved in 
10% neutral buffered formalin immediately after collection. The fixed tissues were then routinely 
processed and embedded in paraffin in an automated tissue processor. Slides were stained with 
haematoxylin & eosin and toluidine blue for analysis, as described in Supplementary table 4.1.  
Slides stained with haematoxylin & eosin were used to assess structural and cellular features, 
whereas slides stained with toluidine blue were used to evaluate the extracellular-matrix.  To 
determine if enrofloxacin or ciprofloxacin had detrimental effects on other organ systems, fixed 
tissue sections of fetal liver, fetal kidney, and placenta were also evaluated after staining with 




MedCalc software v16.4i was used to determine the a priori number of animals required 
to detect a statistical difference between groups using the Monte Carlo’s estimation, with an alpha 
= 0.05, a power of 0.8, and an expected difference between groups of 30% or greater.  While seven 
animals were to be used per group, when no lesions were seen in treated fetal cartilage, the study 
was terminated before all seven control mares were aborted to decrease the number of animals 
sacrificed for the study. Continuous variables were assessed for normality with histograms and 
normal quantile plots. The association between fetal chemistry values and fetal plasma 
fluorquinolones concentrations were analyzed by one way ANOVA.  The association between 
mare trough plasma concentrations and fetal fluid concentrations at each time point were analyzed 
by ANOVA repeated measures. To determine whether mare plasma magnesium levels differed on 
Day 0 and Day 11, plasma magnesium levels were compared with a paired t-test. The 
histomorphometric analyses were evaluated using a non-parametric Kruskal-Wallis one-way 
analysis of variance and any changes were noted on evaluation by the pathologist. Significance 
was set at p < 0.05. Data were analysed using R libraries (R version 3.3.3 )j. 
 
RESULTS 
 Transient loose manure or defecation immediately after drug administration was observed 
in three mares administered 10 mg/kg enrofloxacin.  Two mares had mild vascular irritation by 
Day 11 of intravenous enrofloxacin administration.  No other side effects were observed, and vital 
parameters remained within normal limits for the duration of the study.  Four mares suffered 
varying degrees of cervical lacerations at time of abortion. One mare experienced moderate vaginal 
haemorrhage post abortion and was treated with a 20 L IV bolus Lactated Ringers’ solutionk, 
flunixin megluminel [Banamine®] 1.1 mg/kg IV BID, for two days, and trimethoprim 
sulfamethoxazolem (30 mg/kg PO BID) for seven days.   
Pathology 
No lesions were noted on gross inspection of any fetal articular surface, and representative 
images are shown in Figure 4.1. Four foetuses had clustering of cells in one or more articular 
surface.  Clustering was noted in 3/8 joints (proximal right and left ulna, and proximal tibia, 10 
mg/kg), 2/8 joints (proximal left ulna, proximal right ulna, 5mg/kg), and 1/8 joints in two foals 
(proximal right tibia, control, and proximal left tibia, 5mg/kg). No difference was seen in cell 
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clustering between treatment groups (p=0.62). No other abnormal findings were observed in any 
joint from any foal on histological evaluation.  
 All placentas were grossly normal. All fetal liver samples were unremarkable. One mare 
from the 5 mg/kg group had mild mineralization of the amnion, and one mare from the 10 mg/kg 
group had marked hemorrhage noted in the allantois. One fetus from the 10 mg/kg group had 
moderately swollen and vacuolated proximal convoluted tubule epithelial cells on renal histology. 
Remaining histological evaluations were unremarkable. 
Enrofloxacin and ciprofloxacin 
Both enrofloxacin and ciprofloxacin reached fetal circulation, as indicated by Day 11 fetal 
plasma concentrations (Figure 4.3).  Enrofloxacin and ciprofloxacin crossed the equine placenta 
and accumulated in the allantoic fluid over time (Figure 4.4). Mean ciprofloxacin levels increased 
from 123 ± 94 ng/ml in the allantoic fluid on Day 1, to 876 ± 325 ng/ml (5 mg/kg group) by Day 
11 (p<0.0001). Mean allantoic enrofloxacin concentrations showed a tendency to increase 
(p=0.068), from 195 ± 128 ng/ml on day 1, to 333 ± 228 ng/ml on day 11 (5 mg/kg group).  
Amniotic enrofloxacin concentrations were lower in the 5mg/kg group than in the 10 mg/kg group 
(p=0.02), and increased by day 11 in the 5 mg/kg group (p=0.01) but did not increase in the 10 
mg/kg group (p=0.65). No differences were seen in amniotic ciprofloxacin concentrations between 
groups (p>0.18), although there was a tendency for ciprofloxacin concentrations to increase from 
day 1 to 11 in the 5 mg/kg group (p=0.06) but not the 10 mg/kg group (p=0.11).  While trough 
plasma enrofloxacin levels were not consistently higher in the 10mg/kg group than the 5 mg/kg 
group (p>0.05), mares receiving the higher dose of enrofloxacin had consistently higher trough 
ciprofloxacin concentrations (p<0.05) (Figure 4.5).  
Blood assessments  
While mean fetal plasma creatinine, phosphorus, potassium, alkaline phosphatase (Alk 
Phos), bilirubin, creatinine phosphokinase (CPK), and cholesterol were all higher than reference 
ranges for adult horses, no differences were seen in values between control and treatment groups 
(Table 4.2) (p<0.05). Calcium plasma concentrations were approximately 25% higher than 
published ranges for 24 hour-old foals, although no differences were seen between treated and 
control foetuses (Table 4.2). Mean fetal plasma total protein, globulin, chloride, glucose, and 
aspartate amino transferase (AST) were lower than adult laboratory references range, but there 
was no difference between fetal groups (Table 4.2).  Mare plasma magnesium concentrations were 
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not different at the beginning (2.0 ± 0.1 mg/dL (control), 2.0 ± 0.2 mg/dL (5 mg/kg), 1.9 ± 0.2 
mg/dL (10 mg/kg)), or at the end of the study (1.75=± 0.4 mg/dL (control), 2.0 ± 0.1 mg/dL (5 
mg/kg), 1.9 ± 0.2 mg/dL (10 mg/kg)), and were within the laboratory reference range (1.5- 2.1 
mg/dL) for both time points.  
 
DISCUSSION 
This study investigated whether or not enrofloxacin and its active metabolite distribute to 
the fetoplacental unit, and whether potential toxic effects of fluoroquinolone exposure on the 
foetus are evident. Administration of intravenous enrofloxacin to late pregnant mares did not 
induce any systemic side effects in the mares, even at twice the recommended clinical dose.  Both 
enrofloxacin and its active metabolite ciprofloxacin cross the equine placenta and reach detectable 
concentrations in both the allantoic and amniotic fluid.  Interestingly, while enrofloxacin 
concentrations were similar between amniotic and allantoic fluid, concentrations of ciprofloxacin 
were higher in the allantoic than in the amniotic fluid. While both ciprofloxacin and enrofloxacin 
would be excreted preferentially into the allantoic cavity over the amniotic cavity, it is possible 
that enrofloxacin more readily diffuses back into maternal circulation than ciprofloxacin for 
maternal excretion.  It is also possible that there is placental metabolism of enrofloxacin into 
ciprofloxacin in the late-pregnant mare.  However, neither of these hypotheses has been critically 
evaluated. 
The high concentrations of ciprofloxacin noted by Day 11 were significant, and indicate 
that enrofloxacin might be beneficial against select infections affecting the foetal membranes.  
While study design did not allow for continuous monitoring of antibiotic concentrations in the 
allantoic fluid, trough allantoic fluid ciprofloxacin concentrations remained above the MIC90 of 
common equine uterine E. coli isolates by Day 11 [23]. Given that the pregnancies were terminated 
on the final day of treatment, it is unknown how long ciprofloxacin and enrofloxacin remain in the 
fetal fluids after the last intravenous dose of enrofloxacin. Additionally, it is unknown how 
placental infections will affect drug distribution and transfer across the placenta, so additional 
studies are warranted.  
The demonstration that enrofloxacin and ciprofloxacin cross the equine placenta and reach 
detectable levels in the fetal plasma necessitated evaluation of potential effects on the fetus. No 
lesions were detected on gross examination of the fetal cartilage, despite eleven days of 
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antimicrobial treatment. Previous studies describing fluoroquinolone toxicity observed lesions 
within 24 hours at supratherapeutic doses in broiler chickens [24], or by eight days in foals [11], 
suggesting that lack of gross lesions in this study was not due to insufficient treatment duration.   
Histological evaluation of fetal cartilage also failed to detect evidence of extracellular matrix 
changes, and no fissures or shrunken or pyknotic nuclei were noted in chondrocytes.  Chondrocyte 
clustering, or random chondrocyte arrangement was noted in seven out of 104 treated joints in the 
late term fetuses; however, previous studies assessing equine cartilage development describe 
random distribution of proliferative chondrocytes as normal in the developing fetus and foal [25]. 
While no significant differences were noted in fetal chemistries between treatment groups, 
some parameters were different from published ranges for neonatal foals [26-28].  The observed 
fetal calcium concentrations were consistent with previously published observations that foals 
have plasma calcium concentrations up to 30% higher than adults, a finding that has been attributed 
to active placental transport [27].  While alkaline phosphatase concentrations were elevated in the 
fetuses compared to neonatal reference ranges, alkaline phosphatase is also elevated in late 
pregnant mares, and is known to vary widely in neonatal foals.  The increases seen in fetal plasma 
cholesterol and creatinine were hypothesized to be due to the method of abortion, with placental 
separation and moderate dystocia occurring before fetal delivery and blood sampling.  
Although no differences were noted in fetal plasma creatinine concentrations between 
treatment groups, the plasma creatinine for one fetus in the 10 mg/kg group was 13.7 mg/dL (1211 
!mol/L), which was twice the creatinine concentration of any other fetuses. This fetus was also 
had renal pathology noted on histopathology.  While we cannot rule out enrofloxacin as a cause of 
the changes affecting the proximal convoluted tubules and high plasma creatinine, 
fluoroquinolones have not previously been shown to be nephrotoxic.  In fact, fluoroquinolones are 
frequently prescribed to patients with urinary tract infections or compromised renal function 
[29,30]. All other hepatic and renal samples from treated and control fetuses were normal. The 
changes noted in the chorioallantois and amnion membranes of two mares were presumed to be 
associated with needle puncture during amnion and allocentesis. 
 It has been previously demonstrated that magnesium deficiency causes similar lesions to 
fluoroquinolones in rat cartilage, and in in vitro cultures of equine and canine tendon cells 
[17,18,31,32].  All mares in this study had normal plasma magnesium levels at the beginning of 
the study, and no change was seen in plasma magnesium by the end of the study. Similarly, while 
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no reference ranges were found for fetal magnesium plasma concentrations, fetal plasma 
magnesium was within normal limits for neonatal foals [28] at the end of the study. While it is not 
possible to state if lesions would have been observed in animals that were deficient in magnesium, 
it may be prudent to check plasma magnesium concentrations before instituting fluoroquinolone 
treatment in horses.  
It is important to note that orthopedic disease might not be evident until an animal becomes 
weight bearing. While it appears that enrofloxacin administration to late pregnant mares does not 
cause lesions in the fetus, further studies assessing long term effects of in utero exposure are 
warranted.  Similarly, this study focused on potential side effects in the third trimester, and safety 
of fluoroquinolone administration in the first and second trimester is still unknown.  
In conclusion, we confirmed our hypothesis that enrofloxacin and ciprofloxacin are 
detectable in the fetal fluids and fetus after enrofloxacin administration to late-term mares. 
However, contrary to expectations, exposure to fluoroquinolones in utero did not have detectable 
toxic effects on the cartilage, kidney, or liver of the fetus. Appropriate antimicrobial stewardship 
necessitates the selection of the optimal antimicrobial for a given microorganism without 
compromising patient health. Enrofloxacin administration to pregnant mares should be limited to 
cases of life-threatening infections determined by a microbial culture indicating a resistance to first 
line antimicrobials and a sensitivity to enrofloxacin.  Clients should be informed of the risks of 
fluoroquinolone administration and the unknown effects of fluoroquinolone exposure on the 
developing fetus.  While it appears that enrofloxacin could be an ideal choice for severe infections 
susceptible to enrofloxacin, cases should be selected carefully, as this study does not rule out the 
possibility of a low incidence of toxicity and does not demonstrate safety of administration during 
the first or second trimester of equine pregnancy, nor does it rule out long term complications to 
the foal that was exposed to fluoroquinolones in utero.  
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TABLES AND FIGURES 
 
Table 4.1. Relative mean enrofloxacin and ciprofloxacin concentrations in the fetal fluids and 
plasma of mares and fetuses at time of abortion.  Mares (261 ± 4 days gestation) were administered 
either 5 mg/kg  (n= 7) or 10 mg/kg (n= 6) enrofloxacin intravenously once a day for 11 days before 
abortion. 
 
Drugs Fluid ratios 5 mg/kg 10 mg/kg 
Enrofloxacin 
Maternal: Fetal plasma 1.4 1.6 
Fetal plasma: allantois 0.5 0.4 
Fetal plasma: amniotic 0.7 0.9 
Allantoic: amniotic 1.5 2.1 
Ciprofloxacin 
Maternal: Fetal plasma 4 4.9 
Fetal plasma: allantois 0.02 0.02 
Fetal plasma: amniotic 0.1 0.2 
Allantoic: amniotic 5.7 9.1 
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Table 4.2. Fetal serum chemistries at time of abortion (272 ± 4 days gestation). Mares were untreated (Control, n=3), or treated with 
5mg/kg (n=7) or 10mg/kg (n=6) enrofloxacin intravenously once a day for 11 days before abortion.  Adult range was provided by the 
reference laboratory. All other values are mean ± SD (range). No significant differences were seen between treatment groups for any 
value (p<0.05). Neonatal reference ranges from Axon and Palmer (2008) within an hour of birth, (§) Bauer (1990) at less than 12 hours 













Control 5 mg/kg 10 mg/kg p value 
Creatinine (!mol/L) 70-159 13.3-32.7 460  ±  80 (389-548) 398 ± 124 (150-539) 574 ± 318 (309-1211) 0.39 
BUN (mmol/L) 3.9-8.2 4.3-9.6 6.9 ± 1.6 (5.4-8.6) 7.9 ± 1.6 (6.1-10.0) 7.0 ± 1.1 (5.4-8.2) 0.47 
TP (g/L) 55-73  36 ± 5 (31-40) 39 ± 14 (32-70) 36 ± 4 (31-40) 0.80 
Albumin (g/L) 27-37 
20-50* 
27 ± 02 (25-29) 27 ± 3 (6-33) 26 ± 2 (23-29) 0.75 
Globulin (g/L) 20-46  9 ±  3 (6-11) 12 ± 11 (6-37) 10 ± 2 (8-13) 0.81 
Calcium (mmol/L) 2.6-3.2 
2.4-3.4* 
4.0  ± 1.3 (3.2-5.4) 3.6 ± 0.5 (3.0-4.2) 3.7 ± 0.4 (3.3-4.1) 0.69 
Phosphorus (mmol/L) 0.5-1.3 
1.2-2.4* 
1.9 ±  0.3 (1.6- 2.1) 1.9 ± 0.7 (0.8-2.6) 2.1 ± 0.2 (1.8-2.3) 0.81 
Sodium (mmol/L) 133-142 
148 ± 15§ 
134.0  ± 2.0 (132-136) 133.1 ± 2.5 (130-137) 132 ± 3.1 (128-135) 0.56 
Potassium (mmol/L) 2.5-5 4.4 ± 1.0§ 5.4 ± 0.9 (4.5-6.2) 5.7 ± 1.0 (4.1 -6.8) 6.4 ± 1.3 (5.2-6.8) 0.44 
Chloride (mmol/L) 98-105 105 ± 12§ 99.0 ± 2.0 (97-101) 97.6 ± 1.8 (96-101) 95.2 ± 2.4 (92-99) 0.05 
Glucose (mmol/L) 3.9-6.2 5.9-6.1§ 3.3 ± 0.3 (3.1-3.7) 3.6 ± 1.1 (2.3-5.2) 3.1 ± 0.9 (1.6-4.1) 0.71 
Alk Phos (U/L) 41-137 152-2835 2060 ± 1199  
(1318-3444) 
1525 ± 1002  
(198-3445) 
1501 ± 930 (16-2733) 0.71 
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Table 4.2 (cont.). Fetal serum chemistries at time of abortion (272 ± 4 days gestation). Mares were untreated (Control, n=3), or treated 
with 5mg/kg (n=7) or 10mg/kg (n=6) enrofloxacin intravenously once a day for 11 days before abortion.  Adult range was provided by 
the reference laboratory. All other values are mean ± SD (range). No significant differences were seen between treatment groups for any 
value (p<0.05). Neonatal reference ranges from Axon and Palmer (2008) within an hour of birth, (§) Bauer (1990) at less than 12 hours 







Control 5 mg/kg 10 mg/kg p value 
AST (U/L) 150-294 97-315 68.0 ± 16.1 (51-83) 100.6 ± 61.1 (67-238) 81.2 ± 13.0 (71-99) 0.39 
GGT (U/L) 4-20 8-33  8.7 ± 2.1 (7-11) 8.6 ± 3.8 (5-15) 9.8 ± 2.9 (6-13) 0.51 
Bilirubin (	!mol/L) 8.6-39.3 34.2-51.3 34.2± 10.3 (23.9-42.8) 47.9 ± 8.6 (35.9-58.1) 41.0 ± 10.3 (34.2-59.9) 0.77 
CPK (U/L) 71-300 
65-380 
262 ± 209 (131-503) 360 ± 226 (157-759) 282 ± 69 (219-401) 0.13 
Cholesterol (mmol/L) 1.55-4.45 0.31-1.11 7.58 ± 1.99 (6.08-9.83) 6.88 ± 3.52 (1.66-10.29) 9.54 ± 1.86 (7.45- 11.82) 0.25 
GLDH (U/L) 1-5 
 5.2 ± 3.7 (1.7-9.1) 2.6 ± 0.8 (1.5-3.9) 2.2 ± 0.8 (1.2-3.4) 0.06 
TCO2 (mmol/L) 24-33 
21-34* 
27.0 ± 2.6 (24-29) 26.1 ± 1.3 (24-28) 24.8 ± 3.4 (19-28) 0.46 
Mg+ (mmol/L) 0.6-0.9 
0.3-1.7* 
0.9 ± 0.1 (0.9-0.95) 0.8 ± 0.1 (0.6-1.0 0.8 ± 0.4 (0.1-1.4 0.94 
Triglycerides 
(mmol/L) 





Figure 4.1. Representative images of the proximal articular surfaces of the humerus, radius, femur, 
and tibia in a fetus (272d gestation) from a mare treated with enrofloxacin (10 mg/kg) for 11 
consecutive days. (A) Left radius, B) right radius, C) left humerus, D) right humerus, E) left tibia, 
F) right tibia, G) left femur, H) right femur. No fissures or erosions in the articular surface were 





Figure 4.2. Representative images of the proximal femur cartilage of fetuses from a control mare 
and mares treated with 5 mg/kg or 10 mg/kg of enrofloxacin. Slides in the top row were stained 
with standard H&E, whereas slides in the bottom row were stained with Toluidine Blue.  




Figure 4.3. Mean (± SD) enrofloxacin and ciprofloxacin concentrations in the plasma of fetuses at 
time of abortion.  Mares (261 ± 4 days gestation) were administered 5 mg/kg (n=7) or 10 mg/kg 
enrofloxacin (n=6) intravenously once a day for 11 days, or were administered no drug (control, 





Figure 4.4. Mean (± SD) enrofloxacin (A,C) and ciprofloxacin (B,D) concentrations in the amniotic (A,B) and allantoic (C,D) fluid of 
pregnant mares.  Mares (261 ± 4 days gestation) were administered 5 mg/kg  (n=7) or 10 mg/kg (n=6) enrofloxacin intravenously once 
a day for 11 days, or were administered no drug (control, n= 3). Foetal fluids were sampled on days 1, 5, and 11. Superscripts denote 





Figure 4.5. Mean (± SD) trough enrofloxacin (top) and ciprofloxacin (bottom) concentrations in 
the plasma of mares.  Mares (261 ± 4 days gestation) were administered either 5 mg/kg (n=7) or 
10 mg/kg enrofloxacin (n=6) intravenously once a day for 11 days, or were administered no drug 




Supplementary Table 4.1.  Scoring system used for histologic evaluations of the foal cartilage. 
Adapted from Maslanka and collaborators [37]. 
 
Category Criteria  Evaluation Score 











Cellularity Normal 0 
Hypocellularity 2 
Chondrocytes clusters Absent 0 
Present 2 
Shrunken cytoplasm 
and pyknotic nuclei 
Not numerous 0 
Moderately  1 
Numerous 2 
Very numerous 3 
Necrotic chondrocytes Not numerous 0 
Moderately numerous 1 
Numerous 2 
Very numerous 3 
Spindle-shaped cells Absent 0 
Present 1 


















Lack uptake in matrix in 
cartilage canals 
0.5 
Slight reduction 1 
Moderate reduction 2 
Severe reduction 3.5 
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ABSTRACT 
 Enrofloxacin may be an alternative antibacterial agent to treat select severe infections in pregnant 
mares. A recent study has shown that enrofloxacin and ciprofloxacin cross the equine placenta 
without causing gross cartilage or tendon lesions in the 9-mo fetus; however, long-term effects of 
in utero fluoroquinolone exposure are unknown.  The objective of the following study was to 
assess effects of fetal exposure to enrofloxacin on the resulting foal’s cartilage and tendon strength.  
Healthy mares at 280 d gestation were allocated into four groups: untreated (n=5), therapeutic 
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treatment (7.5 mg/kg enrofloxacin, PO x 14 days, n=6), supratherapeutic treatment (15 mg/kg, PO 
x 14 days, n=6), or treatment of the foals postpartum (n=2). Mares were allowed to carry pregnancy 
to term, and foals were maintained on pasture for five weeks. After that foals were euthanized, and 
articular cartilage and extensor and flexor tendons were examined macroscopically and 
histologically for lesions. Tendon strength was tested by loading until failure. Administration of 
enrofloxacin at recommended doses in late gestation did not result in cartilaginous lesions or 
clinical lameness in any foal by 5-wks-old. Tensile strength was greater in hind tendons than front 
tendons, but no difference was found between foals born from treated and control mares. 
Expectedly, osteochondral changes were present both in foals born from enrofloxacin-treated 
mares and in negative control foals with no apparent association with fluoroquinolone treatment 
during pregnancy. Short-term administration of enrofloxacin to late gestation mares did not result 
in macroscopic or microscopic lesions in the resulting foal by five weeks of age. While further 
research is needed to assess other stages of gestation and long-term foal outcomes, enrofloxacin 
may be useful for select bacterial infections in pregnant mares. 
 
Keywords: fluoroquinolone, ciprofloxacin, pregnancy, fetal toxicity 
 
INTRODUCTION 
Antimicrobial therapy is necessary for pregnant mares with bacterial infections, however 
the toxicity of many antimicrobials is not known. Aminoglycosides and β-Lactam antibiotics 
cross the equine placenta [1] and are commonly used in pregnant mares [2,3]. Cephalosporin 
antibiotics are also commonly and safely used during equine pregnancy, but do not cross the 
equine placenta [4]. Potentiated sulphonamides cross the equine placenta [5] and are frequently 
used to treat infections in late-pregnant mares [2,6,7] despite knowledge that sulphonamides 
have been associated with an increased risk of birth defects in the first trimester in humans [8] 
but rarely in the horse [9]. Conversely, fluoroquinolones are believed to be chondrotoxic to the 
foetus and are avoided in pregnant animals [10–12].   
Enrofloxacin is a lipophilic fluoroquinolone antimicrobial that inhibits topoisomerase I 
(DNA Gyrase) and topoisomerase IV, and has bactericidal activity against Gram-negative and 
some Gram-positive pathogens [13].  Enrofloxacin either undergoes hepatic metabolism into 
ciprofloxacin, or is excreted unchanged in the urine, and both enrofloxacin and ciprofloxacin are 
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effective against many common equine pathogens [13,14]. Quinolones are believed to induce 
arthropathies by chelating divalent cations such as magnesium (Mg2+) [15–19]. In vitro and in 
vivo studies have provided evidence that administration of enrofloxacin can cause tendonitis and 
arthropathies, especially in young, growing animals [10–12].   
While the limited previous research might suggest that enrofloxacin should be avoided in 
pregnant mares, enrofloxacin is reportedly safe to administer during canine pregnancy according 
to manufacturer label.  Two studies have assessed in vivo effects of enrofloxacin in the horse, 
using supratherapeutic doses to attain maximum toxicity [11,20]. In adult horses, long-term (i.e., 
21d) treatment with supratherapeutic doses (i.e., 15 mg/kg and 25 mg/kg q 24 hours) resulted in 
musculoskeletal complications in 3 of 12 animals, while no complications were seen with long 
term treatment with the recommended dose (5 mg/kg q 24 hours)[20]. When four two-week old 
foals were treated with twice the recommended dose (10 mg/kg, IV, q 24 hours) for 8 days, three 
foals became moderately to severely lame and had tibial-tarsal joint effusion with roughening of 
the articular cartilage, suggesting that foals might be more sensitive to cartilage damage [11].  
However, this increased dosage is generally not used and to date no studies have assessed the 
effects of the recommended dose on foals.  
Despite concerns about foetal toxicity, practitioners occasionally treat pregnant mares 
with enrofloxacin when faced with multi-drug resistant infections.  Saving the mare in these 
cases is more important than potential effects on the foetus or might be the only way to prevent 
pregnancy loss.  Additionally, a recent study showed that enrofloxacin and ciprofloxacin cross 
the equine placenta, and that when enrofloxacin is administered intravenously for 11 days in late 
pregnancy, no lesions were detectable in the foetus [21].  However, it is possible that side effects 
might not be apparent until after the resulting foal becomes weight bearing. Traditionally, 
toxicity studies have determined adverse effects based on clinical signs, blood work, and 
histological evaluations of tissues of interest. Given the athletic demands of the horse, and 
reports of tendon rupture in humans after long-term fluoroquinolone use [22,23], it is vital to 
investigate if enrofloxacin affects tendon tensile strength or cartilage strength in foals born from 
enrofloxacin-treated mares. 
The major objectives of this study were to determine: (i) the clinical outcomes of 
enrofloxacin administration at therapeutic doses during late-term pregnancy on the resulting foal, 
(ii) if exposure to enrofloxacin and ciprofloxacin in utero results in cartilage or tendon lesions in 
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5-wks-old foals. The minor objectives of this study were to assess enrofloxacin and ciprofloxacin 
concentrations in mares’ plasma at the beginning and in the middle of the treatment, and in the 
foetal fluids close to foaling. We hypothesized that enrofloxacin administration during late 
gestation would not affect foal health or soundness by five weeks of age. 
 
MATERIALS AND METHODS 
The study protocol was approved by the University of Illinois Institutional Animal Care 
and Use Committee (protocols, #14243 and #17245). The present study was carried out between 
2015 and 2018. Nineteen healthy, light-breed pregnant mares were enrolled in the study at 280 
days gestation.  Mares were kept at the Veterinary Medicine Research Farm at the University of 
Illinois in Urbana, Illinois, where they were housed on pasture and supplemented with grass hay 
and trace minerals.  
 
Animal husbandry and study design  
Clinically healthy multiparous mares (14 ±4 yrs-old) were included in the present study if 
ultrasonography of the caudal placental pole was within normal limits. Mares were randomly 
allocated to four groups: recommended dose of enrofloxacina (7.5 mg/kg, PO, n=6), double 
therapeutic dose of enrofloxacina (15 mg/kg, n=6), negative control (n=5, no enrofloxacin), or 
positive control (n=2, no enrofloxacin administration during pregnancy; foals were treated with 
enrofloxacin 2-3 wks. after birth). Mares were treated for fourteen days. Heparinized blood 
samples were collected via jugular venipuncture on days 1 and 8 of treatment. Blood was collected 
starting at t=0 and then repeated at 2, 3, 4, 6, 8, and 24 hours after enrofloxacin administration. 
The samples were centrifuged at 600 x g for 10 minutes, and plasma samples were harvested and 
stored at -80oC until analysis. Mare plasma magnesium concentrations were measured with an 
automated quantitative analyzerb before enrofloxacin administration on Day 1, and again on Day 
14, immediately before the last dose was administered. The compounded commercial oral 
formulation of enrofloxacin used in this study has been shown previously to be well absorbed by 






Fetal fluid sampling 
In a subset of mares (7.5 mg/kg n= 3 and 15 mg/kg n=2), fetal fluid sampling was 
performed 30-40 days after last enrofloxacin dose, as previously described [25].  Mares were 
sedated with xylazine [Anasedc] 0.4 mg/kg/IV, and butorphanol [Torbogesicd] 0.004 mg/kg/IV, 
placed in stocks, and their ventral abdomens were clipped, and aseptically prepped with betadine 
scrub. After regional analgesia with 10 mL 2% lidocainee, foetal fluids were collected aseptically 
with transabdominal ultrasound guidance using a SonoScape S8 EXP with convex probef, and an 
echotip spinal needleg.  Fluid was collected and saved only if a pure white color (amniotic) fluid 
was obtained. A minimum of 5 mL and maximum of 12 mL was collected, and the needle was 
removed. A new, sterile needle was then used to collect a sample of allantoic fluid, and fluid (5-
12 mL) was collected only if an amber fluid consistent with allantoic fluid was obtained [25].  
 
Foaling management and neonatal care 
All mares carried their foals to term. Mares had pre-foaling mammary gland secretions pH 
assessed daily in the evening to determine the night of foaling as previously described [26,27]. 
Mares were kept in foaling stalls (6 x 4 m) and monitored with an internal video camera system. 
Once signs of stage two of labour were detected, technicians contacted the investigators to 
supervise all parturition. If needed, mares received oxytocine (10 units/IM q30min) to hasten 
release of the fetal membranes. Thereafter, the fetal membranes from all mares were examined 
after parturition for completeness, meconium staining, and signs of hemorrhage and infection. 
Colostrum was administered by nasogastric tube if the foal did not nurse well within three hours 
of birth. Foals’ umbilical navels were submerged in dilute chlorhexidine gluconatee twice a day 
for five days.  Full physical examinations were performed on mares and foals immediately after 
delivery and then at 12-24 hours intervals. Complete blood counts and plasma IgGh were evaluated 
at 12 hours of age, and foals with IgGs < 800 mg/dL were administered 1 L hyperimmune plasmai. 
Foals with total white cell counts < 5,000 x 103 cells/µl were treated with ceftiofur sodium 
[Naxceld] (4.4 mg/kg IV) for three to five days. Mares and foals were maintained on pasture after 
foaling.  
The two foals in the positive control groups were administered 10 mg/kg enrofloxacin PO 
once a day for seven days starting at 2-wks-old (foal 1) or once a day for 10 days starting at 3-
wks-old (foal 2). At 5-wks-old, foals were euthanized with pentobarbital sodium and phenytoin 
68 
 
sodium [Euthasolj], 900 mg/kg IV and 115 mg/kg, respectively. Blood samples were collected in 
heparinized tubes and immediately centrifuged at 600x g for 10 minutes. Plasma samples were 
stored at -80oC until analysis.  
 
Determination of enrofloxacin and ciprofloxacin concentrations 
Concentrations of enrofloxacin and ciprofloxacin were measured by liquid 
chromatography-tandem mass spectrophotomy (LC-MS/MS) in the Metabolomics Laboratory of 
the Roy J. Carver Biotechnology Center, University of Illinois Urbana-Champaign. Validation and 
detailed description of LC-MS/MS methods are reported elsewhere [24]. Between-run and within-
run accuracy and precision were calculated by measuring six samples of enrofloxacin and 
ciprofloxacin at concentrations of 5, 50, and 500 ng/ml, and measurements were repeated on three 
different days. Enrofloxacin had a within-run accuracy of 95.6 ± 2.1 % to 99.1 ± 0.6%, and a 
between-run accuracy of 97.3 ± 2.0% to 98.4 ± 1.0%, and ciprofloxacin had a mean within-run 
accuracy of 95.4 ± 2.3 to 99.6 % ± 1.2 %, and between-run accuracy of 97.0 ± 2.4 % to 99.2 ± 
0.9%. Coefficients of variations between-run and within-run for enrofloxacin ranged from 0.9-
1.6% and 1.1-3.5%, respectively, whereas, coefficients of variations for ciprofloxacin between-
run and within-run ranged from 0.9- 2.4% and 1.0-5.4 %, respectively. Plasma stability data was 
calculated under various conditions (n= 6).  Samples stored in the auto-sampler for 24 h at 15 °C 
had a bias of 3.2-4.8% and samples stored at -75 °C for 2 months had a bias of 1.3-3.4%.  
 
Pathology 
 After euthanasia, foal limbs were disarticulated, and all joint surfaces were inspected for 
gross lesions by a board-certified veterinary pathologist blinded to foal treatment group. The 
extensor tendons were collected mid metacarpus and mid metatarsus from all limbs for histological 
evaluation. Superficial flexor tendons were removed intact, wrapped in saline soaked towels and 
saran wrap and frozen at -80° C for biomechanical testing. The joint surfaces collected for 
histology were selected based on the most affected joints in the positive control foals.  Sections of 
articular cartilage of the distal scapula, distal humerus, distal radius, distal femur, distal tibia, and 
talus were collected from all four limbs using a bone saw. All slices were preserved in 10% neutral 
buffered formalin immediately after collection. The fixed tissues were then routinely decalcified, 
processed and embedded in paraffin in an automated tissue processor. Slides were stained with 
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haematoxylin & eosin for analysis and histological changes graded (Supplemental Table  5.1) as 
previously published elsewhere [39].   
 
Biomechanical testing 
 The right front and hind limb superficial flexor tendons were thawed at room temperature, 
and divided in half axially in the longitudinal plane. The four hemi-tendons were placed in parallel, 
and all four hemi-tendons were imaged by computed tomographyk. Images were acquired with a 
16-slice helical CT scannerk using a Bone+ algorithm (17mAs, 80KV, 5 x 10mm). Mean cross 
sectional area of each hemi-tendon was calculated by averaging the cross sectional area in 10 fields 
using imaging softwarel. For biomechanical testing, each hemi-tendon was tested individually and 
the two values averaged to provide a single value per limb per foal.  For testing, the tendon was 
centred in a hydraulic testing devicem and the tendon ends were secured using custom designed 
cryogrips (Figure 5.1). The grips were serrated and kept cold with dry ice throughout the 
experiment.  
 Testing procedure was slightly modified from previous studies [28,29]. The tendon was 
centered so the distance between grips was 10 cm at the start of testing. Tendons were loaded at 
10N and cycled at 2.5% strain for 5 cycles prior to tensile testing. For testing, tendons were then 
loaded to failure in tension.  Displacement was measured as change in grip-to-grip distance from 
the start of testing until yield load was obtained. Yield stress and maximum stress (N/mm2 = MPa) 
were calculated by dividing the yield load (N) and maximum load (N) by mean cross sectional 
area obtained from the CT scan (mm2).  The elastic modulus was calculated by the yield 
stress/strain.   
 
Statistical analysis 
MedCalc software v16.4n was used to determine the a priori number of animals required 
to detect a statistical difference between groups, with an alpha = 0.05, a power of 0.8, and an 
expected difference between groups of 30% or greater. While six animals were to be allocated per 
group, only nineteen mares were available at 260 days gestation. The decision was made to use 
five control (untreated) mares to minimize euthanasia of healthy foals. Similarly, only two foals 
were treated postpartum to minimize animal suffering once it was determined that lesions were 
detectable in these foals. To determine whether mare plasma magnesium levels differed on Day 0 
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and Day 14, plasma magnesium levels were compared with a paired t-test. Histomorphometric 
analyses were evaluated using a non-parametric Kruskal-Wallis one-way analysis of variance. 
Tendon tensile strength, mare gestation length, foal age, and time from treatment to foaling were 
compared between treatment groups and controls using a one-way ANOVA, and a Tukey HSD 
was used for post-hoc analysis. Day 1 and Day 8 enrofloxacin and ciprofloxacin concentrations 
were compared using paired t tests. Significance was set at p < 0.05. Data were analysed using R 
libraries (R version 3.3.3)p. 
 
RESULTS 
Clinical outcomes and magnesium concentration 
All mares had normal physical examinations for the 14-day treatment period, and no 
adverse effects were seen from oral administration of enrofloxacin, or from transabdominal 
ultrasound-guided fetal fluid sampling. No oral lesions were noted at any point in the study. Mares 
foaled at 339 ± 11 days of gestation, and there was no difference between gestation length and 
treatment group (335 ±7 days (control), 339 ±16 days (7.5 mg/kg), 344 ±12 days (15 mg/kg)). 
Mean time from last enrofloxacin treatment to foaling was 45 ±17 days, and time to foaling did 
not differ between treatment groups (42 ±17 days (7.5 mg/kg), 48 ± 20 days (15 mg/kg)).  
Three of the Standardbred mares experienced dystocias (elbow lock, easily corrected) 
(Control), bilateral carpal flexion (7.5 mg/kg mare), and unilateral shoulder flexion, uterine artery 
haemorrhage (15 mg/kg mare) (Table 5.1). None of the mares retained their fetal membranes 
beyond three hours post-delivery. Upon inspection post-partum, there were no gross abnormalities 
in the fetal membranes of any mare. The foal from the mare with the uterine artery hemorrhage 
required significant traction for foal delivery and had bilateral fetlock effusion for five days after 
birth.  One negative control foal, and one treated foal (7.5 mg/kg), had transient effusion of the 
tibiotarsal and fetlock joints respectively, both of which resolved by one week of age, and no 
lameness was noted in either foal at the end of the study.  One foal in the 7.5 mg/kg group had 
leukopenia and an IgG of 780 at 24 hours of age and was administered 1L hyperimmune plasmai 
(Table 5.1). Foals were 35 ±3 days of age at time of euthanasia, and age did not differ between 
groups (35 ±3 days (control), 35 ±2 days (7.5 mg/kg), 34 ±3 days (15 mg/kg)). The two positive 
control foals were younger at time of euthanasia (26 ±4 days) than the rest of the foals.  
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Mare plasma magnesium concentrations were not different between the control or treated 
groups at the start of the study (0.88 ± 0.16 mmol/L (control), 0.78 ± 0.04 mmol/L (7.5 mg/kg), 
0.78 ± 0.04 mmol/L (15mg/kg)), or after 14 days of enrofloxacin administration (0.82 ± 0.04 
mmol/L (control), 0.78 ± 0.04 mmol/L (7.5 mg/kg ), 0.78 ± 0.04 mmol/L (15 mg/kg )). 
Enrofloxacin and ciprofloxacin concentrations 
Peak plasma concentrations were 1040 ± 228 ng/mL (enrofloxacin) and 210 ± 25 ng/mL 
(ciprofloxacin) for the 7.5 mg/kg group and 1638 ± 246 ng/mL (enrofloxacin) and 327 ± 21 ng/mL 
(ciprofloxacin) for the 15 mg/kg group on Day 1. Day 8 peak plasma concentrations were 1160 ± 
230 ng/mL (enrofloxacin) and 244 ± 52 ng/mL (ciprofloxacin) for the 7.5 mg/kg group, and 2602 
± 1060 ng/mL (enrofloxacin) and 384 ± 87 ng/mL (ciprofloxacin) for the 15 mg/kg group (Figure 
2). Peak plasma enrofloxacin (p=0.085) and ciprofloxacin (p=0.066) concentrations tended to be 
higher on Day 8 than Day 1 in the 7.5 mg/kg group, but were not significantly higher by Day 8 in 
the 15 mg/kg group.  Both enrofloxacin and ciprofloxacin were still detectable in the amniotic (7.4 
± 4.7 ng/mL of enrofloxacin and 15.3 ±12.4 ng/mL of ciprofloxacin) and allantoic (11.2 ±1.0 
ng/mL of enrofloxacin and 148.3 ± 61.1 ng/mL of ciprofloxacin)) fluids thirty to forty days after 
administration of the last dose of oral enrofloxacin. 
Pathology 
After examining all joints from each foal, no gross lesions were noted in any joint of foals 
in the negative control, 7.5 mg/kg or 15mg/kg groups (Figures 5.3 and 5.4). Expectedly, gross 
lesions were noted in 21 of 34 joints examined in one positive control foal and 3 of 34 joints 
examined in the other positive control foal. Lesions noted were superficial and deep erosions in 
the articular surface, with mild to severe joint effusion, fibrin, and synovitis. Distal joint surfaces 
were more severely affected than proximal surfaces, with the exception of the talus, which had 
severe deep erosions (Figure 5.4). Histological evaluation of the extensor tendons were 
unremarkable. 
A total of 239 joints were assessed histologically from the 19 foals (Table 5.2). No 
differences were seen between the negative control, 7.5 mg/kg and 15 mg/kg treatment groups. 
Fissures, spindle cells, and shrunken/pyknotic nuclei were the most commonly observed changes 
(Table 5.2, Figure 5.5). The fissures noted in the deep zone were consistent with chondrifying 
cartilage canals (Figure 5.6).  In addition to the spindle cells and shrunken/pyknotic nuclei noticed 
in the other three treatment groups, the two positive control foals had marked changes noted on 
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histology.  Extensive, deep erosions were noted in the distal humerus, distal scapula, proximal 
tibia and talus, and superficial erosions were noted in the distal tibia, proximal and distal ulna, and 
proximal metacarpus of the foal treated at 14 days of age. Deep erosions of the articular cartilage 
of this foal can be seen grossly in figure 4 and on histology in figure 5.5.   Less severe erosion of 
the distal metacarpus and rare chondrocyte necrosis in the distal humerus and proximal femur were 
noted in the foal treated at 21 days of age.  
Biomechanical testing 
All but four tendon samples failed at mid-tendon via longitudinal extension of the 
interfaces between the collagen bundles. Two tendon samples failed by sharp separation at the grip 
(one for the control group and other from the 15 mg/kg group), and two failed by sharp separation 
mid-tendon (one 7.5 mg/kg, one 15 mg/kg). No differences were seen in the elastic modulus, max 
stress, or yield stress of tendons from control or treated foals. Tendon yield stress was similar 
between treatment groups (Control = 7.6 ± 1.0 MPa), (7.5mg/kg = 8.6 ± 1.5 MPa) and (15 mg/kg 
= 9.2 ± 1.9 MPa). Interestingly, the front limb tendons had a lower elastic modulus than hind limb 
tendons. Similarly, yield stress, max stress, and stiffness were lower in the front limb tendons than 
hind limb tendons (Table 5.3).  
 
DISCUSSION 
Administration of enrofloxacin to late pregnant mares resulted in diffusion of enrofloxacin 
and ciprofloxacin into the fetus and pregnancy fluids, but did not result in apparently chondrotoxic 
lesions in the fetuses [21].  However, it is possible that adverse effects of in utero exposure to 
enrofloxacin may not be apparent until after the resulting foal becomes weight bearing. In the 
current study, administration of enrofloxacin to late pregnant mares failed to cause musculoskeletal 
disease (lameness, tendinopathies, erosions of articular cartilage) in the resulting foals from birth 
to 30 days of age, while foals treated after birth (positive controls) did develop clinical signs and 
pathology similar to those described in a previous report involving administration of enrofloxacin 
to newborn foals [11].  
Cellular changes were noted in the cartilage of foals from all treatment and negative control 
groups consistent with normal cartilaginous changes seen in foals at 30 days of age [30]. Defects 
classified as fissures were consistent with cartilage canals normally noted in developing foals [30]. 
The degenerating cartilage canal vessels and occasional adjacent areas of necrotic cartilage are 
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typical findings, and are interpreted as either normal loss of cartilage canals that occurs during 
development, or early osteochondrosis lesions. Interestingly, the fissures or cartilage canals were 
seen most frequently in the distal scapula, and not in the joints where osteochondrosis lesions 
typically develop, or where lesions were seen in treated foals [11, 31-33]. Superficial and deep 
erosions were seen only in the foals treated with enrofloxacin postpartum.  
No differences were seen in flexor tendon tensile strength after enrofloxacin administration 
to pregnant mares. Flexor tendon CSA was 1/3 of the previously reported CSA for older foals, and 
mean yield stress was approximately 2/3 to ¾ lower than yield stress reported for older foals [29].  
Interestingly, while no changes were seen in any tensile parameters between treatment groups, a 
clear difference was noted between the front and hind tendons. This difference between forelimb 
and hindlimb flexor tendons has not been detected previously in adult horses. While 
fluoroquinolone exposure during pregnancy did not affect flexor tendon tensile strength, it is 
important to acknowledge that mares enrolled in this study were healthy. In humans, risk factors 
for tendonitis or Achilles rupture with fluoroquinolone treatment include concurrent corticosteroid 
use, renal disease, and age (higher in elderly people) [22,23].  The risk of fluoroquinolone 
administration to comprised or older mares remains to be determined.  
Magnesium deficiency causes similar lesions to fluoroquinolones in rat cartilage, and in in 
vitro cultures of equine and canine tendon cells [17,18,34,35].  All mares in this study had normal 
plasma magnesium levels at the beginning of the study, and no change was seen in plasma 
magnesium by the end of the study. While it is not possible to say if lesions would have been 
observed in animals that were deficient in magnesium, it may be prudent to check plasma 
magnesium concentrations before instituting fluoroquinolone treatment in pregnant mares.  
The severe clinical signs seen in one of the two positive control foals demonstrated that the 
enrofloxacin formulation used in this study induced previously described adverse effects in foals 
[11] if administered during a susceptible window in foal development. The adverse effects were 
much more severe in the younger, heavier foal (2-wks-old) when compared to the older but lighter 
foal (3-wks-old), which suggests that there might be a very specific window when foals are most 
susceptible to cartilage damage. All mares in the current study foaled at least 30 days after the last 
dose of enrofloxacin; thus, it remains to be determined if administering a fluoroquinolone close to 
expected foaling date causes lesions in the resulting foal.  
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Incidence of dystocia in this study was 15%, which is similar to previously reported 
incidences of on-farm equine dystocia [36,37]. Two of the three mares that experienced dystocias 
at time of foaling were treated with enrofloxacin during late gestation, and those two dystocias 
resulted in the loss of the foal in one group, and the loss of the mare in the other group.  Given the 
small number of foaling mares herein, and the fact that dystocia rates were comparable to other 
Standardbred breeding farms in the area, it is not possible to establish an association between 
enrofloxacin administration during late pregnancy and dystocia.  
A previous study assessing equine fetal toxicity after fluoroquinolone exposure during late 
pregnancy demonstrated that ciprofloxacin accumulates at high concentrations in the allantoic 
fluid by the 11th day of drug administration, and it was not determined how long ciprofloxacin 
would be detectable in the allantoic fluid after the last dose [21]. While determining the rate of 
ciprofloxacin elimination was not an objective of the current study, allocentesis 30-40 days after 
the last dose of enrofloxacin clearly demonstrated residual ciprofloxacin in the allantoic fluid. 
Concentrations in the amniotic fluid were lower, or not detectable in one mare.  This suggests that 
enrofloxacin might be an alternative antimicrobial for severe placental infections due to the high 
concentrations initially, and the high levels maintained potentially for weeks after the last dose is 
administered parentally. However, since the study was conducted in healthy mares, it is still 
unknown how concurrent disease might affect placental drug transfer.  
Collectively, these findings suggest that enrofloxacin administration to the late pregnant mare 
reaches therapeutic drug concentrations in the fetus and fetal fluids without apparent detrimental 
effects on the cartilage and tendons of the resulting foal. Additionally, ciprofloxacin concentrations 
in the allantoic fluid may remain elevated for many days after administration of the last 
enrofloxacin dose. This suggests that enrofloxacin may be a useful antibiotic option for a select 
group of late pregnant mares suffering severe bacterial infections.  In order to comply with 
appropriate antimicrobial stewardship, enrofloxacin administration should be limited to life-
threatening infections where a microbial culture indicates microbial resistance to first line 
antimicrobials and a sensitivity to enrofloxacin. If enrofloxacin is administered to late pregnant 
mares, clients should be informed of the potential risks of fluoroquinolone administration, as this 
study does not rule out the possibility of a low incidence of toxicity. Additionally, practitioners 
should be aware that both enrofloxacin and ciprofloxacin cross the equine placenta, and that while 
no lesions were detected in the 30 day-old foal, enrofloxacin was administered for only 14 days, 
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and that antibiotics were discontinued at least a month before the mare foaled. Additional studies 
are warranted to investigate longer-term effects on foals after intrauterine exposure to 
fluoroquinolones, as well as exposure in the first or second trimester, or when the mare is treated 
for longer than fourteen days. 
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Figure 5.1: Representative images of computed tomography of the flexor tendons (left), the tendon tensile testing apparatus (middle), 





Figure 5.2. Mean (± SD) enrofloxacin (a) and ciprofloxacin (b) concentrations in the plasma of 
mares on day 1 and day 8 of oral enrofloxacin administration.  Mares (280 ± 4 days gestation) 




Figure 5.3: Representative gross images of the articular surfaces of the scapula (a) and proximal 
femur (b) of 5-wk-old foals at euthanasia. Foals were born from mares that were either untreated 
(Negative Control), treated with 7.5 mg/kg enrofloxacin orally SID x 14d at 280 days gestation 
(7.5mg/kg), treated with 15 mg/kg enrofloxacin SID x 14d at 280 days gestation (15 mg/kg). The 
two positive control foals were not treated during pregnancy, but foals were treated with 10 mg/kg 
enrofloxacin PO SID either for 7 d beginning at 2-wks-old, or for 10 d starting at 3-wks-old.  
 
Figure 5.4: Representative gross images of the articular surfaces the tarsus (a) and distal humerus 
(b) of 5-wk-old foals at time of euthanasia. Foals were born from mares that were either untreated 
(Negative Control), treated with 7.5 mg/kg enrofloxacin orally SID x 14d at 280 days gestation 
(7.5mg/kg), treated with 15 mg/kg enrofloxacin orally SID x 14d at 280 days gestation (15 mg/kg). 
The two positive control foals were not treated during pregnancy, but the foals were treated with 
10 mg/kg enrofloxacin PO once day either for 7 days beginning at 2-wks-old, or for 10 days 






Figure 5.5. Representative histological images (A-C,G,H 10x, D-F 40x) of articular cartilage of the left talus of 5-wk-old foals from 
mares that were either untreated (control, A,D), or treated with 7.5 mg/kg enrofloxacin orally once a day for 14 days (B,E), or 15 mg/kg 
enrofloxacin orally once a day for 14 days (C,F).  Image (G) shows the deep erosion present in the talus of a positive control foal (treated 
with 10 mg/kg enrofloxacin x 7d at 14 days of age), compared to the normal cartilage thickness of the distal scapula of the same foal 
(H). Haematoxylin & eosin stained slides.  




Figure 5.6. Representative histological images (a-c 10x, d-f 40x magnification) of articular cartilage of 5-wk-old foals demonstrating 
cartilage canals and associated changes observed in foals from all treatment groups. Mares were either untreated (control), or treated 
with 7.5 mg/kg enrofloxacin orally once a day for 14 days (7.5 mg/kg), 15 mg/kg enrofloxacin orally once a day for 14 days (15 mg/kg), 
or the mares were not treated during gestation and the foal was treated with 10 mg/kg enrofloxacin orally for 7 days starting at 14 days 
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ABSTRACT 
Enrofloxacin may be a suitable antibacterial agent to treat select unresponsive infections 
in pregnant mares. Recent work has shown that enrofloxacin and ciprofloxacin cross the equine 
placenta without causing gross lesions in the third trimester fetus. However, long-term effects on 
the cartilage of in utero exposure to fluoroquinolones are unknown.  The aim of this study was to 
utilize quantitative magnetic resonance imaging (qMRI) and biomechanical testing to evaluate the 
limbs of foals exposed to enrofloxacin during the third trimester of pregnancy. Healthy mares at 
280d gestation were allocated into three groups: untreated (n=5), therapeutic treatment (7.5 mg/kg 
enrofloxacin, PO, n=5), or supratherapeutic treatment (15 mg/kg, PO, n=6) for 14 days. Mares 
were allowed to foal, and foals were maintained on pasture for 30 days. At 30 days, foal stifles, 
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hocks, elbows, and shoulders were radiographed, foals were euthanized, and foal limbs were 
analyzed by quantitative MRI, structural MRI, and biomechanical testing. Osteochondral lesions 
were detected in both treated and control foals on both radiographs and structural MRI. Severe 
cartilage erosions, synovitis, and joint capsular thickening was identified on foals treated with 
enrofloxacin post-partum. Median cartilage T2 relaxation times differed between joints, but did 
not differ between treatment groups. While further research is needed to address long-term foal 
outcomes, no differences were seen in advanced imaging or biomechanical testing at 30 days of 
age, and enrofloxacin may be useful for select bacterial infections in pregnant mares.  
 
Keywords: fluoroquinolone, ciprofloxacin, pregnancy, fetal toxicity, qMRI  
 
INTRODUCTION 
Antimicrobial therapy is necessary for pregnant mares with bacterial infections; however, 
the toxicity of many antimicrobials is not known. Fluoroquinolones are believed to be 
chondrotoxic to the fetus given the known side effects in growing animals, and fluoroquinolones 
are generally avoided in pregnant animals [1-3].  Quinolones such as enrofloxacin are believed to 
induce arthropathies by chelating divalent cations such as magnesium (Mg2+) [4-8], and in vitro 
and in vivo studies indicate that administration of enrofloxacin may cause tendonitis and 
arthropathies, especially in young, growing animals [2,9,10].  While limited previous research in 
neonates of other species might suggest that enrofloxacin should be avoided in pregnant mares, 
enrofloxacin is reportedly safe to administer during canine pregnancy according to the 
manufacturer label.  
Recent work has shown that enrofloxacin and ciprofloxacin cross the equine placenta 
without causing detectable lesions in the fetus, when enrofloxacin is administered intravenously 
for 11 days in late pregnancy [11]. However, orthopedic lesions such as osteochondral dissecans 
do not become apparent until after birth in the horse [12,13], and it is possible side effects might 
not be apparent until after the resulting foal becomes weight bearing. Traditionally, toxicity studies 
have determined adverse effects based on clinical signs, blood work, and histological evaluations 
of tissues of interest. Given the athletic demands of the horse, and reports of tendon rupture in 
humans after long-term use [14,15] it is vital to confirm that enrofloxacin does not affect the long-
term cartilage health of treated animals.  Additionally, given the dynamic nature of osteochondral 
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lesions in the growing foal, long-term studies need additional ways to evaluate pathology over 
time.  
Currently, magnetic resonance imaging (MRI) is the best non-invasive modality to evaluate 
cartilage, and there are a number of sequences that have been used to evaluate articular and physeal 
cartilage in foals [16-18]. Quantitative MRI (qMRI) can be used to evaluate proteoglycan content 
(T1 mapping) and collagen structure (T2 mapping), and has been used recently to evaluate 
osteochondrosis in the foal stifle [16,17]. T2 mapping has been used to evaluated normal cartilage 
development in humans [19,20], and to evaluate cartilage necrosis after surgically induced femoral 
lesions in goat kids [21], and cartilage repair after surgically induced lesions in rabbits [22]. 
Validation of qMRI for lesion detection in equine toxicology studies would enable long-term 
follow up and potentially limit, or eliminate, the need for terminal studies to determine lesion 
incidence and severity. 
The objectives of this study were (i) to determine if exposure to enrofloxacin and 
ciprofloxacin in utero results in radiographic lesions at 30 days of age, (ii) to determine if qMRI 
enabled the detection of minor lesions not noted on gross or histopathological analysis,  (iii) to 
determine if enrofloxacin administration to pregnant mares affected biomechanical properties of 
the 30-day-old equine stifle, and (iv) to determine if in utero enrofloxacin affected cartilage gene 
expression at 30 days of age. We hypothesized that enrofloxacin administration during late 
gestation would not affect foal health or soundness by 30 days of age. 
 
MATERIALS AND METHODS 
The study protocol was approved by the University of Illinois Urbana-Champaign 
Institutional Animal Care and Use Committee (protocols, #14243 and #17245). The present study 
was carried out between 2015 and 2018. Nineteen healthy, light-breed pregnant mares (10 
Standardbreds, two Quarter Horses, two Thoroughbreds, two ponies, two grade horses, and one 
Tennessee Walking Horse) were enrolled in the study at 280 days gestation.  The mares were kept 
at the Veterinary Medicine Research Farm at the University of Illinois in Urbana, Illinois, where 
they were housed on pasture and supplemented with grass hay and trace minerals.  
Mares were included in the present study if physical examinations and ultrasonography of 
the caudal placental pole were within normal limits. Mares were randomly allocated to three 
groups: recommended dose of enrofloxacina (7.5mg/kg, PO, n=6), double therapeutic dose of 
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enrofloxacina (15 mg/kg, n=6), no enrofloxacin (n=5), or positive control (n=2). Mares in the no 
enrofloxacin and positive control groups were not treated during pregnancy. The oral formulation 
of enrofloxacin used in this study has previously been shown to be well absorbed by pregnant 
mares [23].  
All mares carried their foals to term and mare and foal treatments and outcomes were 
previously described [24].  The two foals allocated to the positive control group were administered 
7.5 mg/kg enrofloxacin PO once a day for seven days starting at 14 days of age (foal 1) or once a 
day for 10 days starting at 21 days of age (foal 2).  At 30 days of age, foals were euthanized with 




Prior to euthanasia, standard four-view radiographs were taken of the carpus, hock, and stifle, and 
two views were taken of the elbow and shoulder. Additionally, two-view radiographs were taken 
of any effusive or swollen fetlock or pastern joint. All radiographs were reviewed by a board-
certified veterinary radiologist (Childs).  
 
Pathology 
 After euthanasia, foal limbs were removed from the foal, and the left limbs were wrapped 
for immediate MRI. After MRI, the left stifle was further dissected, wrapped in saline-soaked 
paper towels and plastic wrap, and frozen at -20ºC until biomechanical testing. The remainder of 
the limbs were then disarticulated, and all joint surfaces were evaluated by a board-certified 
pathologist.  
 
Magnetic Resonance Imaging 
The left front and hind limbs were orientated parallel to the main magnetic field, and 
imaged with a Prisma 3T MRI scannerc.  The imaging protocol included include structural 
imaging for high resolution delineation of cartilage, and quantitative T2 mapping of four joints: 
the scapula-humeral, humerus-radioulnar, femoral-tibial, and tibo-tarsal. Structural imaging 
included the entire joint, and structural scans were then used to place two slice groups of spin-
echo sequences in the center of each condyle, as shown in Fig. 6.1. Because the scapula-humeral 
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joint does not include two condyles, one slice group consisting of five slices was placed in the 
center of the joint (scan time: 5’54’’).    
Structural imaging was performed with a 3D Double Echo Steady State (DESS) sequence 
with a sagittal orientation (Repetition Time: 14.84 ms, Echo Time:  5.04 ms, flip angle: 25⁰, 
Field of view 150 x 140 mm, matrix size: 256, 160 slices, slice thickness: 0.6 mm, GeneRalized 
Autocalibrating Partial Parallel Acquisition (GRAPPA) acceleration factor: 2, phase partial 
Fourier: 7/8, slice partial Fourier: 6/8, scan time 3’6’’). T2 mapping was performed using a 2D 
multi-echo spin-echo sequence (Repetition Time: 2800 ms, 32 echo times linearly spaced from 
14 ms to 448 ms, flip angle: 150⁰, Field of view: 140 x 140 mm, matrix size 256, two slice 
groups with three slices each, slice thickness: 3 mm, slice gap:  0.6 mm, GRAPPA acceleration 
factor: 2, scan time:  6’36’’). All structural MRIs were evaluated by a board-certified equine 
surgeon (Garrett) for cartilage integrity. 
All joints included in the MRI portion of the study were evaluated by a scoring system 
adapted from Smith et al 2016 [25]. Images were scored ordinally based on nine articular 
cartilage or bony lesions. Cartilage signal abnormalities were scored based on changes in signal 
and morphology on the DESS images, and were graded as: 0 = no abnormalities, 1= single 
lesions <5mm, 2= single lesion 5- 10mm, or multiple lesions < 5 mm, 3= single lesion > 10 mm, 
or multiple lesions < 10 mm.  High signal bone lesions were defined as poorly-marginated areas 
of increased signal intensity in normally hypo-intense trabecular or subchondral bone, and were 
evaluated by the size of high signal bone lesion based on regional involvement. A score of 0 
indicated no abnormalities, 1 indicated <25% involved, 2 indicated 25-50% involved, and 3 
indicated > 50% involved. The intensity of a lesion was graded on severity of signal increase 
compared to surrounding subchondral/trabecular bone, and a grade of 0 indicated no 
abnormalities, 1 indicated mild, 2 indicated moderate, or 3 indicated marked signal changes. 
Subchondral bone irregularities were also scored on severity, with 0 defined as a smooth and 
regular chondro-osseous junction, 1= mild subchondral plate irregularity, 2= marked 
subchondral plate irregularity extending to trabecular bone, 3= bone irregularity extending to 
trabecular bone with some normal bone trabecular pattern, and a 4 = cyst like formation.  
Ligaments were defined as normal (0), or abnormal (1). Synovial thickening was evaluated as 
normal, or abnormal based on intensity and distribution of synovium.  A score of 0 indicated no 
abnormalities, indicated mild, 2 indicated moderate, and 3 indicated marked distension.  Joint 
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effusion was graded as normal (0), <33% max distension (1), >33 and <66 % max distension (2), 
or >66 % max distension (3). Osteochondral lesions were identified by number of fragments, 
with 0 = no abnormalities, 1= 1 fragment, 2= 2 fragments, or 3 indicating >2 fragments.  
Osteochondral lesion size was measured, and classified as 0 (no lesions), 1 (< 250 mm2 lesion), 2 
(250-500 mm2 lesion), or 3 (>500 mm2 lesion).  
 
Statistical analysis 
Data were analyzed using R libraries (R version 3.3.3)d. Scores were not normally 
distributed and were reported as median (minimum, maximum).  The Wilcoxon Signed Rank 
Test was used to test the null hypothesis that median scores for pathological changes was not 
different between the control, 7.5 mg/kg, 15 mg/kg, and Positive control groups.  Mean T2- 
relaxation times, and biomechanical testing results were compared by one-way ANOVA, and a 
Tukey HSD was used for post-hoc analysis. Significance was set a p <0.05.  
 
T2- data processing 
T2-maps were generated from the spin-echo sequence using specialized Matlab ®e codes 
written for the study (Supplement 6.1).  This code calculated a T2 relaxation time for each voxel 
by fitting the signal, S, obtained at each echo time to the equation .  Before 
performing the fit, signals from the lowest echo times, 14, 28 and 52 ms were discarded.  Low 
signals obtained at longest echo times were also discarded.  To obtain representative T2 values 
from various regions within the cartilage, a line was drawn across the cartilage, and a seed T2 
time identified from the line generated (Fig. 6.2). This seed T2 time was then used to create a 
map of the cartilage, and a line was drawn down the middle of the cartilage. Mean and standard 
deviation cartilage relaxation time was then calculated (Fig 6.3). This was repeated for five 
different locations in the femoro-tibial joint, and one location in the tibiotarsal, scapula-humeral, 
and humeral-radius joint. Mean relaxation time was calculated for the six different slices through 
the joint. 
 
Cartilage pressure testing 
Cartilage pressure testing was conducted in the laboratory of Dr. Mariana Kersh, in the 
Department of Mechanical Engineering. One tibiofemoral joint per foal (the same limb used for 
( )21 /exp TTEcS -=
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qMRI) was frozen at -80C immediately after quantitave MRI until analysis.  After thawing, the 
stifle was mounted in a custom fixture (Fig. 6.4), which allowed the tibiofemoral joint to be 
placed in a physiologically relevant position for pressure testing using a hydraulic testing devicef. 
Cartilage pressure was measured by a dynamic measurement sensorg, and a dynamic pressure 
map was created that is used to determine average pressure during stifle compression.    
 
Cartilage gene expression 
Full-thickness articular cartilage was harvested from the coxo-femoral joint immediately 
after foal euthanasia, and was snap frozen in liquid nitrogen until processing. RNA isolation was 
done as previously described [26], cartilage was pulverized while still frozen, and then 
homogenized on ice in a buffer of 4M guanidinium isothiocyanate, 0.1 M Tris-HCL, 25 mM EDTA 
and 1% (v/v) 2-mercaptoethanol. Total RNA was isolated by phenol/chloroform extraction and 
precipitated using isopropanol. RNA samples were purified using a QIAGEN RNeasy kitf 
according to manufacturer instructions.  For RT-PCR, one microgram of total RNA was reverse 
transcribed into cDNA using oligo-dT primers.  RT-qPCR was performed in duplicate using the 
7900 HT Fast Real-Time PCR Systemsh, TaqMan Gene Expression Master Mixh and equine 
primer/probes listed in Table 1. Elongation factor-1alpha and GAPDPH were used as reference 
genes. Gene-specific primers were designed for previous studies using sequences available in 
Genbank. Relative expression of genes of interest were normalized to control genes. Equine 
synovial RNA from osteoarthritic joints was used as an additional positive control.  For each gene 
of interest, mean fold change from control foals was calculated for each treatment group by 
comparing mean expression for each treatment group using the 2-DDCT method [27]. Statistical 




 Osteochondral lesions were detected in seven of the eighteen foals (Table 6.2), with lesions 
present in 2/5 Control foals, 3/5 foals in the 7.5 mg/kg group, 2/6 foals in the 15 mg/kg group, and 
neither of the foals in the Positive control group.  Moderate to severe joint effusion was seen in all 
imaged joints of one positive control foal, and mild to moderate effusion was seen in the tibiotarsal 
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joints of the other positive foal, and moderate intracapsular effusion of the tibiotarsal joint of one 
Control foal, associated with an osteochondral defect in the medial malleolus.  
 
Structural MRI 
 Osteochondral lesions were detected in seven of the eighteen foals, as seen on radiographs.  
Moderate to severe joint effusion was seen in the femoro-tibial and tibiotarsal joints of one positive 
control foal, and mild to moderate effusion was seen in the tibiotarsal joints of the other positive 
foal, and moderate intracapsular effusion of the tibiotarsal joint of one Control foal, associated 
with an osteochondral defect in the medial malleolus. In addition, severe cartilage erosion was 
noted on the medial and lateral trochlea of one positive control foal, and in addition to the joint 
effusion noted on radiographs, moderate intracapsular effusion was noted in the scapula-humeral 
and humero-radial joints (Fig. 6.5). The punctate lucencies seen in the medial trochlea of one foal 
from the High group were also noted on structural MRI. Median, minimum and maximum MRI 
scores were significantly different between positive control foals and the other three groups as 
shown in Table 6.3, but no differences were seen between control and in utero exposed foals for 
any category.  
 
Quantitative MRI 
Median cartilage T2 relaxation times differed between joints and but did not differ between 
treatment groups, or within joints, as can be seen in Fig. 6.6.  
 
Biomechanical testing 
No differences were seen between treatment groups in cartilage stiffness (Control 65 ± 12.5 N/mm, 
7.5 mg/kg 49 ± 15 N/mm, 15 mg/kg, 71 ± 17 N/mm) or peak load at failure (Control 600 ± 175 N, 
7.5 mg/kg 700 ± 215 N, 15 mg/kg, 560 ± 310 N).  
 
Cartilage mRNA expression 
Quantitative PCR analysis revealed that expression of most cartilage genes did not differ after in 
utero exposure to enrofloxacin (Fig. 6.7). No significant differences were seen in ADAMST4, 
MMP2, MMP3, or MMP9 expression between groups, and expression of MMP13 was only 
significantly increased in the osteoarthric positive control sample.  Similarly, no differences were 
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seen in Col IIA, Col X, AGG, or Sox 9 expression.  There was a 10-fold increase in Alk Phos 
expression in the positive control foals. 
 
DISCUSSION 
This study was initiated in an effort to enhance the ability to detect potential significant 
cartilaginous changes after in utero fluoroquinolone exposure. Enrofloxacin administration to late 
pregnant mares failed to induce clinical or subclinical disease in the foals in this study, and gross 
and histological observations were similar to those described on advanced imaging.  Radiographs 
were sufficient to pick of osteochondral lesions at a rate similar to lesion discovery on MRI. 
Osteochondrosis was noted in both treated and untreated foals, and there were insufficient numbers 
in this study to determine if treatment increases incidence of lesions. Additionally, many 
osteochondrosis lesions resolve before a year of age in foals, so it is possible that if the study 
duration had been longer, lesions detected before 30 days of age would have resolved. 
Unsurprisingly, MRI detected subtle increases in joint effusion that were not noted on 
physical examination, and joint effusion was seen in both foals treated with enrofloxacin 
postpartum, as well as a control foal with an osteochondral lesion that was not noted at time of 
euthanasia. Additionally, MRI detected mild cartilaginous changes that were previously described 
on gross histology [24], in addition to mild changes in the subchondral bone.  It appears that MRI 
would be a feasible alternative to evaluate ongoing changes in long-term toxicology studies to 
reduce or eliminate the number of animals required for a terminal study. No differences were noted 
in articular cartilage T2 relaxation times between any of the control or treated groups, which 
suggests that enrofloxacin exposure does not affect cartilage in a significant way to affect the water 
content in the cartilage.  The failure to see a difference in relaxation times in the positive control 
animals may be in part due to the fact that the severe cartilage erosion the affected joints prevented 
generation of the same global cartilage map in those joints. Irrespective of the positive control 
foals, the similar T2 relaxation times between in utero exposed foals and control foals suggest that 
cartilage structure was similar between groups.  
The mechanism for the severe cartilage erosions in one foal treated at 14 days of age is still 
unclear.  In vitro studies with equine cartilage did not show an increase in GAG degradation in 
cartilage explants exposed to enrofloxacin [28], and it is possible that either lesions are due to 
decreased GAG production in treated animals, or failures in integrin function and cell adhesion. 
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The failure to detect a difference in mRNA expression in the foals is perhaps not surprising given 
previous findings in vitro at physiological enrofloxacin doses [29].  In vitro work by Davenport et 
al suggested that enrofloxacin concentrations reached 25 µg/ml before having an effect on 
chondrocyte GAG production[28], and work by Beluche et al confirmed that no effects were seen 
in equine explant cultures at enrofloxacin doses of 10 µg/ml, but were seen at 100 µg/ml [29].  
Previous work demonstrated mean synovial enrofloxacin concentrations of 4.71 µg/ml (5 mg/kg 
enrofloxacin PO BID for 4 days) in adult horses [30], which suggests that systemically 
administered enrofloxacin does not reach toxic doses in the synovial fluid when administered at 
recommended dosages in adult horse. Findings in the current study would suggest that similarly to 
adult horses, systemically administered enrofloxacin does not reach toxic concentration in the fetal 
synovial fluid, and that short-term exposure in utero exposure at physiologically relevant doses 
may not have long term effects on the resulting foal.  In contrast, a toxic dose may be achieved if 
administered to the neonate as previously shown [10].  
Minimal changes were seen in mRNA expression even in our positive control foals. One 
explanation is that only two animals were available for this study. A second explanation is the joint 
from which the cartilage was harvested. The acetabulum was chosen to allow for cartilage 
collection immediately after euthanasia without interfering with MRI or histological analyses. 
However, this joint was not affected grossly even in the positive control foals.  In hindsight, given 
the significant differences in cartilage lesions observed in the positive control animals, it is possible 
differences would have been seen in mRNA expression with cartilage harvest from the tarsus or 
scapula-humeral joint.  Unfortunately, the positive control animals were the final animals selected 
in the study, at which point cartilage had already been selected from the in utero exposed and 
control foals. Additionally, cartilage was collected at termination of the experiment, not during, or 
immediately after enrofloxacin exposure.  It is possible that differences would have been noted if 
cartilage had been collected in utero; however, the objectives of this study were to determine 
longer-term consequences to in utero exposure, thus, small changes in expression in utero might 
not have a significant effect on the cartilage of the neonatal foal.  The only significant increase in 
mRNA expression was alkaline phosphatase expression in the positive control foals treated post-
partum. While this has not been described previously in enrofloxacin treated animals, it is perhaps 
not surprising given a reported increase in bone alkaline phosphatase in the synovial fluid of horses 
with active osteoarthritis.  
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In a parallel study looking at foal outcomes, we noted that mare serum magnesium levels 
did not change throughout the course of the study, and that neonatal foal magnesium levels were 
normal [24]. Given that in vitro enrofloxacin studies have shown that media type effects the toxic 
enrofloxacin dose [28], it is also important to consider that fetal effects may be different in 
systemically compromised mares, or mares on poor diets. One limitation of this study was that it 
was conducted in healthy mares, and it is unknown how placentitis would affect placental drug 
transfer.  Additionally, foals were only monitored until one month of age, and it is possible that 
either tendon or cartilage damage may take longer to appear, or that the OC lesions seen here 
would resolve by a year of age, as they do in up to 50% of foals that demonstrate lesions at one 
moth of age (personal communications with Dr. Annette McCoy).  
Further studies assessing long-term effects of in utero exposure are warranted.  Similarly, 
this study focused on potential side effects in the third trimester, and safety of fluoroquinolone 
administration in the first two trimesters is still unknown.  Practitioners should advise clients of 
the current research investigating long-term effects on the foal, and ensure that they are not 
administering supratherapeutic doses. Collectively, these findings suggest that enrofloxacin 
administration to the late pregnant mare does not have apparent detrimental effects on the cartilage 
of the resulting foal. This suggests that enrofloxacin may be a useful antibiotic option for a select 
group of late pregnant mares suffering severe bacterial infections.  
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TABLES AND FIGURES 
 
 Table 6.1.  Primers used for qPCR reactions. 
Gene BP S/AA Primer 
EF1a [32]  328 S CCCGGACACAGAGACTTCAT 
  A AGCATGTTGTCACCATTCCA 
Coll II [33]  S TTCTGGAGACCAAGGTGCTT 
  A CATTCAGGGTGGCAGAGTTT 
Aggrecan [32] 202 S 5'GACGCCGAGAGCAGGTGT 
  A 5'AAGAAGTTGTCGGGCTGGTT 
MMP3 [33]  S 5' GTTGGACAGATCTGCAAGGG 
  A 5' ATGTAAGTGGAGTCACCTCC 
MMP9  S 5’ GACATCGTCATCCAGTTTGG 
  A 5' GTAGAGTCTCTCGCTGGGGC 
TNFa  S 5’ AGCCCATGTTGTAGCAAACC 
  A 5’ GAGACAGCTAAGCGGCTGAT 
MMP13  S 5’ GGTGCAAGCTCATCTGTCAA 
  A 5’ GTGGCTCCAGTTGGAATTGT 
ADAMTS4  S 5' ATGGCTATGGGCACTGTCTC 
  A 5' ATTGAGATGGCCAGAACACC 
MMP2  S 5' TACGATGACGACCGAAAGTG 
  A 5' CCCGTAGAGCTCTTGAATGC 
Coll X [32] 244 S 5' TGCCAACCCAGGGTGTAACAG 
  A 5' ACATTACTGGGGTGCCGTTC 
Sox9 [32] 304 S 5' GAACGCACATCAAGACGGAG 
  A 5' CTGGTGGTCTGTGTAGTCGT 
ALP [32] 260 S 5' CCACGTCTTCACATTTGGTG 
  A 5' AGACTGCGCCTGGTAGTT 
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Table 6.2.  Foal signalment and radiographic findings at 30 days of age. Foals were from mares that were either untreated (control, n=5), or treated 
with 7.5 mg/kg enrofloxacin orally once a day for 14 days (7.5 mg/kg, n=5), or 15 mg/kg enrofloxacin orally once a day for 14 days (15 mg/kg, n=6) 
starting at 280 days gestation.  Positive control foals (n=2) were not treated during pregnancy, but were treated with 10 mg/kg enrofloxacin PO once 




Table 6.3.  Foal cartilage and joint scores based on structural MRI. Scoring system was adopted 
from Smith et al 2016 [157]. Scores are reported as median (minimum, maximum) Foals were 
from mares that were either untreated (control, n=5), or treated with 7.5 mg/kg enrofloxacin orally 
once a day for 14 days (7.5 mg/kg, n=5), or 15 mg/kg enrofloxacin orally once a day for 14 days 
(15 mg/kg, n=6) starting at 280 days gestation.  Positive control foals (n=2) were not treated during 
pregnancy, but were treated with 10 mg/kg enrofloxacin PO once day for either 7 days beginning 
at 14 days gestation, or for 10 days starting at 21 days gestation. * Denotes significantly different 
from the other groups, p< 0.05.  
 
 Control    7.5 mg/kg    15 mg/kg      Positive 
Cartilage signal (0-3) 0 (0-2) 0 (0-1) 0 (0-1) 2 (0-3)* 
Bone Lesions (0-3) 0 (0-1) 0 (0-1) 0 (0-1) 1 (0-2) 
Subchondral bone (0-3) 0 (0-0) 0 (0-0) 0 (0-2) 1 (0-1) 
Synovium (0-3) 0 (0-1) 0 (0-0) 0 (0-0) 2 (0-3) * 
Joint effusion (0-3) 0 (0-2) 0 (0-1) 0 (0-1) 2 (1-3) * 
Osteochondral lesion (0-3) 0 (0-1) 1 (0-1) 0 (0-2) 0 (0-2)  





Figure 6.1.  Structural (DESS) image of the femoro-tibial joint for placement of two slice groups 
(yellow lines) of spin-echo sequences in the center of each condyle in sagittal orientation for T2 
spin-echo sequences. Because the scapula-humeral joint does not include two condyles, one slice 





Figure 6.2.  Median T2 relaxation time calculation for a foal stifle (clockwise from upper left). 
Quantitative map of T2 values with the region of interest highlighted with a red line. T2 values in 
the cartilage are approximately 90 ms, and in the synovial fluid are approximately 180 ms. 
(Upper right) T2 relaxation times across the highlighted region of interest. Seed T2 time is 
highlighted by the blue square.  The corresponding segment of cartilage (lower left), and a 









Figure 6.3. Median T2 relaxation time calculation for a foal distal femur (top row) and foal proximal humerus. The seed time selected 
in figure 6.2 was used to generate the cartilage maps on the left. The corresponding line drawn across the cartilage is shown in the 




Figure 6.4. Stifle cartilage stress-relaxation testing. Top images are of the stifle of a 33-day old 
foal, loaded into the custom designed pot and mounted in the Instron machine. The Tek-scan 







Figure 6.5.  Structural MRI of the tibiotarsal joints (A-D) and femorotibial joints (E-H) of 35 ± 3 day old foals. Limbs were imaged 
immediately after euthanasia. Foal A&E was never treated with fluoroquinolones, Foals B,C,F&G were born to mares treated with 
fluoroquinolones for 14 days at 300 days gestation (B& F, 7.5 mg/kg PO and C&G, 15 mg/kg PO). Foal D&H was treated with 10 
mg/kg enrofloxacin orally for 7 days at 14 days of age.  The red rectangle highlights the severe joint effusion and pericapsular 






Figure 6.6. Mean T2 relaxation times for articular cartilage of the femur, tibia, shoulder, and femoral physis of 35 ± 3 day old foals.  
Foals were born to mares treated with either 7.5 mg/kg oral enrofloxacin (n=5) or 15 mg/kg oral enrofloxacin (n=6) for 14 days during 
the third trimester, from foals never exposed to enrofloxacin (Control, n=4), or from foals treated with 10 mg/kg oral enrofloxacin for 







Figure 6.7. Relative mRNA expression in articular cartilage of the acetabulum of foals from 
mares treated with either 7.5 mg/kg oral enrofloxacin ( n=5) or 15 mg/kg oral enrofloxacin ( 
n=6) for 14 days during the third trimester, or from foals treated with 10 mg/kg oral enrofloxacin 
for 7-10 days at 14 days of age (Positive) compared to foals never exposed to enrofloxacin 
(Control, n=4).  OA is a positive control for mRNA expression from the synovium of a mature 
horse with osteoarthritis. Error bars indicate standard deviation, and * denote significant 
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Supplemental material 6.1: MatLab code for generation of T2 relaxation maps, and for analysis 
of median cartilage relaxation times.  gq is the slice number and is adjusted for the desired 
slice of the desired condyle for analysis.   
 
%first view the dicom using the command: dicomread.  Use the pointer tool 
%to find the center of the vial of interest. 
  
samp = 'A'; 
vial_num = [1 2 3 4 5 6]; 
myxs = [167 145 109 167 145 109]; 
myys = [72 230 139 167 145 109]; 
  
samp_mark = 'ks-'; 
  
npts = 256; 
crad = 1; %this is the radius around center point for making a mask. The mask 
tells which voxels to average. 
  
for gq = 2:2 
  
    ycor = myys(gq); 
    xcor = myxs(gq); 
     
    %set up the meshgrid: 
    %the dist matrix tells you the distance between each voxel and the center 
    %voxel that you previously chose. 
    xvect = [1:npts]; 
    [xx yy] = meshgrid(xvect,xvect); 
    dist = sqrt((xx - xcor).^2 + (yy - ycor).^2); 
     
    masterdir = 
'/Users/ree44767/Desktop/Original_Data/Foal_15_A2/scans/4.stifel/DICOM'; 
    %TEs = [12 50 70 90 110 130 150 200 250 280 300]; 
    cd(masterdir) 
    TEs = [14 28 42 56 70 84 98 112 126 140 154 168 182 196 210 224 238 252 
266 280 294 308 322 336 350 364 378 392 406 420 434 448]; 
    fmd = dir(strcat('IM*')); 
    datl = zeros(size(TEs,2),npts,npts); 
    for pt = 1:size(TEs,2) %loop through files 
        pt2 = (pt-1)*6+gq; 
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        dat = dicomread(fmd(pt2).name); 
        d2 = dicominfo(fmd(pt2).name); 
        TEs_new(pt) = d2.EchoTime 
        figure(1) 
        imshow(dat) 
        imagesc(dat) 
        %sig(pt) = dat(ycor,xcor); 
         
        mask = zeros(npts,npts); 
        mask(find(dist<crad)) = 1; %define the mask 
         
        maski = ones(npts,npts); 
        maski(find(dist<crad)) = 0; %define the mask 
        %                 db = double(d2.RescaleIntercept); 
        %         dm = d2.RescaleSlope; 
        dat2 = double(dat); 
        %          dat2 = dat2.*dm + db; 
        datl(pt,:,:) = dat2; 
         
        modi = dat2.*mask; 
        figure(22) 
        imagesc(dat2.*maski) 
        %pause(0.5) 
        [r, p, v] = find(modi); 
        sig(pt) = mean(v);  %average the intensity of all the points in the 
mask. 
        pt 
    end 
    datl = datl(3:23,:,:); 
    sig = sig(3:23); 
    TEs = TEs(3:23); 
    figure(2) 
    semilogy(TEs,sig,'ks','linewidth',2,'markersize',8) 
    set(gca,'YMinorTick','on') 
    set(gca,'XMinorTick','on') 
    hold on; 
    for i1 = 1:npts 
        i1 
        for i2 = 1:npts 
            yfit = squeeze(datl(1:size(TEs,2),i1,i2))'; 
            [r, c,v] = find(yfit==0); 
            if size(c,2) ~= 0 
                yfit = yfit(1:c(1)-1); 
                xfit = TEs(1:c(1)-1); 
            else 
                xfit = TEs; 
            end 
            yfit = log(yfit); 
%             if (i1 == 193) && (i2 == 151) 
%                 asdf=5 
%             end 
            [ps] = polyfit(xfit,yfit,1); 
            T2m(i1,i2) = 1/ps(1); 
        end 
    end 
    % %1/ps(1) is T2, which is 2333 ms. 
    %ylim([800 1200]) 
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    T2_measurement = 1/ps(1) 
     
    TEsa = [0:.01:400]; 
    Ssa = exp(ps(1)*TEsa + ps(2)); 
    plot(TEsa,Ssa,'k-','linewidth',2) 
     
    set(gca,'TickLength',[0.03 0.03]) 
    set(gca,'Fontsize',26','linewidth',3) 
    xlabel('TE (ms)','fontsize',26) 
    ylabel('Signal a.u','fontsize',26) 
    xlim([0 500]) 
     
    T1s_meas(gq) = -T2_measurement; 
    
cd(strcat('/Users/ree44767/Desktop/Original_Data/Foal_15_A2/scans/4.stifel/DI
COM')); 
    print('-f22', '-
dtiff',strcat('vial_pick_',samp,'_',num2str(vial_num(gq)),'.tif')); 
    print('-f2', '-
dtiff',strcat('T2_',samp,'_',num2str(vial_num(gq)),'.tif')); 
     
    close all 
end 
  
T2m(isnan(T2m)) = 0; 




set(gca,'xticklabel',{' '});  
set(gca,'yticklabel',{' '});  
colorbar('fontsize',16,'linewidth',1) 
% 
% T1_A = T1s_meas(1:7); 
% figure(55) 
% plot(T1_A,samp_mark,'linewidth',2) 



























% set(gca,'xticklabel',{' '});  













lleng = sqrt(range(x)^2+range(y)^2); 
Npts = round(lleng/0.5); 
  
ax = linspace(x(1),x(2),Npts); 




[X,Y] = meshgrid(1:256); 
  
T2q = interp2(X,Y,T2m,ax,ay); 
T2q(isinf(T2q)) = 1E4; 
T2q(isoutlier(T2q)) = median(T2q); 
  
if range(ay) > range (ax) 
    mycoor = ay; 
    mycoor_vox = round(ay); 
    myc_label = 'Y'; 
elseif range(ay) <= range (ax) 
    mycoor = ax; 
    mycoor_vox = round(ax); 







%work at single voxel level: 
  
rax = round(ax); 
ray = round(ay); 
  
clear bm 
for ii = 1:Npts 




 T2vox = interp2(X,Y,T2m,rax,ray); 
T2vox(isinf(T2vox)) = 1E4; 
T2vox(isoutlier(T2vox)) = median(T2vox); 
  
plot(mycoor_vox,T2vox,'rs-') 
% hold on 
% plot(mycoor_vox,bm,'bd-') 
  
[mycor_seed,yseed] = ginput(1) 
  
if range(ay) > range (ax) 
    yseed = round(mycor_seed);     
    xseed = rax(find(ray==yseed));     
elseif range(ay) <= range (ax)     
    xseed = round(mycor_seed);     




    xseed = xseed(1); 
end 
if length(yseed)~=1 
    yseed = yseed(1); 
end 
disp(strcat('Seed T2: ',num2str(T2m(yseed,xseed)))) 
  
seedT2 = T2m(yseed,xseed); 
  
%%%%%% now the make region file %%%%%% 
  
figure(33) 













%smooth the histogram: 
  
[heights,centers] = hist(allT2s); 
% hold on 
% ax = gca; 
% ax.XTickLabel = []; 
n = length(centers); 
w = centers(2)-centers(1); 
t = linspace(centers(1)-w/2,centers(end)+w/2,n+1); 
p = fix(n/2); 
% fill(t([p p p+1 p+1]),[0 heights([p p]),0],'w') 
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% plot(centers([p p]),[0 heights(p)],'r:') 
% h = text(centers(p)-.2,heights(p)/2,'   h'); 
% dep = -70; 
% tL = text(t(p),dep,'L'); 
% tR = text(t(p+1),dep,'R'); 
%hold off 
  
dt = diff(t); 
Fvals = cumsum([0,heights.*dt]); 
  
F = spline(t, [0, Fvals, 0]); 
  
DF = fnder(F);  % computes its first derivative 
% h.String = 'h(i)'; 
% tL.String = 't(i)'; 
% tR.String = 't(i+1)'; 
hold on 
fnplt(DF, 'r', 2) 
hold off 
ylims = ylim;  
ylim([0,ylims(2)]); 
  
%now find the peak: 
  
t2a = median(allT2s)+[-iqr(allT2s)/2:0.01:iqr(allT2s/2)] 
  
%t2a = min(ab):0.01:max(ab) 
bs = fnval(DF,t2a); 
  
[Y ind] =max(bs); 
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ABSTRACT 
 Enrofloxacin may be an alternative antibacterial agent to treat severe infections in pregnant mares. 
While enrofloxacin and ciprofloxacin diffuse to the fetoplacental unit without causing obvious 
lesions in the 9-mo fetus or resulting foal, the effects of fluoroquinolone exposure in the first 
trimester are unknown. Since four to eight weeks of gestation is a critical time for skeletal 
development in the horse, it is possible that fluoroquinolones are more chondrotoxic to the fetus 
in early gestation. The objectives of the following study were to assess effects of 2-wks-exposure 
to enrofloxacin on the equine fetus between 6-8 wks gestation. Healthy mares at 46d gestation 
were allocated into two groups: untreated (n=7), or treatment (7.5 mg/kg enrofloxacin, PO x 14 
days, n=6). Prostaglandin was used to induce abortion 24 hours after the last enrofloxacin dose, or 
on the equivalent day of gestation for untreated mares. Pregnancy fluids from treated mares were 
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analysed for enrofloxacin and ciprofloxacin concentrations. Fetal organs (heart, lungs, spleen, 
kidney, and liver) and limbs were examined histopathologically.  Enrofloxacin and ciprofloxacin 
diffused to the fetal fluids during early gestation and did not result in detectable abnormalities in 
the fetus after 14 days of treatment.  Enrolled mares were healthy during treatment, and antibiotic 
effects may be different in ill animals. It is also possible that histological evaluations were not 
sensitive enough to detect subtle changes or long-term consequences. Short-term administration 
of enrofloxacin to early gestation mares did not result in pathologic lesions in the fetus. While 
further research is needed to assess other stages of gestation and to determine if enrofloxacin 
administration during early pregnancy potentiates osteochondral changes later in life, enrofloxacin 
may be useful for select bacterial infections in pregnant mares. 
Keywords: fluoroquinolone, ciprofloxacin, pregnancy, horse, fetal toxicity  
 
INTRODUCTION 
During pregnancy, antimicrobial therapy is necessary to treat bacterial diseases ranging 
from pneumonia or septic arthritis to peritonitis and placentitis. Enrofloxacin, a fluoroquinolone 
antimicrobial with documented bactericidal activity against Gram-negative and some Gram-
positive equine pathogens [1], would be useful if safe to administer to pregnant mares. 
Fluoroquinolone antibiotics are thought to be chondrotoxic to the fetus, and this drug class is 
generally avoided in pregnant mares. Studies conducted in vitro and in vivo have demonstrated 
enrofloxacin exposure can cause tendonitis and arthropathies, especially in young, growing 
animals [2-4]. Quinolone-induced arthropathy is mediated via chelation of divalent cations such 
as magnesium (Mg2+), which affects fibronectin signalling and integrin function, leading to 
disturbances in cell adhesion, proliferation, and proteoglycan synthesis, and ultimately changes 
in cartilage architecture [5-9].  
Despite concerns about toxicity, clinicians occasionally select enrofloxacin to treat multi-
drug resistant infections when mare survival outweighs potential risks to the fetus. Two recent 
studies suggest enrofloxacin administration in late pregnancy may not affect the fetus or 
subsequent foal [10,11]. However, even if no side effects are seen with fluoroquinolone exposure 
in late pregnancy, it is possible that toxicity would occur in the first trimester, when 
organogenesis and limb development begin [12,13].  
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Normal limb bud development begins around 20 days gestation in the horse, and is 
quickly followed by footpad and elbow joint formation (days 30 to 40). Around this time, the 
equine fetus first begins intrinsic muscular activity such as head movements [14]. Next the 
femorotibial joint develops, from initial cavitation at 45 days gestation, to complete joint 
formation by 65 days [15,16]. Cells present in the interzone of the forming embryonic joint are 
critical for proper joint formation [17,18], as these cells form the articular cartilage, ligaments 
associated with the joint, and synovial lining [19,20,21]. Articular chondrocytes descend from 
progenitor cells present in the interzone, and signals affecting these cells could compromise 
articular cartilage in the resulting foal. Collectively, 45-60 days of gestation is a critical time-
point in equine synovial joint development, making fluoroquinolone exposure potentially 
harmful during this time period.  
The objectives of this study were to determine: (i) if enrofloxacin or its metabolite 
ciprofloxacin crosses the early equine placenta (ii) if exposure to enrofloxacin and ciprofloxacin 
early in pregnancy causes developmental changes in the fetal limbs. We hypothesized that 
enrofloxacin administration during early gestation would affect cartilage development in the 
fetus. 
 
MATERIALS AND METHODS 
The study protocol was approved by the University of Illinois Urbana-Champaign 
Institutional Animal Care and Use Committee (protocol #16129), and the present study was carried 
out between November 2017 and August 2018. Nine healthy, light-breed pregnant mares were 
enrolled in the study at five weeks (45 days) of gestation.  Mares were kept at the Veterinary 
Medicine Research Farm at the University of Illinois in Urbana, Illinois, where they were housed 
on pasture and supplemented with grass hay and trace minerals.  
 
Animal husbandry and study design  
Nine clinically healthy, light-breed multiparous mares were enrolled in the study. Four of 
nine mares were bred for a second gestation to serve as their own treatment or control (Fig 1). The 
mares were 13 ± 4.5 yrs-old and were a mix of breeds (two Standardbreds, three Quarter Horses, 
one Tennessee Walking Horse, one POA, and two mixed breeds). Mares were monitored via 
transrectal ultrasound three times per week, and when a CL was detected, prostaglandin F2 alphab 
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[Lutalyse®] (5 mg/mare IM) was administered to return the mare to estrus. When at least a pre-
ovulatory follicle (follicles >35mm, and moderate endometrial edema) was detected, the mare was 
artificially inseminated with fresh semen, containing a minimum of 500 x 106 progressively motile 
sperm from a Quarter Horse stallion housed at the same facility. Mares were scanned every 24 - 
48 hours to detect the ovulation. When present, post-breeding intrauterine fluid was treated with 
oxytocinc (20 IU IM q12h) and uterine lavage as needed.  
Pregnancy was confirmed at 14 days post ovulation and recheck ultrasound exams were 
repeated at 28 and 45 days. Mares were included in the present study if ultrasonography of the 
pregnant uterus was within normal limits at 45 days gestation (singleton pregnancy with normal 
fetal heart beat, normal fetal fluid echogenicity, and normal cervical tone and appearance). Mares 
were blocked into groups based on date of pregnancy determination, and then randomly allocated 
to two groups: recommended dose of enrofloxacind (7.5 mg/kg, PO, n=6), or no treatment (n= 7). 
Mares were treated orally once a day for fourteen days. The compounded commercial oral 
formulation of enrofloxacin used in this study has previously been shown to be well absorbed by 
pregnant mares [22].  
 
Ultrasound measurements 
Starting on Day 10 of treatment, B mode ultrasonography [EVO Ibexe], fetuses were 
assessed daily for fetal heartbeat and fetal mobility. Fetal mobility was assessed over a set a period 
of 5 minutes, with the number of fetal movements recorded for further comparisons between 
groups and over time. Fetal movements were classified as major (rotation around the axis, or fetal 
movement in the dorso-ventral or cranio-caudal direction), or minor (head nods, limb flexion or 
extension), similar to a previous study in older fetuses [23].  Fetal heart rate (FHR) was evaluated 
at the beginning of the ultrasound and at the end, and the two readings were averaged for one daily 
FHR. 
 
Induction of Abortion and Fetal Fluid Sampling 
At 60 days, abortion was induced as part of a parallel study. Abortion was induced by either 
one uterine infusion of 500 µg cloprostenol sodiumf [Estrumate®] diluted in 8ml of saline (n=6), 
or with an intramuscular injection of 250 µg cloprostenol sodium, q12 h until abortion (n=7). In 
transcervically treated mares, a standard equine AI pipetteg was passed through the cervix, and the 
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solution (sodium chloride-cloprostenol) was placed caudally to the allantochorion membrane 
[24,25]. Fetal heart rate was monitored every six hours by transrectal ultrasound, and at the first 
time point when a fetal heart rate was no longer detected, the mare’s perineum was aseptically 
scrubbed, and the fetus and fetal membranes were manually recovered via transvaginal 
manipulation. After removal, the fetus and membranes were examined, and fluid was aspirated 
from the allantoic and amniotic cavities with a 22-gauge needle and 3 ml syringe. Fetal fluids were 
stored at -80°C until analysis.  Full chemistry panels were run on all fetal fluids harvested.  
 
Determination of enrofloxacin and ciprofloxacin concentrations 
Concentrations of enrofloxacin and ciprofloxacin were measured by liquid 
chromatography-tandem mass spectrophotometry (LC-MS/MS) in the Metabolomics Laboratory 
of the Roy J. Carver Biotechnology Center, University of Illinois Urbana-Champaign. A detailed 
description of LC-MS/MS methods and validation are reported elsewhere [10,22]. Between-run 
and within-run accuracy and precision were calculated by measuring six samples of enrofloxacin 
and ciprofloxacin at concentrations of 5, 50, and 500 ng/ml. Measurements were repeated on three 
different days. Enrofloxacin had a within-run accuracy of 95.6 ± 2.1 % to 99.1 ± 0.6%, and a 
between-run accuracy of 97.3 ± 2.0% to 98.4 ± 1.0%. Ciprofloxacin had a mean within-run 
accuracy of 95.4 ± 2.3 to 99.6 % ± 1.2 %, and between-run accuracy of 97.0 ± 2.4 % to 99.2 ± 
0.9%. Coefficients of variations between-run and within-run for enrofloxacin ranged from 0.9-
1.6% and 1.1-3.5%, respectively. Coefficients of variations for ciprofloxacin between-run and 
within-run ranged from 0.9- 2.4% and 1.0-5.4 %, respectively. Plasma stability data was calculated 
under various conditions (n = 6).  Samples stored in the auto-sampler for 24 h at 15°C had a bias 
of 3.2-4.8% and samples stored at -75°C for two months had a bias of 1.3-3.4%.  
 
Fetal Pathology 
 After the abortion, fetuses were grossly inspected for any defects or lesions (Fig 7.2). Fetal 
limbs were disarticulated from the axial skeleton, and left front and hind limbs were preserved in 
10% neutral buffered formalin immediately after collection.  Samples of fetal liver, lung, kidney, 
and heart were also preserved in formalin for analysis. Fixed tissues were then routinely processed 
and embedded in paraffin in an automated tissue processor. Fetal limbs were sectioned as a whole 
limb in the sagittal plane, and three slides were stained with either haematoxylin & eosin, Mason’s 
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Trichrome, or toluidine blue for analysis. All haematoxylin & eosin stained slides were evaluated 
for structural and cellular changes by two board-certified veterinary pathologists, who analysed 
the tissues blinded as to treatment groups. One pathologist also evaluated the slides stained with 
Mason’s Trichrome and toluidine blue. 
 
Statistical analysis 
G* Power software v 3.1.9.3h was used to determine the a priori sample size, with an alpha 
= 0.05, a power of 0.8, and the expectation that 2/3 of the treated fetuses would be affected. All 
statistical analyses were completed using R libraries (R version 3.3.3)i. Associations between fetal 
chemistry values and treatment group were analyzed by one way ANOVA. Fetal age at abortion, 
time from treatment to abortion, and average fetal heart rate were compared between groups using 
a one-way ANOVA. Significance was set at p < 0.05, and tendency was defined as 0.1> p >0.05.  
 
RESULTS 
Clinical outcomes  
All mares had normal physical examinations for the 14-day treatment period, and no side 
effects were seen from oral administration of enrofloxacin. Mean fetal heart rate before abortion 
was not different between the untreated (147± 12 bpm) and treated (146 ± 7 bpm) mares. No 
differences in fetal movements were observed in the five days leading up to abortion; major 
movements varied from 0 to 2 per 5 minutes, and minor movements varied from 1 to 3 movements 
during the five minutes’ assessment.   
One untreated mare showed signs of colic after the first intramuscular prostaglandin 
administration. The mare was treated with a 10 L bolus of Lactated Ringers’ solutionj and flunixin 
megluminef [Banamine®] (1.1 mg/kg q12h). Prostaglandin treatment was not repeated, and the 
fetus and its membranes were extracted via manual dilation of the cervix. Mares aborted at 62 ± 
0.5 days of gestation, and there was no difference in gestation length between treated and control 
mares. The mean time from the first prostaglandin administration to abortion was 37.3 ±10.6 hours, 
with no difference between treated and control mares.  
Fetal fluid analyses 
One treated fetus was expelled before loss of fetal heartbeat was detected, and when the fetus 
was discovered, no allantoic or amniotic fluid was recovered. In two fetuses recovered from the 
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vagina, only amniotic fluid was obtained. Both enrofloxacin and ciprofloxacin were detectable in 
the amniotic and allantoic fluids at time of abortion, 24 to 48 hours after the last dose of 
enrofloxacin (Table 7.1). The ratio of enrofloxacin: ciprofloxacin concentration was 3.6:1 in the 
amniotic fluid, and 2.1:1 in the allantoic fluid. There were no differences in allantoic fluid 
chemistries between groups. There was a tendency for bilirubin to be decreased (p = 0.10) in the 
amniotic fluid of treated mares, but no other differences were seen (Table 7.2). One mare in the 
untreated group had elevated allantoic CPK, AST, and ALK Phos concentrations, resulting in the 
large standard deviations noted (Table 7.3).  
Fetal Pathology 
 There were no differences noted in the histological features of the front and hind limbs, 
heart, kidney, lung, liver, or spleen of fetuses in the control and enrofloxacin exposed experimental 
groups (Fig 7.3). No differences were seen in proteoglycan content of fetal limbs stained with 
toluidine blue (Fig 7.4), or in collagen or muscle fibers stained with Masson’s trichrome (Fig 7.5). 




The current study hypothesized that in utero exposure to enrofloxacin would have 
chondrotoxic effects on the fetus if exposure occurred at the time of organogenesis or initial 
cartilage development. However, enrofloxacin administration to early pregnant mares failed to 
induce detectable lesions after two weeks of in utero exposure.  These findings are consistent with 
two previous studies showing that administration of enrofloxacin to late pregnant mares did not 
result in apparent abnormalities in the fetal limbs [10] or resulting 30 day old foals [11].  
Previous studies assessing fluoroquinolone exposure during late equine pregnancy 
demonstrated that ciprofloxacin accumulates in the allantoic fluid after 11 days of enrofloxacin 
administration [10], and that low levels of both enrofloxacin and ciprofloxacin were detectable in 
the allantoic fluid long after last treatment [11]. This accumulation was attributed to excretion in 
the fetal urine or diffusion into the allantoic fluid. While the present study design only determined 
fetal fluid fluoroquinolone concentrations 24 to 48 hours after the last dose of enrofloxacin, 
placental drug transfer or diffusion of fluoroquinolones into the fetal fluids occurred in the early 
equine pregnancy as well.  Fluoroquinolones concentrations were lower in the 60-day fetal fluids 
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than concentrations reported in fetal fluids of late pregnant mares [11]; these discrepancies may 
be due to increased blood flow to the fetoplacental unit in the late pregnant mare, increased renal 
excretion in 3rd trimester fetuses, or differences in fetal fluid composition or pH allowing for drug 
accumulation. In 60-day fetal fluids, fluoroquinolone concentrations were similar between the 
allantoic fluid and amniotic fluid, unlike in the late pregnant mare, where ciprofloxacin 
accumulates in the allantoic fluid over time [10]. This supports the hypothesis that ciprofloxacin 
accumulates in the allantoic fluid due to fetal urine excretion in late gestation. In the first trimester, 
fetal kidneys are not fully functional; instead, drug transport is likely due to passive diffusion. The 
study was conducted in healthy mares, and it is unknown how concurrent disease might affect 
placental drug transfer or diffusion.  
 Fetal fluid chemistry parameters were similar to those previously reported [26,27].  Total 
protein in the amniotic and allantoic fluid was higher than previously reported [26,27], possibly 
due to method and timing of fetal fluid collection. In the current study, fluids were collected after 
induction of abortion, likely causing fetal stress and an inflammatory response. In previous studies 
fluids were collected at time of mare death or slaughter and may not have resulted in similar 
inflammation. While amniotic bilirubin concentrations tended to be lower in treated fetuses than 
untreated fetuses, all were within normal limits for the adult equine, suggesting that this difference 
is not clinically relevant. Allantoic fluid concentrations were more variable in this study for many 
parameters, and it is hypothesized that this was due to fluid loss, and potential cross contamination 
as fetal membranes were expelled.  No allantoic membranes were recovered intact, and mixing of 
vaginal secretions and allantoic fluid at the time of conceptus recovery was likely.  
One reason no evidence of cartilage toxicity was found in the 60-day old fetuses may be due 
to the very early stage of articular cartilage development at this time period. Previous studies of 
quinolone-induced arthropathy have suggested that there is a window of susceptibility in young 
animals. Rats are susceptible between three to six weeks of age but not at eight weeks, while dogs 
are susceptible at three months but not at 18 months. Lesions occurred in the weight-bearing joints, 
which implies mechanical forces may also be critical to lesion development. These findings and 
others indicate that the stage of cartilage development is an important factor in quinolone toxicity 
and that the metabolically active chondrocytes facilitating rapid growth are the most susceptible. 
Therefore, it is likely that the mostly undifferentiated articular chondrocytes of the fetuses in this 
study were not negatively affected by enrofloxacin. In addition, there did not appear to be any 
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effects on ossification of the long bone cartilage as it appeared comparable to that in the untreated 
controls (Fig 7.4).   
Collectively, these findings suggest that enrofloxacin administration to the early pregnant mare 
may not result in gross or histologic lesions in the fetus. Enrofloxacin may be a useful antibiotic 
for select pregnant mares suffering life-threatening bacterial infections. Enrofloxacin 
administration should be limited to severe infections where microbial culture indicates microbial 
resistance to first line antimicrobials and a sensitivity to enrofloxacin. Practitioners should be 
aware that both enrofloxacin and ciprofloxacin cross the equine placenta, and that while no lesions 
were detected in the fetus immediately after drug administration, no long-term follow up studies 
were conducted to investigate survival to term and musculoskeletal soundness after 
fluoroquinolone exposure in the first trimester. If enrofloxacin is administered to pregnant mares, 
clients should be informed of the potential risks, as this study does not rule out a low incidence of 
toxicity, or long-term effects of early fetal exposure. Additional studies are warranted to 
investigate longer-term effects on foals after intrauterine exposure to fluoroquinolones. 
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TABLES AND FIGURES 
 
Table 7.1. Concentrations of enrofloxacin and ciprofloxacin in the foetal fluids (ng/ml) at time of 
fetal abortion (62 ± 0.5 days gestation).  Mares were treated with 7.5mg/kg enrofloxacin orally 
once a day for 14 days before abortion. Values are mean ± SD, n=5 (amniotic fluid), n=4 
(allantoic fluid). 
 
 Amniotic fluid Allantoic fluid 
Enrofloxacin 228.4 ± 223 178.1 ± 184.1 





Table 7.2.  Amniotic fluid chemistries at time of abortion (62 ±0.5 days gestation). Mares were untreated (n=7), or treated with 7.5mg/kg 
(n=5) enrofloxacin orally once a day for 14 days before abortion.  Values are mean ± SD (range). No differences were seen between 
treatment groups for any value (p<0.05). Reported ranges published elsewhere x[29]  or y[28].  
Analyte Overall mean Reported ranges Untreated Treated p value 
Creatinine (!mol/L) <17 20.8-25.8y <17 (<17 -35) <17  
BUN (mmol/L) 6.9 ±1.7  6.4-8.5 y 7.8 ±2.4 (5.0- 9.7) 6.3 ±0.8 (5.4- 7.1) 0.5 
TP (g/L) 1.3 ±0.5 0.35 ± .01x 1.6 ±0.4 (1.3-2.0) 1.1 ±0.5 (0.5-1.6) 0.1 
Albumin (g/L) <0.02  <0.02 <0.02  
Calcium (mmol/L) 2.07 ±1.14 1.35 ± 0.52x 2.47 ±1.01 (1.60-3.58) 1.76 ±1.27 (0.90- 3.75) 0.6 
Phosphorus (mmol/L) 1.23 ±0.62  1.52 ±0.37 (1.16-1.91) 1.03 ±0.73 (0.48- 2.07) 0.5 
Sodium (mmol/L) 122 ±10 123- 128y 119 ±11 (107-129) 124 ±10 (109-132) 0.8 
Potassium (mmol/L) 6.6 ±2.3 8.1 ± 5.2x 
2.75- 4.13y 
8.4 ±2.2 (5.9-9.9) 5.2 ±1.2 (4.1-6.9) 0.5 
Chloride (mmol/L) 98 ±10 19.5 ± 4.42x 95.0- 99.8y 97 ± 11(86-108) 100 ±11 (84-107) 0.8 
Glucose (mmol/L) 0.68 ±0.42 0.42 ± 0.33x 0.93 ±0.60 (0.50-1.61) 0.50 ±0.14 (0.39- 0.67) 0.1 
Alk Phos (U/L) 11 ±10 69.6 ± 44.4 19 ±2 (12-33) 5 ±3 (3-10) 0.5 
AST (U/L) 70 ±69  132 ±51 (73-163) 23 ±31 (3- 69) 0.9 
GGT (U/L) 4 ±3   7.0 ±2.7 (5-10) 1.8 ±0.5 (1-2) 0.5 
Bilirubin (	!mol/L) 3.2 ±1.2  3.9 ±1.0 (3.4-5.1) 2.6 ±1.0 (1.7-3.4) 0.06 
CPK (U/L) 44 ±53  65 ±73 (<10-146) 29 ±38 (<10-86) 0.6 
Cholesterol (mmol/L) < 0.6  < 0.6 < 0.6  
GLDH (U/L) 3.7 ±2.4  5.2 ±3.1 (1.6-7.0) 2.6 ±1.0) (1.5-3.9) 0.6 
TCO2 (mmol/L) 14.9 ±6.7  11.0 ±8.9 (4-21) 17.8 ±3.5 (14-22) 0.6 
Mg+ (mmol/L) 0.68 ±0.22  0.71 ±0.22 (0.45-0.86) 0.66 ±0.25 (0.41-0.95) 0.8 
Triglycerides (mmol/L) 0.12±0.07  0.15 ±0.10 (0.06-0.25) 0.10 ±0.02 (0.07- 0.11) 0.8 
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Table 7.3.  Allantoic fluid chemistries at time of abortion (62 ± 0.5 days gestation). Mares were untreated (Control, n=6), or treated with 
7.5mg/kg (n=4) enrofloxacin orally once a day for 14 days before abortion. Values are mean ± SD. No differences were seen between 
treatment groups for any value (p<0.05). Reported ranges published elsewhere x[29]  or y[28].  
 
 
Analyte Reported range Overall mean Control Treated p value 
Creatinine (!mol/L) 24.3-30.3y 19.4 ± 8.4 23.6 ± 13.3 22.1 ± 6.2 0.5 
BUN (mmol/L) 10.4-14.8y 9.73 ± 1.63 8.75 ± 0.74 11.07 ± 0.5 0.2 
TP (g/L) 0.11 ± 0.09x 3.08 ± 3.4 2.7± 3.08 2.5 ± 2.9 0.6 
Albumin (g/L)  <0.02 <0.02 <0.02  
Calcium (mmol/L) 1.03 ± 0.75x 1.17 ± 0.14 1.56 ± 0.5 1.14 ± 0.09 0.8 
Phosphorus (mmol/L)  0.96 ± 0.33 1.32 ± 0.49 0.83 ± 0.13 0.5 
Sodium (mmol/L) 18.1 ± 10.4x 30 ± 20 37 ± 30 22 ±10 0.5 
Potassium (mmol/L) 7.6 ± 5.6x 10.0 ± 7.9 15.4 ± 8.0 4.6 ± 2.6 0.4 
Chloride (mmol/L) 7.5 ± 3.3x 28.0 ± 15.8 33.5 ± 23.3 22.5 ± 9.2 0.5 
Glucose (mmol/L)  1.83 ± 2.0 2.55 ± 2.94 1.0 ± 0.61 0.5 
Alk Phos (U/L) 18.7 ± 13.3x 86 ± 101 110 ± 148 61 ± 79 0.5 
AST (U/L)  106 ± 141 163 ± 217 50 ± 20 0.6 
GGT (U/L)  33 ± 30 47 ± 38 21 ± 25 0.2 
Bilirubin (	!mol/L)  2.2 ± 4.3 4.2 ± 6.0 0 0.5 
CPK (U/L)  468 ± 803 857 ± 1150 80 ± 63 0.5 
Cholesterol (mmol/L)  < 0.6 < 0.6- 0.9 < 0.6  
GLDH (U/L)  2.3 ± 1.3 1.6 ± 1.7 2.0 ± 0.4 0.5 
TCO2 (mmol/L)  6.0 ± 5.2 7.5 ± 6.4 3 ± 2 0.5 
Mg+ (mmol/L)  0.49 ± 0.15 0.51 ± 0.20 0.47 ± 0.14 0.5 
Triglycerides (mmol/L)  <0.11 <0.11 <0.11  
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Figure 7.1: Timeline and flowchart of mare enrollment and progression through the study. Only 6 





Figure 7.2: Representative images of 62-day gestation equine fetuses immediately after retrieval 
at abortion.  Untreated fetus (left), and a fetus from a treated mare (right) that was administered 






Figure 7.3. Sagittal section of the left front hoof (A, B, E, F) and tarsocrural joint (C, D, G, H) of an untreated (A-D) and treated (E-H) 
62-day gestation fetus. Treated fetuses were obtained from mares administered 7.5 mg/kg enrofloxacin PO SID for 14 days, starting at 






Figure 7.4: Sagittal section of the left front humeroradial (A, B, E, F) and fetlock (C, D, G, H) joint of an untreated (A-D) and treated 
(E-H) 62-day gestation fetus. Treated fetuses were obtained from mares that were administered 7.5 mg/kg enrofloxacin PO SID for 14 





Figure 7.5: Sagittal sections of the left hind hoof (A, B, E, F) and tarsocrural joint (C, D, G, H) of an untreated (A-D) and treated (E-H) 
62-day gestation fetus. Treated fetuses were obtained from mares that were administered 7.5 mg/kg enrofloxacin PO SID for 14 days, 
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CHAPTER 8:  CONCLUSIONS AND FUTURE DIRECTIONS 
 
The work described within this dissertation investigated the potential consequences of 
enrofloxacin exposure in utero on the resulting foal. Collectively the works failed to demonstrate 
any postnatal effects of in utero exposure to enrofloxacin. Chapter 3 demonstrated that the 
recommended oral and intravenous enrofloxacin doses are also appropriate for pregnant mares 
with susceptible bacterial infections. This work also highlighted the need to consider bacterial 
MIC when choosing not only an appropriate antimicrobial, but also appropriate dose, and 
suggest the need for further exploration of potential differences in drug absorption, excretion, 
and p450 metabolism in pregnant mares.  
 Intravenous administration of enrofloxacin to third trimester mares in chapter 4 
demonstrated that that both enrofloxacin and its active metabolite ciprofloxacin cross the equine 
placenta, and that ciprofloxacin accumulates in the allantoic fluid over time without causing 
gross or histological lesions in the fetus. Unfortunately, many orthopedic lesions in the horse do 
not develop until the post-natal period, when the animal becomes weight-bearing, and with this 
in mind, Chapter 5 details the treatment of third trimester mares with an oral enrofloxacin, and 
the subsequent evaluation of their foals at 30 days postpartum.  This study demonstrated that 
ciprofloxacin remained detectable in the fetal fluids long after cessation of enrofloxacin 
treatment, and that foals from enrofloxacin-treated mares did not develop orthopedic lesions at a 
faster rate than their controls, nor did they demonstrate any difference in tendon morphology or 
tendon strength post-partum. While these results were encouraging, it is possible that normal 
necropsy procedures are not adequate to detect subtle changes in foal cartilage composition.  
 Multiple modalities were then used to evaluate the 30-day old foals in Chapter 6 to 
determine if more sensitive techniques would detect differences in foal cartilage development. 
Radiographs demonstrated normal foal orthopedic lesions commonly found in the breeds 
included in the study. Structural qMRI described differences in foal cartilage for the first time, 
and demonstrated differences in positive control animals treated postpartum, but no differences 
in foals exposed in utero. Similarly, no difference was seen in expression of multiple cartilage 
associated genes in the resulting foals. 
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The third trimester studies were followed by a pilot study described in Chapter 7, which 
investigated the effects of in utero fluoroquinolone exposure during the first trimester. This study 
looked at 14 days exposure during organogenesis, and did not detect gross or histological 
defects.  
 While the results of the dissertation are encouraging, it is important to acknowledge that 
it is possible even with the advanced imaging and molecular techniques employed in Chapter 6, 
there is still the possibility of a failure of test sensitivity to detect minor effects of treatment that 
may affect cartilage quality or tendon strength over time. Additionally, it is possible that the 
work failed to identify the critical time in gestation where fluoroquinolones may affect cartilage 
development, that an effect may only be seen in diseased or nutritionally compromised animals, 
or that lesions would develop in the mares were treated until parturition.  Further work should be 
completed to determine the effect of placental disease on drug transfer, and also the effects of 
systemic illness on fluoroquinolone pharmacokinetics and pharmacodynamics.   
Collectively the works did not demonstrate any postnatal effects of in utero exposure to 
enrofloxacin. While these findings do not rule out a potential low incidence of toxicity or longer-
term consequences when this fluoroquinolone is administered during an equine pregnancy, the 
findings described above are useful for risk assessment when veterinarians are faced with severe 
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ABSTRACT 
While the onset of puberty and its association with somatic growth and testicular 
development is well described in production animals, similar studies are lacking in peripubertal 
colts. The objectives of this study were to determine the concentrations of reproductive and 
metabolic hormones during the peripubertal period and to assess their relationship with testicular 
development and body fat deposition. Blood samples were collected from 23 healthy Standardbred 
colts via jugular venipuncture between 8:30 and 10:00 am every four weeks for twelve months, 
and plasma samples were stored at -80oC until analysis. The colts were weighed monthly, and 
percent of body fat and testicular volume were estimated by B-mode ultrasound measurements 
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using previously published equations.  Onset of puberty was determined as the month when 
testosterone was two standard deviations above the previous mean.  Plasma FSH, LH, leptin, 
estradiol-17β, androstenedione, IGF-1, insulin, inhibin-A, and inhibin-B were analyzed for a 
peripubertal period of seven months (-3, -2, -1, 0, +1, +2, +3; 0= month of puberty onset).  Spring 
born Standardbred colts underwent puberty at 13 months of age; onset of puberty coincided with 
exponential testicular growth but did not coincide with an increase in cutaneous body fat 
deposition or leptin. Plasma Inhibin B concentrations were significantly increased in the 
postpubertal period, but no increase was seen in Inhibin A, androstenedione, FSH, LH, or estradiol-
17β.  In conclusion, the rise in testosterone and subsequent onset of puberty coincides with rapid 
testicular growth but is not correlated with an increase in gonadotropins, IGF-1, cutaneous body 
fat or leptin in the horse.  




The peripubertal period is poorly documented in horses, particularly when compared to 
other farm animals.  Assessment of semen features (i.e., the first ejaculate containing ≥ 50 million 
total spermatozoa with ≥ 10 % motile sperm) has been used to define the onset of puberty in 
bulls[1-4] and by one study in colts[5]. In ruminants, semen can be obtained via electroejaculation 
regardless of libido or physical ability to mount. However, this method is inefficient in horses and 
requires general anesthesia[6]. Thus, using semen features to determine the onset of puberty 
requires that the colt is mature enough to express good libido and mount a mare or phantom to 
collect semen in an artificial vagina. Training colts to collect semen can be a daunting task and 
might not be successful until weeks or months after puberty has occurred.  
Given these challenges, studies have used changes in gonadotropins and sex steroids to 
assess puberty in colts, and as an alternative method to study puberty in calves[7-9].  In colts, the 
onset of puberty occurs from 11 to 20 months, depending on breed, geographical location, year, 
foaling season (spring vs. fall), and individual variations[5,9-11]. 
The association of metabolism, growth, and development is well studied in peripubertal 
ruminants [2,3,12-15], but not well defined in horses[16,17]. Nutrition influences not only the 
onset of puberty but also long-term testicular function in rams and bulls [12,13,15]. Metabolic 
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regulators (e.g., insulin, leptin, and IGF-1) are thought to modulate gonadotropin and steroid 
production in peripubertal bulls [2,14]. Studies in bulls have shown that not only testosterone but 
also plasma leptin and IGF-1 increase during the peripubertal period, without a corresponding 
increase in gonadotropins[3]. In contrast to females, leptin in both boys and bull calves decreases 
once puberty is reached[18,19]; it is likely that a similar finding may occur in colts. Previous 
studies assessing hormonal changes and weight gain in prepubertal colts over time did not look for 
changes in body fat, leptin, or testicular development[9,17]. Measurement of body fat in 
conjunction with peripheral metabolic regulators is useful to assess energy status [20,21], and 
measuring testicular volume is useful for estimating potential daily sperm output [22].   
Inhibin (subtypes A & B) is produced by the Sertoli cells and is thought to regulate steroid 
secretions via inhibition of FSH [23]. In colts, concentrations of inhibin increase in peripubertal 
animals and may decrease in subfertile or infertile stallions [8,23,24].  While those studies 
quantified total immunoreactive inhibin, other studies have recently shown differences in inhibin 
B and inhibin A in males. Inhibin A predominates over inhibin B in males in other species such as 
the boar, and it is possible that such differences will also be present in colts[25]. 
To date, the associations between testicular development and metabolic and reproductive 
hormones in peripubertal colts are still unclear.  Therefore, the objectives of this study were to 
determine the concentrations of sex steroids, gonadotropins, inhibin-A and –B, and metabolic 
hormones during the peripubertal period, and evaluate their relationship with testicular 
development and body fat deposition.  We hypothesized that an increase in total body fat 
corresponds with an increase in sex steroids and the onset of puberty in the colt. We also 
hypothesized that onset of puberty, as defined by an increase in testosterone, would precede an 
increase in body fat and exponential testicular growth, and that onset of puberty is associated with 
an increase in gonadotropins, testicular and metabolic hormones in colts. 
 
MATERIALS AND METHODS 
Animals and experimental design 
Twenty three Standardbred colts (pre-pubertal male horses) were housed on pasture, at 
farm one (n=9) and farm two (n=14), in central Illinois according to industry standards. Colts 
enrolled in the study had monthly blood samplings, and assessments (rump fat, testicular volume, 
and body weight) carried out from October 2014 to August 2015.  Two colts were sold in May and 
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June, and did not complete the study. All experimental procedures were performed in compliance 
with the Guide for the Care and Use of Agriculture Animals in Research and Training and 
approved by the Institutional Animal Care and Use Committee of the University of Illinois at 
Urbana-Champaign (Protocol # 14174).   
 
Blood sampling and body weight 
Blood samples were collected via jugular venipuncture into heparinized tubes once a month 
between 08:30 and 10:00 am. Blood tubes were kept on ice until centrifugation for 10 min at 600g 
within 2h of sample collection.  Plasma was harvested and stored at -80oC until analysis.  Body 
weight was estimated with a commercial weight tape (Purina Mills, Inc). 
Body fat and testicular volume 
Rump fat was measured using B-mode ultrasound approximately 5 cm lateral to the midline 
at the center of the pelvis, and the left and right side were averaged.  Percent total body fat was 
calculated using an equation derived by Westervelt et al., [26], where body fat is estimated by the 
equation 3.83 + 5.58x, where x= cutaneous rump fat in centimeters. Testicular volume was 
calculated according to the equation derived by Love et al.[22], where testicular volume = 0.5233 




Plasma androstenedione was measured by competitive binding ELISA according to 
manufacturer’s directions (RCAN-AD-208R, BioVendor, Modrice, Czech Republic).  The assay 
uses a rabbit anti-androstendione polyclonal antibody, and androstendione-horseradish peroxidase 
conjugate, and has a reported 100% cross-reactivity with androstenedione, 1.8% with DHEA, 0.2% 
with testosterone, and <0.1 % with estradiol, progesterone, or 5α-DHT. Reported sensitivity is 
0.05 ng/ml.  The ELISA demonstrated an intra-assay CV of 3.4% and interassay CV of 10.1%. 
Estradiol-17β 
Concentrations of estradiol-17β were determined by a competitive binding 
chemiluminescent enzyme immunoassay (Estradiol, Immulite 1000, Siemens Healthcare, 
Malvern, PA) previously used in equine research[127,28]. The assay employs a polyclonal rabbit 
anti-estradiol antibody, and an alkaline phosphatase bound estradiol conjugate.  The assay has a 
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reported range of 20 to 2,000 pg/mL and sensitivity of 15pg/mL. Reported cross-reactivity for this 
assay is 2.09% for estrone, 0.032% for 17α-estradiol, 0.535% for estriol, and not detectable for 
other adrenal and reproductive steroids. Intra- and inter-assay coefficient of variations are less than 
4%.  
Insulin-like growth factor-1  
Concentrations of IGF-1 were analyzed via ELISA (EIA-4140, DRG Instruments GmBH, 
Marburg, Germany), similarly to previous studies.[29-31] The assay uses a monoclonal antibody, 
has a reported cross-reactivity of 100% with IGF-1, 1.02% with IGF-2, and 3.3% with insulin, and 
a sensitivity of 9.75ng/ml, with a range of 9.75-600 ng/ml.  The intra-assay CV was 13%, and the 
interassay CV was 2.8%.  
Insulin 
Insulin was analyzed via ELISA (10-1205-01, Mercodia AB, Uppsala, Sweden, reported 
sensitivity 0.91 µg/ml, range 0.02-1.5 µg/ml. This ELISA uses a mouse monoclonal anti-insulin 
primary and secondary antibody, has no cross-reactivity to C-peptide or proinsulin and has been 
validated for use in the horse[32,33]. The intra-assay CV was 6.2%, and the interassay CV was 
3.9%. 
Testosterone, FSH, LH, and leptin  
Concentrations of FSH, LH, testosterone, and leptin were analyzed via radioimmunoassay 
at Louisiana State University, and the assays were previously validated for use in the horse [34-
37]. Testosterone was extracted from plasma and quantified by radioimmune assay as previously 
described [37]. The testosterone assay used an antibody to testosterone-11β-bovine antibody, and 
a 
testosterone-11 α -tyrosine methyl ester as the radioiodinated antigen. The assay has reported cross 
reactivity of 3.4% with 5α-DHT, 2.2% with 5α-androstane-3β,17β-diol, 2% with 11-
oxotestosterone, 0.95% with 6β-hydroxytestosterone, 0.63% with 5β-DHT, 0.56% with 
androstenedione, 0.20 with epiandrosterone, and less than 0.01% with other steroids. The assay 
had intraassay and interassay CVs of 5.9% and 1.8% respectively, and a sensitivity of 0.006 ng/ml, 
consistent with the established ranges for the assay. 
The leptin assay used commercially available reagents (Multispecies leptin kit, Linco 
Research Inc, St Charles, MO), has a reported cross-reactivity of less than 0.01% with eLH, eFSH, 
equine GH, or equine prolactin, and was previously validated in the horse [36]. 125I-human leptin 
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standards provided by the kit, human recombinant leptin, and three horse plasma pools were used 
to produce parallel inhibition curves. For analysis, equal amounts of sample and guinea pig anti-
multi species leptin antibody were incubated at 5 C for 48 h. One hundred mL 125I-human leptin 
was then added to all tubes, vortexed, and tubes were again incubated 24 h at 5 C. On day 3, 200 
mL of anti-rabbit gamma globulin serum was added to all tubes except total count tubes, tubes 
were vortexed and incubated for 24 h at 5 C. Tubes centrifuged at 1200 x g for 30 min to separate 
antibody-bound leptin from free leptin and the supernatant was decanted. The pellet was washed 
with 1.0mL PBS and samples were again centrifuged. Radioactivity was assessed by solid 
scintillation counting for 1 min. The assay for leptin had a sensitivity of 0.2 ng/ mL, 6% intra-
assay CV and 4% inter-assay CV, consistent with the established ranges. 
The FSH radioimmunoassay was performed as previously described, using a primary anti-
human FSH antiserum prepared in rabbits, and a secondary anti-rabbit gamma globulin prepared 
in sheep [34,38]. Partially purified eFSH (LER-1686-2) was used as a standard. Samples were run 
in duplicate, intra-assay and inter-assay CVs were 7% and 11% respectively, and the assay has a 
sensitivity of 1.4 ng/mL, these results are within the established ranges. The assay has a reported 
cross reactivity of 3.5% with LH, 2.0% with TSH, 0.02% with eCG, and <0.1% with all other 
pituitary hormones. 
LH was measured by radioimmunoassay, as previously described, and used a rabbit anti-
eCG and radioiodinated ovine LH [34]. LER-958-1 was used as a standard. The assay has a 
reported cross-reactivity of 2.4% with eFSH, 3.8% with eTSH, and 28.7% with eCG. Samples 
were run in duplicate, and the LH immunoassay had intraassay and interassay CVs of 6% and 9% 
respectively, and a sensitivity of 0.2 ng/mL. These results are within the established ranges. 
Inhibin A & B 
Concentrations of inhibin A and B were analyzed via ELISA using commercial assays 
(Equine/Canine/Rodent Inhibin A (AL-161) and B (AL-163) Ansh Labs, Webster, TX). Both 
assays are quantitative immunoassays and use mouse monoclonal antibodies against βA- (inhibin 
A assay) and βB- (inhibin B assay) subunits of inhibin for capture, and a monoclonal antibody 
specific to the inhibin α subunit for detection. Assays were run at the Endocrinology Laboratory 
of the University of California-Davis, where the assays were previously validated for use in the 
horse[39]. The inhibin A assay had an intraassay and interassay CVs of 5.9% and 3.2% 
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respectively, and a sensitivity of 2.3 pg/ml. Inhibin B had a sensitivity of 2.3 pg/mL, 5.5% intra-
assay CV and 3.8% inter-assay CV.  
 
Data analysis 
Puberty was determined by the month that plasma testosterone first reached two standard 
deviations above the previous mean plasma concentrations[9]. The peripuberty period was selected 
(-3, -1, -1, 0 (month of puberty), +1, +2, and +3 months) according to Brito et al., [174] and all 
other hormones were analyzed accordingly. Data are also presented according to the equivalent 
sampling age (months) not adjusted for peripuberty (supplementary tables). Data were analyzed 
using RStudio v 0.99.489 (RStudio Team, Boston, MA). Hormone data not normally distributed 
were log-transformed prior to analyses. Variables were analyzed with mixed models, with month 
relative to puberty as the fixed factor, and colt and location as random factors.  Tukey HSD test 
was used for posthoc analysis.  Pearson correlations were performed between variables and 
presented as defined as strong (r≥0.7), moderate (0.3<r≤0.7), or weak (r<0.3) correlations. Data 
are expressed as mean ± SEM. Statistical significance was set at p < 0.05. 
 
RESULTS 
At the onset of puberty, colts were 13 ± 0.2 months of age, weighed 338.4 ± 6.7 kg, with a 
body fat of 6.3 ±0.2%, and a testicular volume of 53.5 ± 7.8 cm3  (Table A.1). Weight and testicular 
volume increased with age, and pre-pubertal measurements were significantly lower than post-
pubertal values (Table A.1). Body fat was significantly lower at puberty than three months before, 
or three months following the onset of puberty (Table A.1). As expected, age was correlated with 
weight, testosterone, and testicular volume (Table A.2). 
 
Steroid hormones 
The month of puberty, plasma testosterone concentrations were 0.5 ± 0.06 ng/ml, and 
estradiol-17β were 46 ± 3.7 pg/ml (Table A.3). Testosterone was moderately correlated with 
testicular volume and body weight (Table A.2), and pre-pubertal testosterone concentrations two 
months before the onset of puberty were significantly lower than post-pubertal concentrations 
(Table A.3).  Plasma androstenedione was 0.6 ng/ml at the month of puberty, and significantly 
higher than three months before the onset of puberty, but not different than any other month (Table 
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A.3).  Androstenedione was weakly correlated with testosterone but not with other variables (Table 
A.2). 
Gonadotropins 
The month of puberty, LH was 0.9 ± 0.4 ng/ml, and FSH was 9.9 ± 1 ng/ml (Table A.3). 
Concentrations of FSH were not significantly different at the onset of puberty and were not 
correlated with age (Table A.2,3). The LH concentrations were moderately correlated with 
testosterone and FSH (Table A.2); however, no significant differences were seen in LH 
concentrations by month of sampling. No significant difference was observed in inhibin-A over 
time, whereas concentrations of inhibin-B were significantly higher by two months post puberty 
compared to concentrations two months pre-puberty (Table A.3). Inhibin-B was moderately 
correlated with testicular volume, weight, and age, and weakly correlated with FSH, body fat, and 
testosterone concentrations (Table A.2).  
Metabolic hormones 
Plasma leptin concentration was 1.4 ng/dl ± 0.31 at onset of puberty, but no significant 
differences in leptin were seen during the peri-pubertal period (Table A.3), and a weak correlation 
was seen with plasma leptin and percent body fat (Table A.2).  Mean insulin concentration at the 
onset of puberty was 0.15 ± 0.04 µg/ml, and was significantly higher than 3 months pre-puberty, 
and lower than 3 months post-puberty (Table A.3). Weak correlations were observed between 
insulin concentrations and body fat and testicular volume, and insulin concentrations were 
moderately correlated with age (Table A.2).  
 
DISCUSSION 
Puberty in colts is associated with changes in serum testosterone and occurs during a time 
of exponential growth.  Given the known associations between body mass and the onset of puberty 
in other species, this study evaluated the relationship between body fat, reproductive and metabolic 
hormones, and the onset of puberty in Standardbred colts. Understanding such relationships is 
critical for improving how prospective sires are raised for maximum fertility. 
Onset of puberty (i.e., 13 month) for Standardbred colts was consistent with previous 
studies involving other horse breeds raised in other parts of the world[8,9,11]. Body weight at 
puberty onset was also similar to those values obtained in spring-born Thoroughbred colts raised 
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in Japan [8] and New Zealand[9]. This finding suggests that onset of puberty is similar between 
these two breeds when animals are raised under standard management conditions.  
Body fat deposits and leptin concentrations were shown to be positively correlated in 
Standardbred horses[20,21]. It is unclear why body fat deposits were not correlated with leptin 
concentrations in the present study. It is possible that the equation developed by Westervelt and 
collaborators [23] does not provide an accurate prediction of body fat in colts as it does for adult 
horses. Additionally, peripubertal colts have very small deposits of subcutaneous fat, and it is 
possible that ultrasound was not sensitive enough to detect small changes in body fat during this 
period.  Of interest, colt plasma leptin concentrations at puberty (1.4 ng/ml) were similar to fit 
Standardbred racehorses (1.02 ng/ml), but calculated % body fat in colts was lower than the same 
racehorses (6.2 ± 0.2 % vs. 11.9 ± 0.3)[21]. 
No correlation was found between plasma leptin and insulin concentrations, which is 
similar to findings comparing fit and unfit Standardbred racehorses[21].  Studies in humans have 
shown that insulin and leptin concentrations are correlated in fasted people, but not in postprandial 
people, and that is one possible explanation for the lack of correlation in the present study [40,41]. 
While the colts were always sampled at the same time every morning, they had access to pasture 
and hay overnight and were not fasted at time of sampling.  Plasma insulin concentrations were 
increased three months post-puberty, when compared to three months pre-puberty, and this 
increase was seen at the same time that a concentrated diet was introduced to the colts in 
preparation for sales.  While this additional grain supplementation may represent a confounding 
factor, all colts were offered the same diet, and the animals were kept under practical commercial 
conditions, with minimal interference from the investigators.  
Growth hormone (GH) is released in a pulsatile manner, and has a short half-life (<15 min), 
so frequent sampling is required for proper assessment[42,43].  While such frequent sampling is 
not feasible in on private farm studies, IGF-1 is more stable in the plasma and has been used as an 
indirect method to measure GH, and as a proxy to assess metabolic energy status[44].  Insulin-like 
growth factor-1 circulates in the blood bound to binding proteins (e.g., IGFB3), which increases 
the half-life of IGF, and modulates IGF-I activity[44-46]. Of interest, both IGF-1 and IGFB3 are 
regulated by GH [47].   Due to GH’s short half-life, and the similarities between IGF-1 and IGFB3 
expression seen in peripubertal colts[44], IGF-1 was chosen as the marker of interest for assessing 
growth hormone concentrations during the peripubertal period.  Previous studies have shown that 
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plasma IGF-1 concentrations are highest in pubertal colts[29,44], and then decrease post onset of 
puberty.  We did not detect a significant difference in plasma IGF-1 concentrations in our sampling 
period, possibly because the decrease in IGF-1 occurs before 12 months of age.  Additionally, 
immunoassays are perhaps not the best choice for IGF-1 analysis as poor correlations have been 
shown between laboratories analyzing human samples, even when automated assays are used[48].  
In this study we were most interested in changes over time, and not in absolute values, making this 
less of a concern. In addition, the while the assay used in the present study has been used by 
previous studies [30,31], it is unclear whether this assay has been validated for the horse. 
Plasma gonadotropins and estradiol did not increase significantly from the pre- to post-
pubertal period, which may be attributed to pulsatile release and timing of sample collection in 
this study. These findings are similar to Wesson and Ginther[11], and Dhakal et al[8] who found 
that FSH and LH concentrations did not increase significantly in the months preceding the onset 
of puberty. While Mizukami et al detected an increase in LH from the fall to spring in yearling 
colts, however those colts were older than the colts in the current study.  A previous study assessing 
gonadotropins in prepubertal colts did not see an increase in LH and FSH until after 70 weeks of 
age[5], and it is possible that these changes occur later in the post pubertal period.  
Aromatase, the enzyme responsible for converting androgens into estrogens, has 
apparently increased expression in the testicles of post-pubertal colts[49] and estrogen has been 
shown to be increased in six post-pubertal Thoroughbred colts[8], however we did not see an 
increase in plasma estrogens in the three months of the post-pubertal period in this study. This 
discrepancy could be due to differences in the assays used between the different studies, 
differences between testicular and plasma concentrations, or diet.  
Inhibin is produced by the Sertoli cells in response to FSH and its concentration in plasma 
has previously been shown to decrease in subfertile stallions and aging men [24,50]. Inhibin 
concentrations decrease at puberty in the rat and ram, while concentrations increase in monkeys 
and man at puberty[51-54]. Developments in immunoassays have made possible to differentiate 
between inhibin-A and inhibin B, and this is the first report of the differences in subtypes in the 
peripubertal colt. While no change was seen in colt plasma Inhibin A concentrations during the 
peripubertal period, the increase in plasma Inhibin B seen in the post-puberty may indicate 
testicular maturation and an increase in Sertoli cell function. In boars, it appears that inhibin A 
predominates over inhibin B at puberty[25], however in colts, we found that inhibin B 
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concentrations predominate over inhibin A at puberty, and inhibin B increases in the post-pubertal 
period. Inhibin is thought to play a role in germinal epithelium maturation, nonetheless, the 
physiological role of different inhibin types in peripubertal colts remains to be determined.  
Testicular growth is regulated by many factors, as demonstrated by studies in ruminants 
[2,3,14].  Restricting nutritional support in young bull calves has been demonstrated to decrease 
LH pulse frequency and result in decreased testicular size at time of puberty[14].  While we did 
not detect a relationship between metabolic status, gonadotropins, and testicular development, this 
study was not designed to assess differences in onset of puberty based on diet, and it is possible 
that differences would be observed in colts fed on different planes of nutrition. Additionally, colts 
were not assessed in the early postnatal period (i.e., less than six months of age), when nutritional 
influences might have played a bigger role on gonadotropin secretion and eventual testicular 
development.  
Onset of puberty, as characterized by increased peripheral testosterone concentrations, 
corresponded with the beginning of exponential testicular growth, an increase in body weight, and 
in increase in plasma Inhibin-B. Contrary to our hypotheses, the onset of puberty did not 
correspond with an increase in body fat, IGF-1, or plasma leptin, and suggests that body fat may 
play a less significant role in the onset of puberty in the horse than other species.   
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Table A.1. Peripubertal Standardbred colt somatic parameters relative to puberty onset. Month 
indicates the month relative to the onset of puberty as determined by increase in plasma 
testosterone. Age indicates the mean colt age each month. Percent body fat was measured 
according the equation 3.83 + 5.58x, where x= cutaneous rump fat in centimeters, and testicular 
volume was calculated as 0.5233 x length x width x height in cm.  All data shown as mean ± SEM.   
 
Time n Age (mo) Body fat (%) Testicular volume (cm3) Weight (kg) 
-3 23 10 ± 0.2 6.9 ± 0.2a 19.2 ±3.7ab 325.9 ±6.4a 
-2 23 11 ± 0.2 6.7 ± 0.3ab 25.6 ± 4.3b 325.9 ±7.1a 
-1 23 12 ± 0.2 6.3 ± 0.2b 36.1 ± 5.9bc 331.3 ± 6.5a 
0 23 13 ± 0.2 6.3 ± 0.2b 53.5 ± 7.8c 338.4 ± 6.7ab 
1 21 14 ± 0.2 6.3 ± 0.2ab 79.1 ± 12.0d 346.5 ±7.6 b 
2 20 15 ± 0.2 6.2 ± 0.3b 85.4 ± 9.0 d 359.6 ± 8.4c 
3 16 15.9 ± 0.2 6.9 ± 0.3a 93.8 ± 11.9 d 380.1 ± 8.1d 





Table A.2. Pearson’s coefficient of correlations for reported measurements.  Testosterone, androstenedione, FSH, LH, estradiol-17β, 




Table A.3. Mean (± SEM) plasma concentrations of testosterone, androstenedione (AND), FSH, LH, estradiol-17β (E2), leptin, insulin, 
IGF-1, inhibin A (IN-A), and inhibin B (IN-B) concentrations in peripubertal Standardbred colts. Time indicates the month relative to 
the onset of puberty as determined by an increase in plasma testosterone two standard deviations above the previous mean. 
 



















-3 23 0.1 ± 0.01d 43.3 ± 3.1 0.1 ± 0.04a 7.3 ± 0.8 0.7 ± 0.3 3.3 ± 0.2 0.06 ±0 .01b 140 ± 17 10.3 ± 2.8 48.5 ± 8.8b 
-2 23 0.1 ± 0.02ad 45.7 ± 2.7 0.2 ± 0.08ab 8.0 ± 0.8 0.6 ± 0.15 1.8 ± 0.3 0.09 ± 0.01ab 116 ± 9 11.7 ± 1.8 54.6 ± 9.5b 
-1 23 0.2 ± 0.03ab 43.8 ± 3.0 0.3 ± 0.06ab 7.7 ± 0.9 0.6 ± 0.3 1.6 ± 0.4 0.10 ± 0.02ab 113 ± 9 13.5 ± 1.7 80.3 ± 11.5ab 
0 23 0.5 ± 0.06c 46.0 ± 3.7 0.6 ± 0.26b 9.9 ± 1.0 0.9 ± 0.4 1.4 ± 0.3 0.15 ± 0.04ab 130 ± 10 11.9 ± 1.2 91.2 ± 11.1ab 
1 21 0.2 ± 0.03bc 46.3 ± 2.9 0.3 ± 0.10ab* 8.9 ± 1.0
 0.7 ± 0.2 1.5 ± 0.3 0.09 ± 0.02ab 120 ± 11 14.8 ± 2.4 89.1 ± 8.5ab 
2 20 0.3 ± 0.05bc 46.6 ± 3.3 0.2 ± 0.06ab 7.3 ± 0.8 0.7 ± 0.3 1.4 ±0.3 0.14 ± 0.02ab 103 ± 9 13.2 ± 1.6 
109.1 ± 
15.3a 
3 16 0.3 ± 0.03bc 45.2 ± 3.3 0.2 ± 0.08ab 8.1 ± 0.8 0.5 ± 0.05 1.3 ± 0.4 0.23 ± 0.03a 101 ± 12 13.1 ± 1.8 
106.8 ± 
10.8a 
Different superscripts within columns denote differences (p<0.05). 
 Testosterone Weight Body fat Testicular volume IGF-1 Age FSH Estradiol-17β Inhibin-B 
Body fat -0.21         
Testicular Volume 0.46 0.65   -0.24    0.41 
Leptin -0.18 -0.34  -0.22  -0.17   -0.24 
LH 0.34 0.17 0.22 0.16   -0.31 0.16 0.36 
FSH 0.35       -0.28 -0.29 
Age 0.53 0.68 -0.17 0.68     0.45 
Weight 0.38         
Androstenedione 0.26  -0.14       
Insulin   0.26 0.21  0.31    
Inhibin-A        -0.22 0.31 
Inhibin-B 0.24 0.34 0.22 0.41  0.45 -0.29   
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Supplemental Table A.1. Standardbred colt somatic parameters from January (Month 1) to August (Month 8) 2015.  Percent body fat 
was measured according the equation 3.83 + 5.58x, where x= cutaneous rump fat in centimeters, and testicular volume was calculated 
as 0.5233 x length x width x height in cm.  All data shown as mean ± SEM.   
 
Month n Age (mo) Body fat (%) Testicular volume (cm3) Weight (kg) 
1 23 10 ± 0.2 6.9 ± 0.2a 19.2 ±3.7ab 325.9 ±6.4a 
2 23 11 ± 0.2 6.7 ± 0.3ab 25.6 ± 4.3b 325.9 ±7.1a 
3 23 12 ± 0.2 6.3 ± 0.2b 36.1 ± 5.9bc 331.3 ± 6.5a 
4 23 13 ± 0.2 6.3 ± 0.2b 53.5 ± 7.8c 338.4 ± 6.7ab 
5 21 14 ± 0.2 6.3 ± 0.2ab 79.1 ± 12.0d 346.5 ±7.6 b 
6 20 15 ± 0.2 6.2 ± 0.3b 85.4 ± 9.0 d 359.6 ± 8.4c 
7 16 15.9 ± 0.2 6.9 ± 0.3a 93.8 ± 11.9 d 380.1 ± 8.1d 
Superscripts denote significantly different parameters (p<0.01). 
 
Supplemental Table A.2.  Hormone concentrations in peripubertal Standardbred colts. Mean (± SEM) plasma testosterone (T4, ng/ml), 
androstenedione (AND, ng/ml), FSH (ng/ml), LH (ng/ml), estradiol (E2, pg/ml), leptin (LEPT, ng/ml), insulin (INS, μg/ml), IGF-1 
(ng/ml), inhibin A (INH-A, pg/ml), and inhibin B (INH-B, pg/ml) concentrations in Standardbred colts from January (Month 1) to 
August (Month 8) 2015.  Superscripts denote significantly different parameters (p<0.01). 
 
Mo. T4 AND FSH LH E2 LEPT INS IGF-1 INH-A INH-B 
1 0.03 ± 0.01a 0.02 ± .01a 10 ± 1.6a 0.4 ± 0.06ab 35 ± 2.0 1.3 ± 0.4 0.1 ± 0.02abc 102 ± 22 NA 45.0  ± 9.8bc 
2 0.06 ± 0.01a 0.1 ± 0.02ab 8  ± 0.6a 0.4 ± 0.03ab 41 ± 2.8 1.5 ± 0.2 0.10 ± 0.01a 131 ± 15 11.1± 2.2 42.2 ± 7.6c 
3 0.09 ± 0.02ae 0.3 ± 0.10ab 7.7 ± 0.8ab 0.4 ± 0.03ab 51 ± 3.2 1.7 ± 0.3 0.08 ±.01a 170 ± 50 11.0 ± 1.8 56.2 ± 8.4bc 
4 0.26 ± 0.04b 0.2 ± 0.10ab 7.7 ± 1.0ab 0.3 ± 0.06a 47 ± 3.6 1.6 ± 0.4 0.10 ± 0.04ab 109 ± 8 13.2 ± 1.7 77.2 ± 8.2abc 
5 0.48 ± 0.26c 0.6 ± 0.3ab 10.4 ± 0.8b 0.5 ± 0.06b 42 ± 3.0 1.5 ± 0.3 0.14 ± 0.03ab 134 ± 10 13.1 ± 1.4 94.1 ± 8.9ab 
6 0.24 ± 0.16b 0.3 ± 0.10ab 9.1 ± 1.0a 0.4 ± 0.03ab 46 ± 3.0 1.4 ± 0.3 0.05 ± 0.01a 166 ± 50 15.0 ± 2.3 92.1 ± 10.4ab 
7 0.29 ± 0.22b 0.2 ± 0.06ab 8.1 ± 0.7a 0.4 ± 0.04ab 46 ± 3.1 1.4 ± 0.3 0.18 ± 0.02bc 103 ± 9 12.2 ± 1.7 101.8 ± 8.8ab 
8 0.21 ± 0.14be 0.2 ± 0.07ab 7.8 ± 0.8a 0.5 ± 0.04ab 44 ± 3.5 1.5 ± 0.4 0.23 ± 0.03c 100 ± 11 13.3 ±1.6 110.8 ± 18.4a 
LH only 5-4 interaction is significant (p<0.004) and 8-4 p=0.05  
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ABSTRACT 
Urospermia is known to affect semen quality in many mammals, including stallions. 
Determinations of semen pH and creatinine and urea concentrations have been used to diagnose 
urine contamination in raw stallion semen. Unfortunately, practitioners suspecting urine 
contamination in cooled-shipped samples have no proven means to confirm the presence of urine. 
Therefore, the objectives of this study were (1) to assess the effects of urine contamination on 
sperm motility of extended fresh and cooled-stored stallion semen, (2) to evaluate the usefulness 
of semen color, odor, pH, and creatinine and urea concentrations for urospermia diagnosis, and (3) 
to evaluate the accuracy of a commercial blood urea nitrogen test strip in diagnosing urine 
contamination in extended-cooled stallion semen. Thirty-seven ejaculates were obtained from 11 
stallions with no history of urospermia before division into 5 mL aliquots, and contamination with 
stallion urine. Each resulting sample was assessed for sperm motility, color, odor, pH, creatinine, 
and urea nitrogen concentration using both a semiquantitative test strip (Azostix), and a 
quantitative automated analyzer before and aftercooling for 24 hour. Sperm motility parameters, 
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pH, and creatinine and urea concentrations were analyzed using mixed models. Urine 
contamination decreased total and progressive motility in all samples before and after cooling (P 
< 0.05). Mean control total motility was 80% at 0 hour and 67% at 24 hours, whereas urine-
contaminated samples ranged from 30% to 71% at 0 hour and 27% to 61% at 24 hours. Control 
mean urea (29 mg/dL) and creatinine (0.6 mg/dL) concentrations were significantly different (P < 
0.05) from all urine-contaminated samples (158 mg/dL and 11.6 mg/dL, respectively) at 0 hour. 
Similarly, control mean urea (8 mg/dL) and creatinine (0.9 mg/dL) concentrations were 
significantly different than all urine-contaminated samples at 24 hours. Odor assessment presented 
moderate sensitivity (65%) and high specificity (100%), while color assessment presented low 
sensitivity (47%) and moderate specificity (79%) for urine in extended semen. Azostix strips were 
highly sensitive (95%) and specific (97%). Assessment of color, odor, and pH are not reliable 
methods to diagnose urine in experimentally contaminated cooled-stored stallion semen. Sperm 
motility parameters (in raw and cooled semen) are significantly reduced by the presence of urine 
in a concentration dependent. The results of the present study indicated that determination of urea 
and creatinine concentrations can be used to diagnose urospermia and that Azostix can be used as 
a point of care method for diagnosing urine contamination in extended cooled stallion semen. 
Keywords:  urospermia, stallion, semen, urea, creatinine 
 
INTRODUCTION 
Contamination of semen with urine (urospermia) is a well-recognized ejaculatory 
dysfunction that affects the quality of raw semen and may affect fertility in stallions [1-3]. The 
effects of urine on semen quality appear to be mediated by an increase in semen pH and osmolarity 
[4]. In one report at a referral hospital, urine contamination was the second most common 
ejaculatory dysfunction in stallions [5] Contamination of the semen with urine can occur at any 
time during ejaculation and can manifest as a continual or intermittent problem with an 
unpredictable pattern [6-9]. Urospermia has been associated with many conditions ranging from 
neoplasia or fractures that interfere with normal lumbosacral neurological pathways, to 
osteomyelitis, herpes-virus 1, sorghum toxicosis, cystitis, hyperkalaemic periodic paralysis, or 
idiopathic causes [1,6,7,10]. Overall, idiopathic causes appear to be the most prevalent [3,8].  
Different management practices have been attempted to manage stallions presenting with 
recurrent urospermia, from encouraging  stallions to urinate before collection or breeding, to 
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urinary bladder catheterization prior to collection, fractionated semen collection with open 
artificial vagina, or pharmacological intervention with drugs such as imipramine hydrochloride to 
improve bladder sphincter control [1-3,6,9]. However, the multifaceted and unpredictable 
occurrence of urospermia makes management and treatment difficult [2,7], and pharmacological 
interventions such as bethanechol, imipramine or furosemide are not always effective  [11]. 
While it has been shown that extending semen appears to mitigate the effects of urine 
contamination on sperm motility [4], the effects of urospermia on the motility or fertility of cooled 
stallion semen is not documented.  A large amount of urine contamination can be easily detected 
in raw semen by evaluation of odor and color  [3,7], but diagnosis of urine contamination in 
extended cooled-shipped semen can be challenging. In practice, urine contaminated ejaculates may 
be shipped due to lack of knowledge of the personnel collecting and processing the semen, or for 
fraudulent reasons without disclosure to the practitioner breeding managing the mare. Thus, 
objective means to detect urine contamination in cooled-shipped semen are warranted from both 
the practical standpoint and legal standpoint (e.g. grounds for another semen collection and 
shipping). Creatinine (>2mg/dl) and urea (>25-30mg/dl) concentrations have been suggested to be 
useful to diagnose urine contamination in raw stallion semen [3,12,13] and the use of strip-paper 
has been used as a screening tool for urine contamination in raw semen, where urea levels >39 
mg/dl indicate urospermia [12]. However, it remains unknown whether urine contamination can 
be properly diagnosed in cooled-extended semen using common means to assess urine 
contamination. We hypothesized that urine contamination affects sperm motility in extended 
cooled-stored semen in an amount-dependent manner, and that measuring creatinine and urea can 
accurately diagnose urospermia in extended cooled-stored semen but not color, odor, or semen pH 
assessments. The objectives of this study were: (i) to assess the effects of different amounts of 
urine contamination on sperm motility of extended fresh and cooled-stored stallion semen, (ii) to 
evaluate the usefulness of semen color, odor, pH, creatinine and urea concentrations for diagnosis 
of urine contamination in fresh extended and extended-cooled stallion semen, and (iii) to evaluate 
the accuracy of a commercial blood urea nitrogen test strip in diagnosing urine contamination in 






MATERIALS AND METHODS 
Animals, urine and semen collection  
Eleven reproductively healthy light breed stallions (4 Standardbreds, 4 Quarter Horses, 3 
Thoroughbreds), averaging 9 yrs. old (range 5 to 15 yrs. old), with no known history of 
urospermia were enrolled in this study. All stallions were handled in accordance with the United 
States Department of Agriculture Guide for Care and Use of Agricultural Animals in Research, 
in accordance with the University of Illinois Institutional Animal Care and Use Committee 
protocol #1400. 
All animals were housed at the same research facility in small turnout runs, and fed similar 
grass/alfalfa hay diets. Free catch urine samples were obtained from three of the enrolled stallions, 
pooled and frozen at -20oC until further use.  Each stallion was collected on a dummy phantom, 
with a teaser mare present in the breeding shed using a Missouri model artificial vagina (NascoTM, 
Fort Atkinson, Wisconsin). Stallions were collected at two to three day intervals over a two-week 
period in November of 2014 until a total of thirty-seven ejaculates were obtained. The artificial 
vagina was lubricated (Priority Care1, First Priority Inc., Elgin IL) and fitted with a clean inline 
sperm filter (Har-VetTM ,Spring Valley, WI ) for each semen collection.  
 
Raw semen evaluation & processing  
Immediately after semen collection, each ejaculate was assessed for initial motility using 
Computer-Assisted Sperm Analysis (CASA) using settings recommended by the manufacturer 
(Spermvision, Minitube of America, Verona, Wisconsin). Semen was extended with a milk 
protein-based extender (INRA 96 IMV, Maple Grove, Minnesota) to 25 million sperm/mL. A 
small aliquot (10 µL) of extended semen was placed on a heated slide with a coverslip, and 
assessed using CASA. Parameters analyzed included total percent of sperm motility, progressive 
sperm motility, sperm velocity parameters (VCL: curvilinear velocity (µm/s), VAP: average 
pathway velocity (µm/s), VSL: straight-line velocity (µm/s)) and coefficients (LIN: linearity (%), 
STR: straightness (%), WOB: wobble (%)) were assessed for all samples using CASA.   
Sperm concentration in raw semen was analyzed in standard fashion using a 
spectrophotometer according to the manufacturer’s recommendations (Equine Densimeter, 
Animal Reproduction Systems, Chino, California). Measurement of semen pH was attained using 
a hand-held pH meter (LAQUA Twin, Horiba Instruments, Irvine, California). The sample well 
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was filled until the bottom of the chamber was covered, and a reading was recorded when a stable 
measure was achieved. A standard buffer solution (pH=7) was used to calibrate the pH meter 
immediately before each analysis. The loading chamber was thoroughly rinsed with bi-distilled 
water and gently wiped dry between each analysis.  
Each ejaculate was divided into five 5 mL aliquots, and either 0, 0.25, 1, 1.5, or 5 mL of 
pooled stallion urine was added (Figure 1).  Every semen sample was then assessed for urea 
nitrogen concentration using a semi-quantitative test strip designed to assess urea nitrogen in whole 
blood (Azostix®, Siemens Healthcare Diagnostics, Tarrytown, New York) using a method similar 
to that used by Althouse et al [12]. Briefly, each Azostix® strip has a reagent pad that contains 
both urease and bromothymol blue. When a sample is placed on the reagent pad, urea present in 
the sample is hydrolyzed by urease to ammonium hydroxide and carbon dioxide. Ammonium 
hydroxide is alkaline and increases the pH.  Bromothymol blue is used to indicate the change in 
pH, and will cause a concentration dependent change in reagent pad color. Simply, the more urea 
in a sample, the darker green the strip will become.  For this study, the reagent pad was fully 
immersed with the sample being tested.  After 60 seconds, the pad was rinsed thoroughly with 
distilled water, and immediately directly compared to the color chart on the side of the Azostix® 
bottle.  The corresponding category closest to the color of the reagent strip was recorded, and if 
there was any ambiguity, the higher concentration was chosen. No change in color was recorded 
as negative for the presence of urea. The four color categories corresponded, from lightest to 
darkest, to (5-15 mg/dl), (15-26mg/dl), (30-40 mg/dl) and (50-80 mg/dl).  Azostix® strips were 
graded as positive for urine contamination if the strip read >5 mg/dl in the raw and 5mg/dl in the 
extended cooled semen samples.   
Semen odor was assessed as positive or negative for urine by three observers. Photographs 
were acquired of each sample by placing the test tube against a white background (Figure1). All 
tubes were identified by a random number, and semen color was graded at a later time as positive 
or negative by three observers who assessed the color via photograph, blinded to treatment group.   
The semen aliquots were reassessed for sperm concentration and semen pH, and 1 mL of 
each sample was removed and frozen for later analysis of urea and creatinine using a quantitative 
automated analyzer (Beckman Coulter, Pasadena, California).  The remainder of each aliquot was 
then extended with a commercial milk-based extender (INRA96, IMV Technologies, Maple 
Grove, Minnesota 55369) to a final concentration of 25 million sperm/mL. Total and progressive 
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motility were re-assessed with CASA, and the samples were then packaged in Whirl-paks (Nasco, 
Fort Atkinson, Wisconsin) and stored in commercial semen containers (Equitainer I, Hamilton 
Research, Inc., Ipswich, Massachusetts) for 24 hours.  
 
Semen cooling and evaluation  
At 24 hours, the semen containers were opened, and the samples were allowed to warm in 
an incubator to 37°C for 10 minutes before analysis. Semen pH, motility, color and odor were 
assessed for all samples as described above. Assessors were blinded to degree of urine 
contamination for both color (Fig 2) and odor assessments. Each sample was then retested using 
the commercial urea test strip as published elsewhere [12] and described above.  
 
Statistical analyses 
Statistical analyses were carried out with a commercially available software (JMP 11, SAS 
Institute, Cary, NC). Sperm motility, concentrations of creatinine and urea, and semen pH were 
analyzed using mixed models and when significant differences found, post hoc comparisons were 
made with LSD’s test. Sensitivity and specificity for odor, color, and Azostix® were calculated 
using the urea nitrogen and creatinine concentrations.  Agreement’s tests were performed between 
evaluators for color and odor. Mean concentrations were calculated for urea nitrogen and 
creatinine in the control samples.  The threshold for a urine free sample was calculated as three 
standard deviations above the mean concentration for a negative sample. Significance was set at 
p<0.05. Data were expressed as means ± SEM.  Arbitrarily, specificity and sensitivity were 
classified as low (<60%), moderate (60-80%) and high (>80%). 
 
RESULTS 
None of the ejaculates presented spontaneous urine contamination as demonstrated by the 
low concentrations of urea (26 ± 1 mg/dl) and creatinine (0.6 ± 0.3 mg/dl).  There were no 
significant effects of stallion for motility parameters and urea and creatinine levels in raw semen 
samples.  Total and progressive motility decreased in all samples pre and post cooling in a dose-
dependent urine contamination (p<0.05) (Table B.1). There were significant effects of treatment 
(p<0.001) and time by group interaction for total and progressive motility (p<0.0001). As 
expected, total and progressive sperm motilities were significantly reduced in urine contaminated 
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samples, both in raw and extended cooled-stored semen (Table 1).  Sperm velocity parameters 
(VCL: curvilinear velocity (µm/s), VAP: average pathway velocity (µm/s), VSL: straight-line 
velocity (µm/s)) and coefficients (LIN: linearity (%), STR: straightness (%), WOB: wobble (%)) 
were assessed for all samples using CASA.  Results for VCL and VAP for samples contaminated 
with 50% urine were significantly different (p<0.01) than all other samples at both 0 and 24h 
(Table1). VSL was significantly greater for control and 9% contaminated samples than for 23% 
and 50% contaminated samples at both 0 and 24h.  No difference was observed between any 
samples for sperm coefficient measurements (LIN, STR, and WOB) at either 0 or 24 h (Table B.1).  
 Initial raw semen pH was lower than urine contaminated semen (p< 0.05) (Table B.2). This 
difference was not observed after extension and cooling for 24h, as the pH of the control group 
was not significantly different than the urine contaminated groups. The group with high percent of 
urine contamination (50%) had a pH significantly higher than the control groups and remaining 
contaminated groups (9 to 23%) (Table 2).  
As expected, creatinine and urea concentrations were greater as increasing amounts of urine 
was added to the raw semen (Table B.2). Specificity and sensitivity for creatinine and urea were 
very high (Table B.3). Overall odor and color assessment of raw and cooled extended semen 
presented a wide range of sensitivity from low to high depending on the amount of urine 
contamination (Table 4). However, color and odor assessment of raw and extended semen 
contaminated with varying amounts of urine presented high specificity (Table B.4).  
All negative controls tested negative at 0 h (37/37), and one positive sample tested negative 
(1/148).  Azostix® test strips were highly sensitive and specific for raw semen (Table B.5).  All 
but one negative control tested negative (36/37) after extension and cooling, and all but six positive 
samples tested positive after extension and cooling (142/148).  All false negatives were in the small 
degree of urine contamination group (9%).  Azostix® were highly sensitive and specific for 
detecting urine in cooled extended semen (Table 5).  
 
DISCUSSION 
We demonstrated that creatinine, urea and Azostix® are highly specific and sensitive 
methods to evaluate urine contamination in fresh and cooled extended stallion semen. Creatinine 
and urea determinations in raw semen have been used to confirm urospermia in practice  [3,8].  
Here we documented that these two analytes can be used to diagnose urospermia in extended 
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semen samples as well. Previously, it had been demonstrated that Azostix® is an effective tool to 
diagnose urine contamination in raw semen samples [12], however, its effectiveness for extended 
semen has been questioned [3,13]. Using an experimental approach we confirmed that Azostix® 
can be a useful screening tool to detect even small amounts of urine contamination. Recently, in 
our practice, we have had the opportunity to put the findings of the present study to test in a Quarter 
Horse stallion and an Arabian stallion presenting with recurrent urospermia. The ejaculates were 
contaminated with apparently moderate and small amounts of urine and smelled like urine. We 
determined urea and creatinine concentrations and used Azostix® in raw semen samples and 
cooled extended semen (25 million sperm/mL) in 3 ejaculates. Results of these clinical cases fully 
support the findings of the present study obtained under experimental conditions (IC and RE 
unpublished).  
The Azostix® manufacturer recommends waiting at least 60 seconds to read the test strip 
against the scale provided in the back of the container. We followed the manufacturer 
recommendations, but Althouse and collaborators [12] reported the occurrence of false positives 
if rinsing and reading was performed after 10 seconds. We did not find an increase in false positives 
when preforming the Azostix® analysis per manufacturer recommendations (waiting for 60 
seconds) for blood urea nitrogen analysis. Even after waiting 60s, control samples remained 
negative for urine contamination. It is unknown if Azostix® has changed over the years but based 
on our present findings, we recommend following the manufacturer instructions.  It is notable that 
the only false negative results were recorded for samples in the 9% urine contamination group. As 
demonstrated here, Azostix® is highly sensitive and specific when used to diagnose urine 
contamination in cooled semen, regardless of the percentage of urine contamination.   
Practitioners in need of further diagnostics can submit semen samples for urea and 
creatinine concentrations. Samples with a urea concentration greater than 30 mg/dl or creatinine 
greater than 2.0 mg/dl are considered contaminated with at least a small amount of urine according 
to Hurtgen [14].  Our findings agree with Hurtgen’s value  [14] for creatinine for raw semen 
samples, but we found that his urea concentration was much lower than all 37 ejaculates evaluated 
in the present study, as the urea concentrations for all control semen samples were averaged 26 
mg/dl ± 1 while all contaminated samples had a urea concentration greater than 95mg/dl.    
Similarly, with the exception of one sample, all control samples had a creatinine of less 
than 1.7 (0.8 ± 0.3), and all contaminated samples had a creatinine greater than 3.5mg/dl.  Our 
158 
 
findings suggest that potential thresholds for urea and creatinine concentrations in cooled extended 
samples should be >12 mg/dl and >1.3mg/dl respectively. Although these values could be highly 
variable in a clinical setting, these suggested values may offer some potentially useful reference 
values for practicing clinicians. 
On the other hand, odor and color assessment are not sensitive methods to detect small 
amounts of urine in cooled extended semen samples, though both methods were highly specific 
regardless the amount of urine contamination. Color is not only influenced by urine contamination, 
but also by semen concentration, extender used, and the cleanliness of the ejaculate.  Failure to 
properly wash the penis and remove smegma before collection can result in debris in the ejaculate 
and a change in color. Similarly, odor was a poor diagnostic tool for small amounts of urine 
contamination, but it was highly specific for moderate to high amounts of urine contamination in 
raw and cooled-extended semen. Odor may also be influenced by the stallion, extender used, or 
failure to assess odor after collection. If urine smell or color can be detected in cooled semen, the 
semen is likely contaminated with urine, which warrants further confirmation by objective 
methods such creatinine, urea and Azostix®.  
While semen pH appears to be a highly useful tool to diagnose urine contamination in raw 
semen [4,15], it does not appear to be useful to assess urine contamination in extended-cooled 
samples. In our study, pH of control samples at 24h did not differ statistically to groups containing 
9% to 23% of urine. However, pH of the group containing a high amount of urine contamination 
was significantly higher than the control group. While this is an interesting finding, its use in 
clinical practice may be difficult as there was a small numeric difference between the samples. 
As expected, urine contamination affects initial sperm motility and also motility after 
cooling for 24 hours, even when a small amount of urine is present. Urine contamination was found 
to have a more pronounced effect on reduction of sperm motility in raw semen as compared to the 
cooled stored samples. Semen extension with a commercial milk protein-based semen extender 
may mitigate some of the urine’s detrimental effects on stallion semen survival as suggested by 
Griggers et al. [4], perhaps by correcting the detrimental effects of a hypertonic solution and 
alkaline pH.  However, as demonstrated here even a small amount of urine contamination (less 
than 10% of total semen volume) has deleterious effects on sperm motility, and may go unnoticed 
by personnel packaging and shipping semen.  Thus, Azostix® strips represent a point-care means 
of testing for the presence of urine for practitioners presented with a semen shipment that has 
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unexplained poor motility or a suspicious color or odor. While it has been shown that urine 
contamination affects sperm motility [4], there have been no controlled studies showing effects of 
urine on fertility, but apparently reduction in fertility was associated with urospermia in a 
Thoroughbred stallion [1], but its effect on fertility of urine contaminated and then cryopreserved 
semen has not been demonstrated.  In addition to decreased motility, it has been hypothesized that 
urine in the ejaculate may cause uterine irritation similar to that seen in mares with urovagina 
which can subsequently affect fertility. Naylor and collaborators reported no pregnancies from an 
HYPP H/H stallion with confirmed recurrent urospermia [10].  Other case reports have 
documented pregnancies from cooled shipped urine-contaminated samples where processing 
involved centrifugation [3]. Previous studies have reported stallion pregnancy rates per season 
have ranged from 35% to 80% for horses with urospermia [1,3,6], and variations may be in part 
due to the fertility of mares being bred. In our practice, we have had multiple ejaculates presented 
with perceived variable amounts of urine contamination resulting in pregnancies when young 
fertile mares were bred, but pregnancies were not confirmed when older subfertile mares were 
bred with urine contaminated semen.   
In conclusion, semen pH, color and odor are not reliable tests for detection of small 
amounts of urine contamination in cooled-shipped samples, but a commercial blood urea nitrogen 
test strip can detect the presence of even small concentrations of urine in raw samples, and 
moderate degrees of urine contamination in cooled and extended samples. Practitioners in need of 
further diagnostics can submit semen samples for urea and creatinine concentrations. While this 
study provides practitioners information regarding potential threshold values for urea and 
creatinine concentrations when presented with ejaculates with suspected urospermia, work still 
needs to be done on the effects of urospermia on fertility, and improving semen quality of 
urospermic samples.  
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ABSTRACT 
Urospermia is a common ejaculatory dysfunction of stallions. Current practice suggests 
that urine contaminated semen should not be used for cryopreservation. The aim of this study was 
to determine effects of urine contamination on semen cryopreservation. Sixty-five ejaculates from 
eight stallions were divided into no urine (CONT), low (20% urine, LOW), and high (50% urine, 
HIGH) samples. Semen was extended with a commercial cooling extender, cushion-centrifuged, 
resuspended to 200 million/mL in a commercial egg-yolk based extender, and cryopreserved. A 
subset of ejaculates (n=20) were split in two after cushion-centrifugation, and one half of the 
ejaculate was submitted to a single-layer gradient centrifugation before cryopreservation. Sperm 
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motility were assessed pre- and post-freezing with an automated sperm analyzer. Semen pH, 
creatinine, and urea concentrations were assessed in raw samples, after urine contamination and 
after centrifugation and extension. Statistical analyses were performed with ANOVA and Tukey’s 
posthoc. There was a significant reduction in total and progressive sperm motilities (i.e., %TM 
and %PM, respectively) with increasing urine contamination pre-freezing (%TM 67±1.7, %PM 50 
± 2.2, CONT), (%TM 60.3 ±1.7, % PM 42.5 ± 2.1, LOW), and (%TM 41.3 ± 2, %PM 21.3 ± 1.5, 
HIGH). Post-thaw motilities for CONT (%TM 54 ± 2.3, %PM 40.8 ± 3.3) and LOW (%TM 51.7 
± 1.8, %PM 36.2 ± 2.1) were not different, but were higher than the HIGH (%TM 31.5 ± 1.2, %PM 
17.1 ± 1.0) (p<0.05). Post-thaw sperm viability was significantly lower in the HIGH (54.7 ± 2.4) 
than in the CONT (63.8 ± 2.3) or LOW (64.6 ± 3.4) groups. Semen creatinine and urine levels 
were significantly higher with increasing urine contamination, and were significantly decreased 
after centrifugation and resuspension in freezing extender. Pre-treatment semen pH was 
significantly lower than semen contaminated with low or high amounts of urine, and pH decreased 
significantly after centrifugation and resuspension. Semen contaminated with a small amount of 
urine may be suitable for cryopreservation, whereas highly contaminated semen might not be 
usable. Although urine was mostly removed in this fashion, the initial exposure to high quantities 
was sufficient to decrease sperm motility pre- and post-freezing, whereas low urine contamination 
was not as detrimental.   
Keywords: Urospermia, sperm parameters, semen cryopreservation, horses 
 
INTRODUCTION 
Urine contamination of semen is one of the most common ejaculatory dysfunctions in 
stallions[1]. Occurrence of urospermia is unpredictable and may present as a rare, isolated event, 
intermittently, or frequently [2-4]. Unfortunately, some stallions may present with urospermia 
throughout their entire breeding career, which makes the breeding management for optimal fertility 
a true challenge in clinical practice [3,5] . 
Urospermia has been associated with a wide range of conditions, such as neoplasia or 
fractures that interfere with normal lumbosacral neurological pathways, osteomyelitis, equine 
herpesvirus 1, sorghum poisoning, cystitis, and hyperkalemic periodic paralysis [5,10,11]. 
However, idiopathic causes appear to be the most prevalent, which challenges the ability to 
properly treat or manage the condition [11,12]. Different management practices have been 
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implemented for stallions presenting with recurrent urospermia, including encouraging stallions to 
urinate before collection or mating, urinary bladder catheterization before collection, fractionated 
semen collection, and pharmacological intervention with drugs such as imipramine hydrochloride 
to improve bladder sphincter control [2-4,13-15]. Unfortunately, even implementing these 
techniques does not prevent urospermia in some stallions [2,5,11,14]. 
Detrimental effects of urine on semen appear to be mediated by alkaline pH, high 
osmolality and possibly the high concentration of crystals [2,5-7]. However, it is currently 
unknown how the different sperm cell compartments and functions are affected by urine 
contamination. Urine might also interfere with fertility by inducing endometrial inflammation in 
mares mated by affected stallions [5]. The adverse effect of urine on both sperm quality and 
endometrium may be mitigated by extension and centrifugation [8,9]. Immediate extension in 
semen extender, followed by cushioned centrifugation and resuspension seems to help preserve 
quality of urine contaminated semen [9]. However, to the best of our knowledge, this method does 
not account for damage to semen in collections where urospermia was not expected and sperm are 
exposed to urine for a prolonged period during processing.   
Up until now, no studies have evaluated the effects of urine contamination on stallion 
semen cryopreservation. Unfortunately, genetically and economically valuable stallions may 
present ejaculates that are intermittently or constantly affected by urine contamination, which 
imposes a major barrier to effectively cryopreserve semen from these stallions. Currently, the most 
acceptable clinical practice is to discard ejaculates contaminated with urine and repeat semen 
collection in hopes of obtaining a urine-free sample. It is assumed that semen cannot be 
cryopreserved from stallions with recurrent urospermia. Our clinical experience suggests that it 
might be possible to freeze mildly urine-contaminated semen with apparent success. Therefore, 
we felt compelled to critically address this question in the present study and provide evidence-
based recommendations for the use of urospermic semen during cryopreservation. The results 
would be particularly relevant for valuable studs that experience urospermia but have low sperm 
counts or are difficult to re-collect due to orthopedic, neurologic or behavioral impairment. 
Additionally, we were interested in determining if using gradient centrifugation, which selects for 
viable sperm, would improve standard semen freezing in urine-contaminated samples. 
We hypothesized that semen experimentally contaminated with low, but not high, amounts 
of urine can be successfully cryopreserved with only marginal changes in sperm quality compared 
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to control samples. Therefore, the objectives of this study were to evaluate the effects of urine 
contamination on sperm parameters of cryopreserved stallion semen and to determine if single-
layer gradient centrifugation improves semen quality of cryopreserved semen. 
 
MATERIALS AND METHODS 
The present study was performed from January to February 2017. The Institutional Animal 
Care Unit Committee under the protocol # 14200 approved all procedures carried out in the present 
study.  
Animals and semen collections 
Eight healthy mature light breed stallions (four Standardbreds, one Appaloosa, one Paint 
and two Quarter Horses) from 5-18 years of age (mean 9.5 ±1.4 years) were enrolled in the study. 
The animals were housed in stalls at the Illinois Veterinary Teaching Hospital, College of 
Veterinary Medicine, University of Illinois Urbana-Champaign and fed similar grass/alfalfa hay 
diets.  
Free catch urine samples were collected one week before the experiment from three of the 
stallions enrolled in the study. Urine was pooled, split into 100 mL aliquots, and then froze at -
20oC until use. One week before the experimental collections, three clean out collections were 
performed per stallion. Stallions were then collected at 2 to 3 day intervals on a dummy mount, 
using a Missouri artificial vagina (Nasco Fort Atkinson, Wisconsin) until five (n=3 stallions) to 
ten (n=5 stallions) ejaculates were obtained. The artificial vagina was lubricated (Priority Care1 
First Inc., Elgin Illinois) and fitted with a clean in-line sperm filter (Har-Vet, Spring Valley, 
Wisconsin) and a collection plastic bag (Whirl-Paks Nasco, Fort Atkinson, Wisconsin) for each 
semen collection.  
The gel-free portion of each ejaculate was weighed and grossly assessed for the presence 
of contaminants. Semen pH was measured using a commercially available hand-held pH meter 
(LAQUA Twin, Horiba Inc., Irvine, CA, 92618) [8]. A small aliquot of raw semen was frozen in 
cryovials for measurement of creatinine and urea using an automated quantitative analyzer 
(Beckman Coulter, Pasadena, CA 92821). Urine free ejaculates were defined as those with no 
visible gross contamination with urine (e.g., high volume, pungent urine smell, and yellow-tinged), 
presenting semen pH ≤7.7, and urea and creatinine concentrations of ≤40 mg/dl and ≤ 2ng/ml, 
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respectively [2,6-8,15,16]. All sixty-five ejaculates collected attained the definition criteria of 
urine free ejaculates, therefore, further processed and included for the analyses.  
 
Experimental design 
Immediately after collection, semen concentration was determined using a 
spectrophotometer (Equine Densimeter, Animal Reproduction Systems, Chino, California) 
according to the manufacturer’s instructions. Semen was then allocated into six 50 mL conical 
tubes, and for each ejaculate, a control, low, and highly contaminated group were created. The 
control group (CON) had 10 mL of raw semen added to the tube, whereas, the low (LOW) and 
high (HIGH) urine contamination groups had 8 mL and 5 mL of raw semen added to the tubes. 
Urine aliquots of 100 mL were thawed overnight in a refrigerator and warmed at 37oC immediately 
before use. Two milliliters of urine was added to each LOW tube, and 5 mL of urine was added to 
each HIGH tube. Once the semen had been exposed to urine for two minutes at room temperature, 
each of the six tubes was extended to 40 mL with a milk-based semen extender (Equi-Pro® Cool 
Guard®, Timentin, Minitube of America, Vernon, Wisconsin).  This length of exposure accounts 
for the estimated time that the semen would be directly exposed to urine before semen extender 
could be added during routine collection and processing. Final semen concentrations pre-
centrifugation ranged from 20 million/ml to 79 million/ml.  
Following extension, 1 mL of cushion solution (Maxifreeze®, IMV, Maple Grove, MN) 
was added to the bottom of each conical tube using a long spine needle (18G 3.5’’) as previously 
described [17].  Semen was centrifuged at room temperature (1000 x g, 20 minutes). Following 
centrifugation, the supernatant was aspirated with a Sink Vacuum Aspirator Pump® (Animal 
Reproduction System, Chino, California) and discarded. The cushion solution was aspirated with 
a long spinal needle and discarded. The sperm pellet was resuspended and concentration was 
determined with a hemocytometer. For a subset of ejaculates (n=20), a portion of the resuspended 
semen was submitted to gradient centrifugation before freezing using a commercially available 
silane-coated silica solution (EquiPureTM Nidacon, Mölndal, Sweden). Three milliliters of Equi-
PureTM were placed on the bottom of 15 mL conical tube, thereafter, 1 billion of sperm cells 
resuspended on 6 mL of INRA 96 (IMV, Maple Grove, MN) were carefully loaded on top of the 
colloid solution. Then the semen was centrifuged at 400 g for 30 minutes. After centrifugation, the 
EquiPureTM and any semen within the gradient, or still resting on top of the gradient were aspirated 
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and discarded.  The selected sperm pellet was aspirated from the bottom of the tube, the percent 
of yield was calculated, and the resulting sperm were resuspended in a freezing extender.  
Thereafter, the semen (with/out gradient) was extended to a final concentration of 200 million 
sperm/mL, with a commercially available freezing extender (Botucrio® Botupharma, Botucatu Sao 
Paulo, Brazil).  The extended semen was manually loaded into 0.5 mL straws and cooled at 5oC 
for 20 minutes. Straws were then placed 4 cm above liquid nitrogen for 15 minutes before plunging 
into liquid nitrogen. Cryopreserved samples were stored in nitrogen tanks until further analyses.  
 
Sperm motility analyses 
Immediately before semen freezing (i.e., after centrifugation and extension), and after 
freezing and thawing, each ejaculate was assessed for sperm motility parameters by Computer-
Assisted Sperm Analysis (CASA) (Spermvision II®, Minitube of America, Verona, Wisconsin) 
[238]. Thawing was performed by submerging straws into a 37oC water bath for at least 30 
seconds. Semen was extended with a temperature matched milk protein-based extender (INRA 
96® IMV, Maple Grove, Minnesota) to 20 million sperm/mL. A small aliquot (5 µL) of extended 
semen was placed on a heated slide and motion characteristics of a minimum of 1000 cells were 
analyzed in a least ten different fields. The preset values for  the computer-assisted sperm analyzer 
system were as follows: static cell area 14 to 80 µm2; straightness (STR) threshold for progressive 
motility, 90; average path velocity threshold for progressive motility, 40; average path velocity 
threshold for static cells < 9.5; cell intensity, 106;  and light-emitting diode illumination intensity, 
1800 to 2550. Parameters assessed included total percent of sperm motility, progressive sperm 
motility, sperm velocity parameters (curvilinear velocity [VCL, µm/s]; average path velocity 
[VAP, µm/s]; straight-line velocity [VSL µm/s]; and coefficients (linearity [LIN, %] and 
straightness [STR %]).  
 
Statistical analysis 
Data were analyzed using RStudio v 0.99.489 (RStudio Team, Boston, MA).  Normality 
of data was confirmed within histograms and using a Shapiro-Wilk test of the residuals. Sperm 
motility were analyzed by mixed models, with treatment group considered a fixed effect and 
stallion and ejaculate number as random effects. When significant, posthoc comparisons were 
made with Tukey’s HSD test. Simple correlations were determined between urine contamination 
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measures and motility variables.  Data are expressed as mean ± SEM. Statistical significance was 
set at p < 0.05.   
 
RESULTS 
Semen creatinine and urine levels were significantly higher with increasing urine 
contamination, and were significantly decreased after centrifugation and resuspension in freezing 
extender (Table C.1). Pre-treatment semen pH was significantly lower than semen contaminated 
with low or high amounts of urine, and pH decreased significantly after centrifugation and 
resuspension. There was a significant reduction in total and progressive sperm motility with 
increase in urine contamination pre-freezing (Table C.2). Post-thaw motilities for control and low 
were not different from one another but were higher than the high group, and significantly lower 
than pre-freeze parameters (Table C.2).  Similarly, VCL, VAP, and VSL were all significantly 
lower in highly contaminated semen than in the control or low groups on both pre-freeze and post-
thaw examinations (Table C.2). Semen pH, creatinine, and urea concentrations were strongly 
correlated with total and progressive motility on pre-freeze (Table C.3), and post-thaw analysis 
(Table C.4). 
Gradient centrifugation did not improve total motility parameters in the control groups, but 
did improve pre-freeze total and progressive motilities in the low and high groups,  and improved 
significantly post-freezing total and progressive motility in the high contaminated group (Table 
C.5). After gradient centrifugation, there were no differences in post-thaw total motility between 
treatment groups. While progressive motility improved, post-thaw progressive motility in the high 
group was still significantly lower than the control group (Table C.5). No differences were seen 
pre-freeze in the other sperm motility parameters (VCL, VSL, and VAP) between the non-gradient 
samples, and the samples subjected to gradient centrifugation other than a slight increase in pre-
freeze VAP in the high group after gradient centrifugation (Table C.6).  This difference 
disappeared on post-thaw evaluation.  Percent yield after gradient centrifugation did not differ 
between treatment groups (Control 49.7 ± 5.5 %; Low 45.6 ± 5.4%; High 55.8± 5.5%, p = 0.43), 







Our findings in the present study suggest that urine contamination affects stallion semen in 
a dose-dependent manner. Additionally, our results appear to support our hypothesis and clinical 
experience that mildly contaminated ejaculates from stallions affected by conditions causing 
persistent urospermia can still be processed for cryopreservation. While the in vitro results in this 
study suggest that semen freezing ability is not affected by low urine contamination, further studies 
are needed to determine the effects clinical urospermia on the cryopreservation of semen, and to 
determine the effects on fertility after insemination with the frozen-thawed urospermia samples.  
It is hypothesized that urine is detrimental to semen motility because urine increases semen 
pH and osmolarity. Griggers et al [6] demonstrated that both alkaline pH and high semen 
osmolarity have negative effects on semen motility. Studies have suggested that the deleterious 
effects of urine contamination can be mitigated by extension of the urine contaminated semen with 
milk-based extenders in both raw [6] and cooled-stored semen [8]. A subsequent study suggested 
that cushion centrifugation was also useful for mitigating the effects of urine contamination on 
cooled stallion semen [9]. Herein, we demonstrated that cushion centrifugation and standard 
extension for cryopreservation appeared to effectively remove urine from the experimentally 
contaminated ejaculates, as evidenced by the reduction in creatinine and urea after centrifugation. 
Although urine was mostly removed in this fashion, the initial exposure to high quantities was 
sufficient to decrease sperm motility pre- and post-freezing, whereas low urine contamination was 
not detrimental.   
While pre-freeze motilities were different between groups, no differences in motility were 
seen between the control and low contamination groups on post-thaw examination, suggesting that 
the centrifugation and freezing process eliminated the effects of low amounts of urine on semen 
parameters. Highly contaminated samples (50% urine) had significantly lower progressive and 
total motilities both pre-freeze and on post-thaw examination. Parameters used to assess degree of 
urine contamination (pH, urea, and creatinine) were highly correlated with total and progressive 
motility on both pre -freeze and post-thaw evaluations, suggesting that these parameters might be 
useful for determining when an ejaculate is still suitable for cryopreservation. 
When semen was subjected to additional gradient centrifugation before freezing, pre-freeze 
total motility improved in the both urine-contaminated groups, and pre-freeze progressive motility 
improved in all groups. Similarly, post-thaw total and progressive motilities were improved in 
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highly contaminated ejaculates subjected to gradient centrifugation before freezing, suggesting 
that additional processing may improve semen quality in contaminated ejaculates.  This suggests 
that highly contaminated samples might be used if further processed, and if the breeding dose is 
adjusted for the lower post-thaw motilities.  When faced with a stallion with persistent urospermia, 
the combination of semen processing, coupled with an increase in breeding dose, may allow these 
stallions to be successfully cryopreserved. Interestingly, post-thaw progressive motility decreased 
in the control group that was subjected to gradient centrifugation, suggesting that single layer 
gradient centrifugation may be detrimental to normal sperm. 
Gradient centrifugation selects for viable sperm, and increased yield would be expected in 
higher quality ejaculates with little to no urine contamination.  This is important to consider when 
the decision is made to retain and process highly contaminated ejaculates, as lower yields would 
be expected. Interestingly, no differences were detected between treatment group yields after 
gradient centrifugation in the current study. It is important to note that this may be due to small 
sample size, as yield data was not available for all ejaculates, and there was a large variation in 
yield between ejaculates. Nevertheless, the data herein suggests a reasonable use of gradient 
centrifugation to improve semen quality in highly contaminated ejaculates of valuable stallions 
with potentially comparable yields.  
Given the effects of urine on both pre-freeze [6,8,9] and post-thaw semen parameters, the 
next logical steps would be to confirm that gradient centrifugation can improve semen quality in 
clinical urospermia cases and to evaluate effects of different semen processing methods on fertility.  
Urospermia is thought to affect female fertility by inducing endometrial inflammation after 
breeding [5]. In the current study, we have demonstrated that centrifugation removes the majority 
of urea and creatinine, which may prevent endometrial irritation when using processed urine-
contaminated samples for artificial insemination. Therefore, it would be interesting to determine 
if the removal of urine from a highly contaminated sample combined with an increase in sperm 
dose to overcome the effects on sperm motility can produce comparable pregnancy rates. 
Developing a protocol such as this may prove useful for valuable stallions who are otherwise 
difficult to collect. 
In conclusion, this study has demonstrated that cushioned centrifugation can remove the 
majority of urea and creatinine from urine contaminated ejaculates, and that ejaculates with 20 % 
or less urine contamination may still be cryopreserved with satisfactory results. Highly 
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contaminated ejaculates may be improved with processing before cryopreservation but will still 
have lower post thaw progressive motility parameters than uncontaminated ejaculates. Therefore, 
use of these samples will depend on individual stallion fertility and management of the mare being 
bred. We predict that stallions and horse owners will directly benefit from the results of the present 
study, as it provides suggestions on how to manage urospermic samples, and potential parameters 
for deciding when an ejaculate is freezable.   
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Table C.1. Mean ± SEM – Semen pH, urea (mg/dL), and creatinine (mg/dL) concentrations pre- 
and post-centrifugation (n=40 ejaculates from eight stallions).  
  Pre-centrifugation (raw)  Post Centrifugation 
Groups n pH Urea Creatinine pH Urea Creatinine 
Control  40 7.5 ± 0.04a 28 ± 1.5a 0.8 ± 0.2a 6.8 ±0.03d 2.4 ± 0.2d 1.8 ± 0.1d 
Low 40 8.3 ± 0.03b 322 ± 10b 40 ± 1.3b 7 ± 0.03e 15 ± 2.0e 3.1 ± 0.1d 
High 40 8.6 ± 0.02c 721 ± 17c 87.2 ± 1.7c 7.2 ± 0.02f 48 ± 5.1a 7.1 ± 0.6e 
Control group represented samples not contaminated with urine; Low group was contaminated 
with 20% of urine contamination; High group was contaminated with 50% urine. Mean extender 




Table C.2. Mean ± SEM – Stallion sperm motility parameters pre-freezing (after cushion centrifugation and extension) and post-thawing 
(n=8 stallions/64 ejaculates).  
 
  Pre-freezing 
n TM PM VCL VAP VSL 
Control 64 67  ± 1.7ax 50 ± 2.2ax 152 ± 2.5ax 76 ± 1.1ax 60 ± 3ax 
Low 64 60 ± 1.7bx 42 ± 2.1bx 145 ± 2.8bx 73 ± 1.2ax 57.5 ± 2ax 
High 63 41 ± 2cx 21 ± 1.5cx 118 ± 6.7cx 58 ± 1.5bx 45 ± 2.3bx 
  Post-thaw 
n TM PM VCL VAP VSL 
Control 64 54 ± 2.3ay 41 ± 3.3ay 102 ± 3ay 56 ± 1.4ay 43 ± 1.2ay 
Low 64 52 ± 1.8ay 36 ± 2.1ay 102 ± 2.7ay 57 ± 1.3ay 44 ± 1.1ay 
High 63 31 ± 1.2by 17 ± 1by 86 ± 2.3by 48 ± 1.1ay 37 ± 1by 
 
C: control group; L: low urine contamination group; H: high contamination group. TM: percent of total sperm motility; PM: percent of 
progressive sperm motility; VCL curvilinear sperm velocity (µm/s); VAP average path velocity (µm/s); VSL straight-line velocity 
(µm/s); LIN coefficient of linearity (%). Control group represented samples not contaminated with urine; Low group was contaminated 
with 20% of urine contamination; High group was contaminated with 50% urine. Different superscripts within columns (abc) and rows 




Table C.3.  Coefficients of correlation between urine contamination parameters and semen 
parameters, before cryopreservation (pre-freeze) (n=8 stallions/64 ejaculates). 
 
Parameter pH Creatinine Urea 
Total Motility -0.52** -0.69** -0.67** 
Progressive Motility -0.53** -0.70** -0.73** 
VAP -0.50** -0.67** -0.77** 
VCL -0.49** -.54** -0.63** 
VSL -0.38** -0.60** -0.73** 
pH  0.86** -0.86** 
**p<0.0001, * p<0.005  x p<0.05 
 
Table C.4.  Coefficients of correlation between urine contamination parameters and semen 
parameters after cryopreservation (post-thaw).  Pre – and Post- specify parameters before 
extension and centrifugation, or after centrifugation and re-suspension in freezing extender (n=8 
stallions/64 ejaculates). 
 
Parameter pH Pre Creatinine Post Creatinine Pre Urea Post Urea 
Total Motility -0.43** -0.77** -0.63** -0.84** -0.69** 
Progressive Motility -0.39** -0.70** -0.60** -0.77** -0.70** 
VAP -0.30* -0.49** -0.52** -0.58** -0.64** 
VCL -0.30* -0.43* -0.47** -0.52** -0.60** 
VSL -0.29* -0.43* -0.47** -0.51 ** -0.61** 
Pre Creatinine   .80**   
Pre Urea   0.99**   0.84** 
**p<0.0001, * p<0.005  x p<0.0 
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Table C.5. Mean ± SEM –Stallion sperm motility parameters after cushion centrifugation followed by single layer centrifugation (GR) 






Total motility (%) Progressive motility (%) Total motility (%) Progressive motility (%) 
Non-gradient Gradient Non-Gradient Gradient Non-gradient Gradient Non-gradient Gradient 
Control 79 ± 2.1
ax 80 ± 2.4ax 63 ± 3.1ax 67± 2.7ay 61 ± 2.8ay 60 ± 3.1ay 54 ± 2.3az 47 ± 
3.7axy 
Low 75 ± 2.1abx 79 ± 2.0ay 60± 3.1abx 67 ± 2.1ay 61 ± 2.9az 59 ± 3.8az 52 ± 1.8az 45 ± 3.4abz 
High 69 ± 2.1bx 73 ± 2.6ay 46± 3.1bx 54 ± 3.5ay 48 ± 3.1bz 52 ± 3.2ax 32 ± 1.2bz 35 ± 3bx 
TM: percent of total sperm motility; PM: percent of progressive sperm motility; VCL curvilinear sperm velocity (µm/s); VAP average 
path velocity (µm/s); VSL straight-line velocity (µm/s); LIN coefficient of linearity (%). Control group (n=20) represented samples not 
contaminated with urine; Low group (n=20)  was contaminated with 20% of urine contamination; High group (n=20) was contaminated 
with 50% urine. Different superscripts within columns (abc) and rows (xyz) for the same parameter denote differences  (p<0.05).  
 
 
Table C.6. Mean ± SEM –Stallion sperm motility parameters after cushion centrifugation followed by single layer centrifugation (GR) 
or not (NGR) pre-freezing and post-thawing (n=5 stallions/20 ejaculates). 
 
 Pre-freezing Post-thawing 
 VCL VSL VAP VCL VSL VAP 
Groups NGR GR NGR GR NGR GR NGR GR NGR GR NGR GR 
Control 160 ± 8
ax 158 ± 
3ax 






99 ± 4ay 44 ± 
2.4ay 














































TM: percent of total sperm motility; PM: percent of progressive sperm motility; VCL curvilinear sperm velocity (µm/s); VAP average 
path velocity (µm/s); VSL straight-line velocity (µm/s); LIN coefficient of linearity (%). Control group represented samples not 
contaminated with urine (n=20); Low group was contaminated with 20% of urine contamination (n=20); High group was 
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ABSTRACT 
Most epididymal flushes are performed after a catastrophic injury, acute, or chronic illness and 
are the last chance to save genetic material from a valuable stallion; this not only prevents test 
freezing for the particular animal but also means that the starting semen quality is likely poor. 
This necessitates that the protocol used for epididymal flushes be optimized to achieve the best 
possible recovery of the least damaged sperm. The objective of this study was to compare the 
effects of direct flushing of the epididymis with freezing extender to flushing with cooling 
extender and centrifugation. Epididymides were dissected away from the testes, and each vas 
deferens was catheterized. For the centrifugation method, the epididymis was flushed using 5 mL 
of a skim milk–based extender, followed by 20 mL of air, and then, semen was diluted to 50 
million/mL before centrifugation and processing. Epididymides used for the noncentrifugation 
method were flushed directly with a commercial semen freezing extender. Semen was loaded in 
0.5-mL straws at 200 million/mL, cooled and frozen. Post-thaw samples were evaluated for total 
and progressive sperm motility using a computer-automated sperm analyzer. Additionally, post-
thaw samples were stained with fluorescent probes and subjected to flow cytometry for 
assessment of sperm viability, mitochondrial potential, acrosome integrity, and chromatin 
stability. No significant differences were observed between the two groups for any of the sperm 
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parameters evaluated. In conclusion, although centrifugation does not appear to be detrimental to 
epididymal sperm, it also does not seem necessary for semen processing. 
 
INTRODUCTION 
Epididymal sperm is routinely harvested in clinical practice as a method to cryopreserve 
a stallion’s genetics following unexpected death, injury, or routine castration [1]. Viable 
pregnancies from epididymal sperm have been achieved since 1957; however, pregnancy rates 
have historically been lower with epididymal sperm than with traditional frozen semen [2–4]. 
Although the basic principle of the technique is simple, much variation exists in protocols to 
harvest and process epididymal sperm. Recent efforts to improve the procedure have focused on 
the potential benefits of seminal plasma addition, optimal breeding technique, and identification 
of the best freezing extender [1,2,5–10]. Advances in technique and freezing extenders have 
resulted in improving pregnancy rates in recent years [2–5,11]. Despite these improvements, 
cryopreservation of epididymal semen has not been standardized. 
Epididymal sperm can be harvested by direct aspiration, slicing and flotation, or 
retrograde flushing of the cauda epididymis [1,12,13]. Retrograde flushing appears to be the 
most practical and consistent technique, results in better sperm yield, and is most commonly used 
in clinical practice [1,3,6,14]. Still, there is a debate about how to process semen after collection 
via retrograde flushing with many practitioners considering semen centrifugation a necessary 
intermediate step. Centrifugation is required for cryopreservation of ejaculated semen to 
concentrate semen by removing seminal plasma and to improve sperm cell interaction with 
cryoprotectants [15]. Though traditional centrifugation (600g/10 minutes) yields a poor recovery 
of 55%–60%, cushioned centrifugation (1,000g/20minutes with 1- to 3.5-mL cushion solution) 
can result in higher sperm yields (89%–91%) [16]. Still, the necessity of centrifugation in 
processing epididymal semen is questionable because retrograde flushing yields very high sperm 
concentration. Additionally, it is possible to flush the epididymis with freezing extender, which 
eliminates the need for centrifugation and subsequent loss of sperm [5].  
Despite the sperm loss associated with centrifugation, increased processing time, and cost 
of additional extenders and cushion solution, some practitioners still advocate the use of 
centrifugation [3,17]. It is suggested that epididymal proteins can block sperm capacitation and 
need to be removed by centrifugation to achieve appropriate fertilization potential. To date, there 
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have been no studies comparing sperm functions (e.g., membrane integrity, acrosome integrity, 
mitochondrial potential, sperm motility parameters) and DNA damage of epididymal semen 
cryopreserved with and without centrifugation. Fluorescent probes have been widely used to 
assess sperm quality of various species as other sperm functions than motility can be assessed.  
The triple stain method has been used to simultaneously assess sperm viability and 
mitochondrial membrane potential in many species, including the stallion [18–20]. 
Metachromatic staining can assess chromatin stability with acridine orange (AO) based on the 
susceptibility of the sperm DNA to acid-induced denaturation in situ [21]. Acrosome integrity 
can be assessed using a combination of FITC-PNC (peanut agglutinin conjugated with 
fluorescein isothiocyanate) and propidium iodide (PI) [22]. Collectively, these stains can be used 
to provide a more in-depth assessment of semen quality when comparing semen processing 
protocols. 
The objective of this study was to compare the quality of post-thaw sperm obtained either 
from direct flushing of the epididymis with freezing extender without centrifugation or from 
flushing the epididymis with cooling extender and processing by centrifugation. We 
hypothesized that there would be no difference in sperm motility parameters, sperm viability, 
acrosome integrity, or chromatin stability between the two methods. 
 
MATERIALS AND METHODS 
Animals and Semen Processing 
Stallions presented for elective castration during the Junior Surgery course at the Veterinary 
Teaching Hospital. of the University of Illinois Urbana-Champaign were enrolled in this study. 
These horses were admitted under a teaching protocol (#14204) that has been reviewed and 
approved by the University of Illinois Institutional Animal Care and Use. One testicle from each 
stallion was used for each method evaluated here as described in the following section. Testes 
were collected at castration (n= 8 animals) and held at room temperature until processing within 
an hour of surgical removal. The testicles were rinsed using sterile saline, and the epididymides 
were dissected from the testicles to expose the cauda epididymis and vas deferens. The vas 
deferens was then catheterized using a 12-G catheter.  
For the centrifugation group, the epididymis was flushed using 5 mL of a skim milk–
based commercially available extender (Botu-Semen, Botupharma, Botucatu, Brazil) at room 
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temperature, followed by 20 mL of air. Semen was then processed by routine laboratory 
procedure [23]. Briefly, the concentration was assessed by hemocytometer, semen was diluted to 
a concentration of 50 million/mL with Botu-Semen, and then centrifuged with 1-mL cushion 
solution (MaxiFreeze, IMV Technologies, L’Aigle, France) (1,000 G 20 minutes) [17,23]. The 
supernatant and cushion were removed, and the remaining semen pellet was resuspended with a 
commercial egg yolk based semen freezing extender containing dimethylformamide and glycerol 
(Botu-Crio, Botupharma, Botucatu, Brazil) to a concentration of 200 million/mL. Semen was 
loaded in 0.5-mL straws and cooled at 5C for 20 minutes, frozen in liquid nitrogen vapor for 15 
minutes, and then plunged in liquid nitrogen before storage [24]. The non-centrifuged sample 
was collected by flushing with 5mL of semen freezing extender at room temperature, followed 
by 20 mL of air [5]. The resulting sample was diluted to a concentration of 200 million/mL and 
processed for freezing in the same manner as the centrifugation group [24]. 
Semen samples were thawed in a 37C water bath for 30 seconds. Sperm motility 
parameters were evaluated with a computer-assisted sperm analyzer using default equine settings 
(Sperm-vision II, Minitube of America,Verona, WI) and a procedure previously described [25]. 
Parameters analyzed included percent total sperm motility, percent progressive motility, sperm 
velocity parameters (curvilinear velocity [VCL] [mm/s]; average pathway velocity [mm/s]; and 
straight-line velocity [VSL] [mm/s]), and coefficients (linearity [LIN] [%], straightness [STR] 
[%], and wobble [%]). 
 
Fluorescent Probes for Sperm Evaluation 
Additionally, post-thaw samples were stained with fluorescent probes and analyzed by 
flow cytometry for assessment of viability and mitochondrial potential using triple stain (SYBR-
14/PI/JC-1), acrosome integrity (FITCPNA/ PI), and chromatin integrity (AO). The 
LIVE/DEAD Sperm Viability Kit (SYBR-14 and PI dyes; #L-7011) and JC-1 dye (#L-7381) 
were purchased from Molecular Probes, Inc. (Eugene, Oregon). Fluorescein isothiocyanate–
conjugated pea (Pisum sativum) agglutinin (FITCPNA; #L-7381) was purchased from Sigma 
Chemical Co (St. Louis, MO). Acridine orange C.I. (#04539-500) was purchased from 
Polysciences, Inc (Warrington, PA). Dimethyl sulfoxide, anhydrous (#D12345), triton X-100 
surfactant detergent solution (#85111), and phosphate- buffered saline (pH 7.4) (#10010-023) 
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were purchased from Thermo Fischer Scientific (Waltham, MA). All other chemicals used were 
reagent grade and purchased from Sigma-Aldrich. 
 
Assessment of Sperm Viability and Mitochondrial Membrane Potential (SYBR-14/PI/JC-1) 
The triple stain assay has been used to simultaneously assess sperm viability and 
mitochondrial membrane potential in many species, including the stallion [18–20]. Staining 
solution was prepared on the day of analysis by combining 5 mL SYBR-14 (0.02 mM), 5 mL PI 
(2.4 mM), and 1 mL JC-1 (3 mM) per milliliter of HEPES buffer (10 mM Hepes, 150 mM NaCl, 
pH 7.4), creating working concentrations of 100 nM(SYBR-14), 12 mM(PI), and 3 mM(JC-1); 5 
mL of thawed semen was added to 0.5 mL of staining solution to create a final concentration of 2 
million spermatozoa/ mL. Samples were mixed by reverse pipetting 10 times and subsequently 
incubated in the dark at 37C for 30 minutes before flow cytometric analysis. 
Samples were analyzed using a BD LSR II Flow Cytometry Analyzer (BD Biosciences, 
San Jose, CA) at the Roy Carver Biotechnology Center, University of Illinois Urbana- 
Champaign. The three dyes were excited using a 488-nm argon excitation laser. A total of 10,000 
gated events were recorded. Two-dimensional plots of green versus red fluorescence events were 
drawn, and debris was gated based on those events that emitted minimal fluorescence. As 
previously described [18], four sperm populations in the SYBR-14/PI/JC-1 stained sperm 
preparations were observed (Fig. D.1). Presumptively viable cells made up both populations 1 
and 2, with the high green fluorescent signal from SYBR-14 uptake in the head. Population 1 
included the viable sperm cells with midpieces that stained orange, exhibiting higher red 
fluorescence, due to J-aggregates formation from high mitochondrial membrane potential (LIVE, 
POLARIZED). Population 2 included the viable sperm cells with midpieces that only weakly 
stained orange, exhibiting lower red fluorescence, due to depolarization and monomer formation 
(LIVE, DEPOLARIZED). Population 3 represented the nonviable sperm cells, exhibiting high 
red fluorescence due to PI uptake in the head, which also fluoresced a faint green in the midpiece 
due to monomer formation (DEAD). Population 4 included sperm cells not closely associated 






Assessment of Acrosome Integrity 
Acrosome integrity was assessed using a combination of FITC-PNC (peanut agglutinin 
conjugated with fluorescein isothiocyanate) and PI as described elsewhere [16,21]. Staining 
solution was prepared by combining 0.625 mL PI (2.4 mM) and 1 mL FITC-PNA (1 mg/mL) per 
milliliter of phosphate-buffered saline; 5 mL of thawed semen was added to 0.5-mL staining 
solution to create a final concentration of 2 million spermatozoa per milliliter. Flow cytometric 
analyses were carried out as described above with the exception that FITC-PNA fluorescence 
was detected at 515–545 nm fluorescence detector 1. Nonsperm events were gated out of 
analyses as judged by scattering properties. Four sperm populations in the FITC-PNA/PIstained 
sperm preparations were present (Fig. D.2). Population 1 included sperm cells that were viable 
(PI negative) with an intact acrosome (FITC-PNA negative). Population 2 encompassed sperm 
cells that were viable (PI negative) with a damaged acrosome (FITC-PNA positive). Populations 
3 and 4 contained dead sperm (PI positive) with intact (FITC-PNA negative) or damaged (FITC-
PNA positive) acrosomes, respectively. These populations were divided into quadrants, and the 
frequency of each population was quantified. 
 
Assessment of Sperm Chromatin Stability 
Metachromatic staining assessed chromatin stability with AO based on the susceptibility 
of the sperm DNA to acid-induced denaturation in situ [21,26]; 10 mL of thawed semen was 
diluted in 990 mL phosphate-buffered saline to a final concentration of 2 million 
spermatozoa/ml. Acid-induced denaturation of DNA in situ was attained by adding 0.4 mL of an 
acid detergent solution (0.17% Triton X-100, 0.15 M NaCl, and 0.08 N HCl; pH 1.4) to 0.2-mL 
diluted semen. After 30 seconds, the cells were stained by adding 1.2 mL of a solution (0.1 M 
citric acid, 0.2 M Na2HPO4, 1 mM EDTA, 0.15 M NaCl; pH 6.0) containing 6 mg/mL AO. The 
stained samples were subsequently incubated in the dark at 37C for 3 minutes before flow 
cytometric analysis.  
Flow cytometry analysis was carried out as above using a 488-nm argon excitation laser. 
Fluorescent data of all events were collected until at least 5,000 gated events were recorded. 
Cells were plotted based on red and green fluorescence intensity (Fig. D.3). Two populations 
were discerned by drawing a diagonal line between the groups of the cell with stable chromatin 
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(INTACT DNA) to the left of the line and cells with loose chromatin (DAMAGED DNA) to the 
right of the line. The frequency of each of these populations was quantified. 
Data analyses were carried with R version 3.2.2 (https://www.r-project.org/). Normality 
was checked with Shapiro–Wilk, and data analyses were performed with one-way analysis of 




There were no significant differences between the centrifugation and non-centrifugation groups 
for any of the sperm motility parameters evaluated (Table D.1). Representative images of flow 
cytometry are presented in Figs. 1–3. Both groups demonstrated sperm motility parameters 
compatible with normal fertility in stallions (Table D.1). Similarly, there were no significant 
differences in DNA fragmentation index, acrosome intactness, or sperm mitochondrial potential 
(Table D.2). Representative dot plots for the triple stain can be seen in Fig. 1, which shows the 
similarity in profile between the two treatments, and the percent of live sperm with polarized 
membranes is shown in Table D.2. Fig. D.2 depicts dot plots representative of the FITC/ PI 
analysis showing similar acrosomal integrity between the two treatments. The sperm chromatin 
structure assay is depicted in Fig. D.3, with similar profiles for the two treatment groups. 
 
DISCUSSION 
This study demonstrates that centrifugation of epididymal stallion semen is not superior 
to the non-centrifugation method for cryopreservation. Post-thaw motility was high in this study 
and was consistent with the high motility seen in other studies that used Botu-Crio extender 
[5,17]. Epididymal sperm processed by either method showed similar post-thaw total and 
progressive motility to other recent studies that centrifuged semen, with other studies reporting 
total motilities of 44%–61% and progressive motilities of 19%–26% [5,27]. Motility was higher 
in this study than that observed by Alvarez et al [28], which is likely due to the percent glycerol 
used in that study and not differences in technique. Other semen motility parameters (VCL, VSL, 
LIN, and STR) were also similar to recent studies [5,27]. Overall, post-thaw epididymal sperm 
total motility has improved in the past few years from original reports of less than 30% [2,4,29–
31] to greater than 50% in more recent work [3,5,27].  
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DNA fragmentation index was similar between groups and in line with another study 
evaluating the relationship between fertility and DNA damage in stallions [28]. Similarly, 
percent live, acrosome-intact sperm was close to other reported data. Although we did not see a 
decrease in membrane integrity or acrosome integrity after centrifugation, we also did not see an 
improvement in motility, sperm integrity, or acrosome integrity. 
A recent study evaluating epididymal semen from stallions that died of colic found that 
initial semen parameters (total motility, progressive motility, and mitochondrial potential) were 
significantly poorer than parameters from epididymal flushes of testicles collected by routine 
castration [27]. Interestingly, the authors found that after successive centrifugation and cooling to 
5C in freezing extender, all parameters improved in the colic group. They found no significant 
differences in motility, mitochondrial potential, or sperm membrane integrity between the 
healthy and colic groups on post-thaw examination. That study did not, however, have a group 
that was processed via direct flushing of the epididymis without washing, and it is unclear if the 
parameters would have improved post-thaw without additional processing [27]. Though we 
found no benefits in using centrifugation to process semen from healthy stallions, further studies 
would be needed to compare these two methods in stallions that died from certain diseases. 
Previous studies have also addressed the benefits of adding seminal plasma to the 
flushing technique, to simulate normal semen exposure to seminal plasma [1,6]. The rationale 
behind this technique is the need for seminal plasma proteins to initiate motility in live but 
quiescent sperm. However, reports are contradictory, with some authors finding no difference in 
post-thaw parameters despite the addition of seminal plasma, whereas others found that seminal 
plasma improved post-thaw motility, at least in some stallions [6,7,10,27,32]. Our post-thaw 
motility results were comparable to the improving post-thaw motilities seen in recent years, 
without the addition of seminal plasma [27,33]. 
Although semen centrifugation is a necessary step for the cryopreservation of equine 
semen collected by an artificial vagina, the current results suggest that it is not necessary to 
cryopreserve semen collected from epididymal flushes from healthy stallions. Semen collected 
by flushing contains no seminal plasma and is already concentrated at a sufficient concentration 
to allow immediate extension and freezing. Centrifugation may still be of benefit to practitioners 
wishing to minimize straws per breeding dose by freezing at concentrations as high as 800 
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million sperm/mL. However, the advantage of centrifugation is questionable given the decreased 
total recovery of sperm. The extra steps involved in the centrifugation method can be time-
consuming and do not result in improved motility, membrane integrity, or DNA integrity. 
In summary, no differences were seen between epididymal sperm processing protocols 
for any of the post-thaw parameters evaluated. This suggests that there is no need to centrifuge 
semen collected via epididymal flushes before freezing and allows the practitioner to save time, 
money, and potentially increase total sperm yield. 
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Figure D.1. Representative flow cytometry dot plot for the triple stain assay (SYBR-14/PI/JC-1) 
for the centrifugation group (A) and non-centrifugation group (B). Units indicate fluorescence 
intensity, with high SYBR-14 producing green fluorescence (x-axis) and high PI producing a red 
fluorescence (y-axis). The top left quadrant corresponds to dead sperm (high PI-positive events 
and low SYB-14). The bottom right quadrant corresponds to viable sperm (high PI-positive 
events and low PI). The top right quadrant represents moribund sperm, with both high PI and 
high SYBR-14 fluorescence. The bottom right quadrant corresponds to debris or low fluorescing 




Figure D.2. Representative flow cytometry dot plots for acrosomal integrity assay, FITC-PNA, 
and propidium iodide for the centrifugation group (A) and noncentrifugation group (B). Units 
indicate fluorescence intensity, with high FITC-PNA producing green fluorescence (x-axis) and 
high PI producing a red fluorescence (y-axis). The first unstained population of viable sperm is 
in the lower left quadrant, with low PI and intact acrosomes (low FITC-PNA). The upper 
quadrants represent the populations of dead sperm (high PI), with damaged acrosomes (high 
FITC-PNA) on the right and intact acrosomes (low FITC-PNA) on the left. The fourth 
population in the lower right quadrant (low PI and high FITC-PNA) corresponds to viable 
acrosome damaged sperm. PI, propidium iodide. 
 
Figure D.3. Representative plots for the chromatin stability assay (acridine orange) for the 
centrifugation group (A) and the non-centrifugation group (B). Units indicate fluorescence 
intensity, with binding to double-stranded (intact) DNA producing green fluorescence (y-axis) 
and binding to single-stranded (damaged) DNA or RNA producing a red fluorescence (x-axis). 
Lower left quadrant represent unstained (discarded) debris. Upper left quadrants represent sperm 
with good chromatin integrity (intact DNA) that fluoresce green. Lower right quadrants represent 











1. Bruemmer JE. Collection and freezing of epididymal stallion sperm. Vet Clin North Am 
Equine Pract 2006;22:677–82. 
2. Morris L, Tiplady C, Allen WR. The in vivo fertility of cauda epididymal spermatozoa in 
the horse. Theriogenology 2002;58:643–6. 
3. Stawicki RJ, McDonnell SM, Giguère S, Turner RM. Pregnancy outcomes using stallion 
epididymal sperm stored at 5C for 24 or 48 hours before harvest. Theriogenology 
2016;85:698–702. 
4. Barker CAV, Gandier JCC. Pregnancy in a mare resulting from frozen epididymal 
spermatozoa. Can J Comp Med Vet Sci 1957;21:47–51. 
5. Papa FO, Melo CM, Fioratti EG, Dell’Aqua JA, Zahn FS, Alvarenga MA. Freezing of 
stallion epididymal sperm. Anim Reprod Sci 2008;107:293–301. 
6. Heise A, Thompson PN, Gerber D. Influence of seminal plasma on fresh and post-thaw 
parameters of stallion epididymal spermatozoa. Anim Reprod Sci 2011;123:192–201. 
7. Neuhauser S, Rheinfeld S, Handler J, Rheinfeld S, Handler J. Evaluation of frozen-
thawed stallion epididymal sperm with and without addition of seminal plasma. J Equine 
Vet Sci 2012;32:503. 
8. Neuhauser S, Rheinfeld S, Handler J. Comparison of the effects of four freezing methods 
on motility characteristics, morphology, and viability of postthaw stallion epididymal 
sperm. J Equine Vet Sci 2014;34:882–8. 
9. Sostaric E, Aalberts M, Gadella BM, Stout TAE. The roles of the epididymis and 
prostasomes in the attainment of fertilizing capacity by stallion sperm. Anim Reprod Sci 
2008;107:237–48. 
10. Neuhauser S, Dörfel S, Handler J. Dose-dependent effects of homologous seminal plasma 
on motility and kinematic characteristics of post-thaw stallion epididymal spermatozoa. 
Andrology 2015;3:536–43. 
11. Monteiro GA, Guasti PN, Hartwig FP, Dellaqua JA, Alvarenga MA, Papa FO. 
Cryopreservation and fertility of ejaculated and epididymal stallion sperm. Anim Reprod 
Sci 2011;127:197–201. 
12. Sharma RK, Padron OF, Thomas AJ, Agarwal A. Factors associated with the quality 
before freezing and after thawing of sperm obtained by microsurgical epididymal 
aspiration. Fertil Steril 1997;68:626–31. 
13. Hewitt DA, Leahy R, Sheldon IM, England GCW. Cryopreservation of epididymal dog 
sperm. Anim Reprod Sci 2001;67:101–11. 
14. Roels K, Leemans B, Ververs C, Govaere J, Hoogewijs M, Van Soom A. Collection and 
freezing of equine epididymal spermatozoa. Vlaams Diergeneeskd Tijdschr 
2014;83:321–5. 
15. Amann RP, Pickett BW. Principles of cryopreservation and a review of cryopreservation 
of stallion spermatozoa. J Equine Vet Sci 1987;7:145–73. 
16. Bliss SB, Voge JL, Hayden SS, Teague SR, Brinsko SP, Love CC, et al. The impact of 




17. Stawicki RJ. How to process stallion epididymal sperm in your practice. Am Assoc 
Equine Pract 2015;61:485–9. 
18. Love CC, Thompson JA, Brinsko SP, Rigby SL, Blanchard TL, Lowry VK, et al. 
Relationship between stallion sperm motility and viability as detected by two 
fluorescence staining techniques using flow cytometry. Theriogenology 2003;60:1127–
38. 
19. Volpe S, Leoci R, Aiudi G, Lacalandra GM. Relationship between motility and 
mitochondrial functional status in canine spermatozoa. Reprod Domest Anim 
2009;44(Suppl 2):275–8. 
20. Gaczarzewicz D, Udała J, Piasecka M, Błaszczyk B, Stankiewicz T. Storage temperature 
of boar semen and its relationship to changes in sperm plasma membrane integrity, 
mitochondrial membrane potential, and oxidoreductive capability. Turk J Biol 
2015;39:582–94. 
21. Martinez-Pastor F, Johannisson A, Gil J, Kaabi M, Anel L, Paz P, et al. Use of chromatin 
stability assay, mitochondrial stain JC-1, and fluorometric assessment of plasma 
membrane to evaluate frozen thawed ram semen. Anim Reprod Sci 2004;84:121–33. 
22. Robles V, Martinez-Pastor F. Spermatogenesis methods and protocols. Spermatogenes. 
Hertfordshire: Methods Protoc.; 2013. p.175–86. 
23. Schnobrich M, Roach J, Ellerbrock R, Bradecamp E, Alvarenga M, Kline K, et al. 
Comparison of cushioned centrifugation and Sperm-Filter filtration on sperm longevity 
and morphology of cooled stored equine semen. J Equine Vet Sci 2016;43:S67–8. 
24. Canisso IF, Carvalho GR, Morel MD, Ker PG, Rodrigues AL, Silva EC, et al. Seminal 
parameters and field fertility of cryopreserved donkey jack semen after insemination of 
horse mares. Equine Vet J 2011;43:179–83. 
25. Ellerbrock R, Canisso I, Feijo L, Lima F, Shipley C, Kline K. Diagnosis and effects of 
urine contamination in cooled-extended stallion semen. Theriogenology 2016;85:1219–
24. 
26. Stewart JL, Shipley CF, Katich AS, Po E, Ellerbrock RE, Lima FS, et al. 
Cryopreservation of white-tailed deer (Odocoileus virginianus) semen using soybean-, 
liposome-, and egg yolk-based extenders. Anim Reprod Sci 2016;171:7–16. 
27. Gloria A, Carluccio A, Petrizzi L, Noto F, Contri A. Characteristics of frozen epididymal 
spermatozoa from stallions that died 12 to 36 hours after colic surgery. Theriogenology 
2015;85:345–50. 
28. Álvarez C, Gil L, González N, Olaciregui M, Luño V. Equine sperm post-thaw 
evaluation after the addition of different cryoprotectants added to INRA 
96                                               extender. Cryobiology 2014; 69:144–8. 
29. Bruemmer JE, Reger H, Zibinski G, Squires EL. Effect of storage at 5Con the motility 
and cryopreservation of stallion epididymal spermatozoa. Theriogenology 2002;58:405–
7. 
30. Tiplady CA, Morris LHA, Allen WR. Stallion epididymal spermatozoa:pre-freeze and 
post-thaw motility and viability after three treatments. Theriogenology 2002;58:225–8. 
31. Braun J, Sakai M, Hochi S, Oguri N. Preservation of ejaculated and epididymal stallion 
spermatazoa. Theriogenology 1994;41:809–18. 
190 
 
32. Aurich JE, Kühne A, Hoppe H, Aurich C. Seminal plasma affects membrane integrity 
and motility of equine spermatozoa after cryopreservation. Theriogenology 1996;46:791–
7. 
33. Monteiro GA, Guasti PN, Rocha AS, Martin I, Sancler-Silva YFR, Freitas Dell’Aqua CP, 
et al. Effect of storage time and temperature of equine epididymis on the viability, motion 
parameters, and freezability of epididymal sperm. J Equine Vet Sci 2013;33: 169–73 
 
